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List of abbreviations
Genes and proteins
ABCA1 ATP-binding cassette subfamily A member 1 
ACAD10 Acyl-CoA dehydrogenase family member 10 
ACADSB Acyl-coenzyme A dehydrogenase, short/branched chain 
ADAMTS9-AS2 ADAM metallopeptidase with thrombospondin type 1 motif 9 antisense RNA 2 
APOE Apolipoprotein E 
ARHGAP21 Rho GTPase activating protein 21 
ARMS2 Age-related maculopathy susceptibility 2 
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C10orf88 Chromosome 10 open reading frame 88 
C2 Complement component 2 
C20orf85 Chromosome 20 open reading frame 85 
C3 Complement component 3
C5 Complement component 5
C9 Complement component 9 
CCT3 Chaperonin containing TCP1 subunit 3 
CD63 CD63 molecule 
CETP Cholesterylester transfer protein 
CFB Complement factor B 
CFD Complement factor D
CFH Complement factor H 
CFHL-1 Complement factor H-like protein 1 
CFHR4 Complement factor H related 4
CFI Complement factor I
CNN2 Calponin 2 
COL10A1 Collagen type X alpha 1 chain 
COL4A3 Collagen type IV alpha 3 chain 
COL8A1 Collagen type VIII alpha 1 chain 
CTRB1 Chymotrypsinogen B1 
CTRB2 Chymotrypsinogen B2
CXCL8 C-X-C motif chemokine ligand 8 
FBN2 Fibrillin 2 
HIF1A Hypoxia inducible factor 1 alpha subunit
HTRA1 HtrA serine peptidase 1 
IL-6 Interleukin 6 
KCNT2  Potassium sodium-activated channel subfamily T member 2 
KMT2E Lysine methyltransferase 2E 
LIPC Lipase C, hepatic type
MAC-IP Membrane attack complex inhibitory protein
MIR6130 MicroRNA 6130 
MMP9 Matrix metalloproteinase 9 
12 
NPLOC4 NPL4 homolog, ubiquitin recognition factor 
NRP1 Neuropilin 1 
PEDF Pigment epithelium-derived factor
PGF Placental growth factor
PILRA Paired immunoglobin like type 2 receptor alpha 
PILRB Paired immunoglobin like type 2 receptor beta
PLA2G12A Phospholipase A2 group XIIA 
PRLR Prolactin receptor 
RAD51B RAD51 paralog B 
RDH5 Retinol dehydrogenase 5 
RORB RAR related orphan receptor B 
SERPINF1 Serpin family F member 1 
SKIV2L Ski2 like RNA helicase 
SLC16A8 Solute carrier family 16 member 8 
SPEF2 Sperm flagellar 2 
SRPK2 SRSF protein kinase 2 
SYN3 Synapsin III 
TGFBR1 Transforming growth factor beta receptor 1 
TIMP3 Tissue inhibitor of metallopeptidases 3 
TMEM97 Transmembrane protein 97 
TNFRSF10A TNF receptor superfamily member 10a 
TRPM3 Transient receptor potential cation channel subfamily M member 3 
TSPAN10 Tetraspanin 10 
UNC93B1 Unc-93 homolog B1 
VEGF(A) Vascular endothelial growth factor (A)
VEGFR1/FLT1 Vascular endothelial growth factor receptor 1 / fms related tyrosine kinase 1
VEGFR2/KDR Vascular endothelial growth factor receptor 2 / kinase insert domain receptor
VTN Vitronectin
Other abbreviations
aHUS Atypical hemolytic uremic syndrome 
AMD Age-related macular degeneration
AP Alternative pathway
AREDS Age-Related Eye Disease Study
BMI Body mass index
BMSC Bone marrow-derived stem cells
Bp Base pair
BrM Bruch’s membrane
BRAMD  Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with 
Exudative Age-Related Macular Degeneration
BVZ Bevacizumab
CATT Comparison of AMD Treatments Trials
CDD Conserved Domain Database
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Chr Chromosome
CI Confidence interval
CIDR Center for Inherited Disease Research 
CIRCL Cologne Image Reading Center and Laboratory
CMT Central macular thickness
CNV Choroidal neovascularization
CP Classical pathway
CRT Central retinal thickness
CS Contrast sensitivity
CSMT Central subfield macular thickness
DA Disk area
ECM Extracellular matrix
ERC European Research Council
ETDRS Early Treatment Diabetic Retinopathy Study
ETR Manchester Eye Tissue Repository
EUGENDA European Genetic Database
FA Fluorescein angiography
FDA Food and Drug Administration
FFA Fundus fluorescein angiography
Fw Forward
GA Geographic atrophy
GWAS Genome-wide association study
hCNSSC Human central nervous system stem cells
HDL  High-density lipoprotein
hESC Human embryonic stem cell
HLA Human leukocyte antigen
IAMDGC International AMD Genomics Consortium
iPSC Induced pluripotent stem cells
IVAN Alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation 
LD Linkage disequilibrium
LDL  Low-density lipoprotein
logMAR Logarithm of minimal angle of resolution
LP Lectin pathway
MA Minor allele
MAC Membrane attack complex
MAF Minor allele frequency
N Number
NA Not applicable
nAMD Neovascular age-related macular degeneration
NF Not found
NI Not indicated
nvAMD Neovascular age-related macular degeneration
OCT Optical coherence tomography
OR Odds ratio
14 
PBST Phosphate buffered saline with Tween-20
PCA Principal components analysis
PLIER Probe Logarithmic Intensity Error 
PRN Pro re nata
QC Quality control
RAC Rare allele count
RAP Retinal angiomatous proliferation
RPE Retinal pigment epithelium
Rv Reverse
SAB Standard assay buffer
SD Standard deviation
SE Standard error
SKAT-O Optimal unified sequence kernel association test
SNP Single nucleotide polymorphism
SPR Surface plasmon resonance 
TE Treat-and-extend
TFT Total foveal thickness
TLR Toll-like receptor
VA Visual acuity
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Introduction
Adapted from “Exploring the use of molecular biomarkers for precision medicine in  
age-related macular degeneration”
Molecular Diagnosis and Therapy, 2018 June; 22(3):315-343
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“All men naturally desire knowledge. An indication of this is our esteem for the 
senses; for apart from their use we esteem them for their own sake, and most of 
all the sense of sight. Not only with a view to action, but even when no action is 
contemplated, we prefer sight, generally speaking, to all the other senses. The 
reason of this is that of all the senses sight best helps us to know things, and 
reveals many distinctions.” 
 Metaphysics 1st book, Aristotle, 350 B.C.E
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1 Age-related macular degeneration (AMD) 
1.1 AMD leads to vision loss in the elderly
In the process of vision, reflected light enters the eye through the cornea and is focused 
onto the retina, located in the posterior section of the eye (Figure 1A). The retina is the light-
sensitive tissue that transforms light photons into electrical signals, which are transmitted 
to the brain and allow visual perception. It is composed of a layer of supporting cells, the 
retinal pigment epithelium (RPE) and the neurosensory retina, which consists of several 
layers of neural cells including the photoreceptors. Nutrients, oxygen, biomolecules, fluids 
and metabolic waste products are exchanged between the RPE and the bloodstream via 
the vessel network of the choroid (the choriocapillaris), passing through its innermost 
extracellular matrix layer; the Bruch’s membrane (Figure 1A). 
figure 1		Vision	process	and	AMD
A) Schematic representation of the eye, the retina and the choriocapillaris. Light enters the eye 
and is projected onto the retina. The macula is located in the center of the retina. In the retina, 
the photoreceptors are located in the outer section, adjacent to the retinal pigment epithelium 
(RPE). The Bruch’s membrane is a collagen- and elastin-rich layer located between the RPE and the 
choriocapillaris. B) Depiction of vision loss in AMD patients. Vision of a healthy individual on the left 
and distortion of vision in an AMD patient on the right. 
Age-related macular degeneration (AMD) is a progressive disease that leads to the degene-
ration of the macula, which is located in the center of the retina (Figure 1A). The macula is 
A
B
healthy individual AMD patient
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responsible for central vision, sharp vision and color vision. Consequently, AMD patients 
lose their central vision field, have blurred vision and have less ability to discriminate 
colors (Figure 1B).
The prevalence of AMD increases exponentially with age (Figure 2). While around 1% of 
people between 65 and 69 years old are affected by AMD, in the 80-84 year range 7% are 
affected, and in the 85-89 year range the prevalence reaches 14%. Approximately half of 
these AMD patients are visually impaired.1 
figure 2			Estimated	prevalence	of	advanced	AMD	per	age-category	in	Europe	(adapted	from	
Colijn	JM	et	al.,	2017)
1.2  Age-related macular degeneration is a highly prevalent 
disease and impacts quality of life
AMD is the leading cause of blindness in the elderly in the Western world, and the third 
most common cause of severe visual impairment worldwide.2,3 The prevalence is higher in 
Europeans compared to Asians and Africans.4 Due to an increased aging of the population, 
the number of people affected by the disease in Europe is expected to rise up to 4.8 million 
by 2040. Worldwide, that number is expected to reach 26.2 million.4,5 Considering that 
half of these patients are expected to be visually impaired, health care efforts need to be 
intensified in order to reduce the number of AMD patients who suffer from vision loss in 
the coming years.5
AMD impacts quality of life mainly due to visual acuity loss; it can impair face recognition 
and daily life activities such as reading, watching TV, cooking, travelling, cleaning, self-
care, shopping and driving. AMD patients also have a higher risk of falling, and fear of 
falling results in limitation of activities. As a consequence, AMD patients require up to 
eight times more assistance. Moreover, AMD patients experience poorer life satisfaction, 
greater stress, and higher rates of depression compared to healthy individuals.6
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1.3 Clinical characteristics of AMD
The hallmark of AMD is the presence of drusen. Drusen are deposits of extracellular debris 
that localize under the RPE, recognizable as yellowish spots on photographs of the fundus of 
the eye (Figure 3). Drusen are a possible consequence of RPE disruption, and contain lipids, 
lipoproteins and inflammatory factors, suggesting a local chronic inflammatory state.7-9 
Aging can lead to drusen formation, however, the number of drusen around the macular 
zone in AMD is notably higher compared to what would be expected in a healthy retina. In 
early stages, AMD is characterized by the appearance of more than 10 small drusen or 1-14 
intermediary-sized drusen, and pigmentary changes can also be observed (Figure 3A).10 
When drusen increase in number and size, AMD is classified as intermediate AMD (Figure 
3B). While in these stages visual acuity is well preserved,11 AMD patients can progress to 
an advanced stage in which vision loss occurs.12 Advanced AMD can be classified in two 
types: geographic atrophy (GA, Figure 3C) and choroidal neovascularization (CNV, Figure 
3D). CNV, also referred to as neovascular AMD (nvAMD), involves the abnormal growth 
of blood vessels from the choriocapillaris invading the retina, with subsequent leakage 
and bleeding, and provokes a vision-threatening scar in the macula. GA is characterized 
by atrophy of the retina, resulting from gradual loss of photoreceptors, RPE cells and the 
choriocapillaris.13,14 The prevalence of both advanced types is similar,4 however, nvAMD 
accounts for most of the visual acuity loss caused by AMD.15
figure 3		Fundus	photographs	of	AMD	patients	
A) Early AMD; the arrow indicates the drusen in the macular zone. B) Intermediate AMD.  
C)  Geographic atrophy. D) Choroidal neovascularization.  
The patients depicted in this figure were included in the studies presented in this thesis.
A
C
B
D
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1.4  Risk factors for AMD development – Genetic factors play a 
major role
AMD is a multifactorial disease; both environmental and genetic factors influence disease 
risk. Increasing age is the strongest risk factor for AMD development. Other factors 
that have consistently been associated with AMD risk are smoking, previous cataract 
surgery and family history of AMD. Smokers have approximately two times more chance 
of developing AMD compared to non-smokers (odds ratio [OR]≈2), making smoking the 
strongest modifiable risk factor for AMD. Patients who have undergone cataract surgery 
have approximately a three-fold increased chance of developing AMD (OR≈3), and family 
members of an AMD patient have a six-fold increased chance (OR≈6). Other reported 
environmental factors that potentially influence disease risk are higher body mass index, 
history of cardiovascular disease and hypertension.16
Genetic factors play a major role in the disease etiology, explaining up to 71% of the 
disease variation.17 The first single nucleotide polymorphisms (SNPs) found to be 
associated with AMD were rs1061170 or p.Y402H in the complement factor H (CFH) gene 
and rs10490924 or p.A69S in the age-related maculopathy susceptibility 2 (ARMS2) gene, 
both conferring a nearly three-fold increase in the risk of developing AMD.18-21 The largest 
case-control association study performed to date for AMD included 16,144 patients and 
17,832 controls, and identified 52 independent genetic variants across 34 loci (Table 1). 
Additionally, this study assessed whether genetic variants could explain the phenotypic 
differences observed between GA and CNV, the advanced types of AMD. SNP rs142450006, 
located in the MMP9 gene, was found to be associated exclusively with CNV. Moreover, 
besides the 52 independently associated genetic variants, four genes showed a rare 
variant burden associated with AMD: CFH, CFI, TIMP3 and SLC16A8.22 
1.5 Pathways involved in AMD etiology
Although many of the underlying mechanisms of AMD still need to be elucidated, several 
pathways are known to be involved in the disease pathogenesis. These pathways include 
angiogenesis, complement system, lipid metabolism and extracellular matrix remodeling.
1.5.1 Angiogenesis
Angiogenesis is the process of formation of new vessels, sprouting from pre-existing 
ones. In AMD, angiogenesis occurs in the neovascular form, in which new leaky vessels 
are formed in the choroidal microvascular bed.14 Under normal conditions, vessels in the 
choroid are quiescent. However, hypoxia, inflammation and oxidative stress can lead to the 
production of angiogenic factors, which in turn induce the breakdown of the endothelial cell 
basal membrane, the proliferation and migration of endothelial cells, and the degradation 
of the surrounding extracellular matrix, eventually leading to new vessel formation.23,24 
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table 1		34	loci	influence	the	risk	of	AMD	development	(adapted	from	Fritsche	et	al.,	2016)
Vascular endothelial growth factor A (VEGFA, also referred to as VEGF) has been established 
as the key mediator of pathological neovascularization in the eye.25 In AMD, elevated VEGF 
levels were found in post-mortem retinas and choroidal neovascular membranes of eyes of 
AMD patients, as well as in animal models with induced choroidal neovascularization.26-29 
Inhibition of VEGF in mice was also found to inhibit choroidal neovascularization.30 In 
addition, more recent genetic studies showed that genetic variation in the VEGFA gene is 
associated with AMD risk.31
Chr. Locus name Number of signals Lead variant Major/ minor allele OR P-value
1 CFH 8 rs10922109 C/A 0.38 9.6 × 10−618
2 COL4A3 1 rs11884770 C/T 0.9 2.9 × 10−8
3 ADAMTS9-AS2 1 rs62247658 T/C 1.14 1.8 × 10−14
3 COL8A1 2 rs140647181 T/C 1.59 1.4 × 10−11
4 CFI 2 rs10033900 C/T 1.15 5.4 × 10−17
5 C9 1 rs62358361 G/T 1.8 1.3 × 10−14
5 PRLR-SPEF2 1 rs114092250 G/A 0.7 2.1 × 10−8
6 C2-CFB-SKIV2L 4 rs116503776 G/A 0.57 1.2 × 10−103
6 VEGFA 1 rs943080 T/C 0.88 1.1 × 10−14
7 PILRB-PILRA 1 rs7803454 C/T 1.13 4.8 × 10−9
7 KMT2E-SRPK2 1 rs1142 C/T 1.11 1.4 × 10−9
8 TNFRSF10A 1 rs79037040 T/G 0.9 4.5 × 10−11
9 TGFBR1 1 rs1626340 G/A 0.88 3.8 × 10−10
9 TRPM3 1 rs71507014 GC/G 1.1 3.0 × 10−8
9 MIR6130-RORB 1 rs10781182 G/T 1.11 2.6 × 10−9
9 ABCA1 1 rs2740488 A/C 0.9 1.2 × 10−8
10 ARMS2-HTRA1 1 rs3750846 T/C 2.81 6.5 × 10−735
10 ARHGAP21 1 rs12357257 G/A 1.11 4.4 × 10−8
12 RDH5-CD63 1 rs3138141 C/A 1.16 4.3 × 10−9
12 ACAD10 1 rs61941274 G/A 1.51 1.1 × 10−9
13 B3GALTL 1 rs9564692 C/T 0.89 3.3 × 10−10
14 RAD51B 2 rs61985136 T/C 0.9 1.6 × 10−10
15 LIPC 2 rs2043085 T/C 0.87 4.3 × 10−15
16 CETP 2 rs5817082 C/CA 0.84 3.6 × 10−19
16 CTRB2-CTRB1 1 rs72802342 C/A 0.79 5.0 × 10−12
17 TMEM97-VTN 1 rs11080055 C/A 0.91 1.0 × 10−8
17 NPLOC4- 
TSPAN10
1 rs6565597 C/T 1.13 1.5 × 10−11
19 C3 3 rs2230199 C/G 1.43 3.8 × 10−69
19 APOE 2 rs429358 T/C 0.7 2.4 × 10−42
19 CNN2 1 rs67538026 C/T 0.9 2.6 × 10−8
20 MMP9 1 rs142450006 TTTTC/T 0.85 2.4 × 10−10
20 C20orf85 1 rs201459901 T/TA 0.76 3.1 × 10−16
22 SYN3-TIMP3 1 rs5754227 T/C 0.77 1.1 × 10−24
22 SLC16A8 1 rs8135665 C/T 1.14 5.5 × 10−11
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VEGFA is expressed by a variety of cells, including the RPE and immune cells. Transcription 
of the VEGFA gene leads to several alternatively spliced isoforms, with VEGFA
165
 being 
the most highly expressed in the RPE.32,33 The tyrosine kinase receptor VEGFR-2 is the 
key receptor for angiogenesis and is the predominantly expressed receptor on vascular 
endothelial cells.34 Neuropilin 1 (NRP-1) is a co-receptor for VEGFR-2 that upon VEGF 
binding enhances the transduction signal up to 6-fold (Figure 4A).35,36 One of the key 
regulators of VEGF expression is hypoxia-inducible factor 1α (HIF-1α), which in hypoxic 
conditions will induce VEGF expression.37 Inflammatory cytokines such as IFN-γ, TNF-α 
and IL-1β can also promote VEGF expression.38 Besides the pathological effect of elevated 
VEGF levels, further studies have observed that VEGF represents a survival factor required 
for neuronal cells and blood vessel homeostasis, and is constitutively produced at low 
levels by several cell types of the retina.39,40
figure 4		The	VEGFA	and	complement	pathways	are	targets	for	therapy	for	AMD	
VEGF = Vascular endothelial growth factor, VEGFR = Vascular endothelial factor receptor, FLT-1 =  
Fms related tyrosine kinase 1, KDR = Kinase insert domain receptor, FB = Complement factor B,  
FD = Complement factor D, FH = Complement factor H, C3 to 9 = Complement component 3 to 9, 
MAC = Membrane attack complex, Complement factor I = FI. 
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C4bC2b, C3(H
2
O)Bb and C3bBb are C3 convertases, C4bC2bC3b and C3bBbC3b are C5 convertases. 
A red line towards the target indicates inhibition, whereas a green line indicates augmentation. 
A) Schematic representation of the VEGFA pathway in which therapies used for the treatment of 
neovascular AMD are depicted. VEGFA can bind either to VEGF receptor 1 (VEGFR-1 or FLT-1) or to 
VEGF receptor 2 (VEGFR-2 or KDR). Binding to VEGFR-1 can positively or negatively regulate VEGFR-2 
activity. Upon VEGF binding to VEGFR-2, the receptor is phosphorylated, which in turn leads to the 
activation of signaling pathways for proliferation, migration and survival of endothelial cells, as well 
as to increased vascular permeability. B)  Schematic representation of the complement cascade 
in which complement inhibiting therapies in clinical trials are depicted. The complement system 
can be initiated by three different pathways: the classical pathway , activated by antibody-antigen 
complexes, the lectin pathway, activated by lectin or ficolin binding to carbohydrates, and the 
alternative pathway (AP), which is constitutively activated at a low level due to the spontaneous 
hydrolysis of small amounts of C3 into C3
H2O
. All three pathways lead to the formation of C3 
convertases (C4bC2b for the CP and LP, and C3(H2O)Bb for the AP) that catalyze a proteolytic 
cleavage of the central component C3 into the potent anaphylatoxin C3a and the opsonization 
molecule C3b, which can be further cleaved into C3d on the cell surface. At the cell surface, factor 
D (FD) cleaves C3b-bound factor B (FB) to Ba and Bb, the latter forming the AP C3 convertase 
(C3bBb). This convertase will then cleave more C3, initiating an amplification loop. The alternative 
pathway can also be activated through properdin. Properdin recognizes pathogens or apoptosis 
markers and attracts C3b to the targeted cell surface generating and stabilizing new convertases. 
This amplification leads to a high amount of deposited C3b that, downstream, will bind the C3 
convertases forming the C5 convertases (C4bC2bC3b for the CP and LP, and C3bBbC3b for the 
AP). The C5 convertases will then cleave complement C5 into C5a and C5b initiating a common 
terminal pathway. C5a is another potent anaphylatoxin and C5b can bind complement C6 and C7. 
This complex binds to the cell membrane and recruits C8 and several molecules of C9 to form the 
membrane-attack complex (MAC), a pore capable of osmotic cytolysis. In order to regulate the 
rapid activation and exponential effects of the complement cascade, soluble and membrane-bound 
proteins act as inhibitors. Factor H (FH) is the main regulator of the AP, inhibiting the system at 
different levels. It disassembles C3Bb convertases by competing with Bb. C3b can also be degraded 
by Factor I (FI), of which FH is a cofactor. FH recognizes the host cells by surface pattern binding, 
having an essential role in preventing self-attack. Another inhibitor of the system acting on the 
terminal pathway is MAC-inhibitory protein (MAC-IP, also known as CD59), which also recognizes host 
cells, and inhibits the formation of the MAC. 
1.5.2 The complement system
The complement system is an integral part of our innate immunity and connects the 
innate to the adaptive immune response. It consists of a complex network of plasma 
and membrane-associated proteins that, in order to maintain homeostasis and protect 
against foreign intruders, are capable of orchestrating a rapid and efficient response via 
inflammation, opsonization and cytolysis (Figure 4B).41 
The first evidence for the involvement of the complement system in AMD came from 
histological and molecular analysis of drusen components, which revealed components 
of the complement cascade such as C3a and vitronectin.42-45 The first genetic studies 
corroborated this finding when the genetic variant p.Y402H in the CFH gene was found 
to be strongly associated with AMD.18-20 Further genetic studies revealed AMD-associated 
variants in the CFI, C2/CFB, C3, C9 and VTN complement genes (Table 1).22 Finally, systemic 
measurements of complement activation fragments revealed elevated levels of Ba, Bb, 
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C3a, C3d, and C5a in AMD patients compared to controls, suggesting a chronic over-
activation of the complement system.46-52 A life-long aberrant activation of the complement 
system determined by genetic variants, together with an environment with high oxidative 
stress, may lead to a chronic level of inflammation in the aging retina, resulting in the 
degeneration of the macular structures.53 
1.5.3 Lipid metabolism
The lipid metabolism is also known to be involved in AMD pathogenesis. Genetic variants 
in the hepatic lipase C (LIPC), cholesterylester transfer protein (CETP), apolipoprotein E 
(APOE), ATP-binding cassette subfamily A member 1 (ABCA1) lipid-related genes have 
been seen to modulate AMD disease risk (Table 1).22,54 Moreover, variants in these genes 
and in the VEGFA gene have also been associated with high-density lipoprotein (HDL) 
cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol and/or triglyceride 
levels.55 Other evidence supporting the relevance of the lipid metabolism in AMD is the 
accumulation of lipids in drusen, which represent around the 40% of their content.8,56 
Systemic levels of lipids, lipoproteins and fatty acids have been evaluated and, although 
no clear associations have been found for the majority of the measurements, several 
studies suggest that elevated HDL cholesterol levels might be associated with a higher risk 
for AMD development.57 
1.5.4 Extracellular matrix remodeling
Extracellular matrix remodeling is regulated by matrix metalloproteinases (MMPs) and 
tissue inhibitors of metallopeptidases (TIMPs), and is known to be altered in AMD.58 Aging 
leads to a thickening of the Bruch’s membrane, altering its permeability and limiting the 
exchange of metabolites between the choroid and the RPE. This, in turn, contributes to 
drusen formation.59 Moreover, MMP degradation of components of the capillary basement 
membrane for new vessel outgrowth takes place in the neovascularization process.60 
Further evidence of an altered extracellular matrix integrity in AMD comes from genetic 
studies, in which genetic variants in the tissue inhibitor of metalloproteinases 3 gene 
(TIMP3) and the metalloproteinase 9 (MMP9) have been associated with AMD. Additionally, 
genetic variants in fibrillin 2 (FBN2, involved in elastic fiber assembly), transforming growth 
factor beta receptor 1 (TGFBR1, involved in extracellular matrix production), collagen 
type VIII alpha 1 chain (COL8A1) and collagen type X alpha 1 chain (COL10A1) have been 
described to influence AMD disease risk (Table 1).22,61-63 
1.6 Therapeutic options for AMD
1.6.1 Supplements
Dietary supplementation with vitamins and zinc is proven to reduce the risk of progression 
to advanced AMD. These supplements act against oxidative stress, which is thought to be 
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one of the drivers of AMD pathogenesis.64,65 Oxidative stress refers to a disturbance in the 
balance between the production of reactive oxygen species and antioxidant defenses. The 
retina is highly susceptible to oxidative stress due to the sunlight exposure, high oxygen 
consumption and high concentration of polyunsaturated fatty acids. Moreover, oxidative 
stress increases with age and is associated with smoking, another AMD risk factor.65 
The notion that oxidative stress may play an important role in AMD development and 
progression led to development of the Age-Related Eye Disease Study (AREDS) clinical trial 
that evaluated the effect of high doses of vitamin C, vitamin E, beta-carotene and zinc on 
AMD progression. In 2001, the AREDS trial concluded that patients with intermediate AMD 
in at least one eye receiving this formulation reduced their risk of progression to advanced 
AMD by 25% at 5 years. Moreover, in those patients, a 19% reduction in moderate vision 
loss was additionally observed.66 An AREDS2 supplementation trial followed in 2013, 
describing an improved formula with lutein and zeaxanthin substituting beta-carotene. This 
formula showed the same effects, but is preferred as beta-carotene conferred risk for lung 
cancer in former smokers.67 Clinicians have rapidly adopted the AREDS recommendations 
and the oral use of antioxidants combined with zinc is currently prescribed for intermediate 
or unilateral advanced AMD. 
Supplements have been proven to reduce AMD progression in the overall patient 
population. However, the effect of these supplements is variable and the protective 
effects on progression to advanced AMD range from an OR of 0.47 to an OR of 0.91.66 The 
identification of factors involved in this variability could lead to an improvement in the 
treatment strategy and therefore on its effects. Indeed, the patient’s genetic background 
may be one of the factors underlying these differences, as may influence the effects of 
the individual components of the formula. Therefore, it has been hypothesized that the 
effectiveness of the treatment with dietary supplements in reducing disease progression 
may improve tailoring the prescription to each individual genetic makeup.
1.6.2 Anti-VEGF antibodies for neovascular AMD
The discovery of VEGF as the main driver of pathological neovascularization, lead to the 
development of anti-VEGF therapies for cancer, and soon also for the CNV form of AMD.68 
Nowadays, the gold-standard treatment for CNV consists of intravitreal injections of anti-
VEGF antibodies. Anti-VEGF antibodies for CNV treatment include ranibizumab (Lucentis; 
Novartis, Basel, Switzerland, and Genentech Inc., South San Francisco, USA), bevacizumab 
(Avastin, Genentech, South San Francisco, USA), and aflibercept (EYLEA, Regeneron 
Pharmaceutical Inc, Tarrytown, USA, Figure 4A). 
Ranibizumab is a recombinant monoclonal antibody fragment against all VEGFA isoforms, 
which was approved by the United States Food and Drug Administration (FDA) for the 
treatment of CNV in 2006 after showing efficacy in the MARINA and ANCHOR trials.69,70 
Bevacizumab is a full-length monoclonal antibody, also against all VEGFA isoforms. This 
drug has been approved by the FDA for the treatment of several cancer types, however, 
it is administered off-label for the treatment of CNV. The Comparison of AMD Treatments 
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Trials (CATT) and the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) 
clinical trials demonstrated similar outcomes after bevacizumab treatment compared to 
ranibizumab.71-74 The anti-VEGF agents ranibizumab and bevacizumab are administred 
as a loading dose of three monthly injections and the follow-up treatment differs among 
clinics. The most used strategies are pro re nata (PRN) and treat-and-extend (TAE). In the 
PRN, patients are followed monthly but only injected when needed, whereas in the TAE 
protocol, patients receive an injection every visit, but the time between visits is extended 
or shortened depending on the disease progression.75,76 Finally, aflibercept consists 
of key domains of VEGFR1 and VEGFR2 fused with a portion of human antibody. Unlike 
ranibizumab and bevacizumab, aflibercept binds VEGFA, VEGFB and placental growth 
factor (PGF), acting as a VEGF decoy-receptor. Aflibercept was granted the FDA approval in 
2011, and has similar efficacy outcomes as ranibizumab, however, a less frequent dosing is 
needed, once every two months instead of monthly (Figure 4A).77,78
The use of anti-VEGF drugs to treat CNV has significantly changed the prognosis of the 
disease and has led to significant improvements in visual acuity. Nevertheless, a more 
detailed analysis of individual patient outcomes shows that not all patients benefit equally 
from this therapy. Vision remains stable or improves in approximately 80% of the patients, 
but 20% of treated patients continue to lose vision despite treatment.69,70 Along the same 
line, anatomical changes in the retina after treatment, reflecting fluid clearance, are also 
variable among patients.71
Understanding the reasons underlying this variability in treatment outcome after anti-VEGF 
injections can help improve treatment strategies, but also would allow early identification 
of poor responders, and would enable individual treatment optimization. Clinical and 
epidemiological factors that have repeatedly been associated with worse treatment 
outcome include baseline parameters such as older age, larger neovascular lesion, larger 
retinal tissue thickness and lower visual acuity.79 These factors are highly correlated and 
indicative of longer disease duration, highlighting the importance of initiating treatment 
in an early phase. Nevertheless, these factors cannot fully explain the wide range in 
treatment outcomes.80 Due to the highly heritable nature of AMD, it has been hypothesized 
that genetic factors may influence treatment outcome. Genetic markers are independent of 
disease duration and therefore may explain treatment outcome variability. 
1.6.3  Under development: Complement inhibiting therapies for geographic 
atrophy in AMD
Anti-VEGF treatment is only applicable to CNV, which affects only half of the advanced AMD 
patients. For the other half, who suffer from GA, no treatment is available yet. A prime 
candidate target in AMD is the complement system, and several therapies aiming to inhibit 
complement activity are being developed (Figure 4B).81 These therapies aim to slow down 
disease progression and to prevent the development of GA, but may also be useful for CNV 
patients in combination with anti-VEGF drugs. 
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Complement-inhibiting therapies that have gone through clinical trials include APL-2, 
Lampalizumab, Eculizumab, Tesidolumab, CLG561, Zimura and AAVCAGsCD59 (Figure 4B). 
These drugs inhibit the complement system at different levels of the proteolytic cascade.
APL-2 (Apellis Pharmaceuticals, Crestwood, USA), a reformulated version of POT-4, is a 
cyclic peptide inhibitor of complement component 3 (C3). This drug is currently being 
tested in a phase II clinical trial (https://clinicaltrials.gov, NCT02503332). In a press 
release, Apellis Pharmaceuticals communicated that this clinical trial has resulted in a 
significant reduction in the rate of geographic lesion growth over 12 months.82 Lampalizumab 
(Genentech Inc., South San Francisco, CA) is an antigen-binding fragment of a humanized 
monoclonal antibody that targets complement factor D (FD). The phase II clinical trial for 
Lampalizumab (MAHALO) has been completed, and yielded promising results with a 20% 
reduction in atrophy area progression at month 18 for the monthly treated group compared to 
placebo.83 Lampalizumab is currently being evaluated in two phase III clinical trials (SPECTRI 
and CHROMA, NCT02247531 and NCT02247479 respectively). Recently, Genentech revealed 
in a press release that SPECTRI did not meet its primary endpoint of reducing mean change 
in GA lesion area, and that they are expecting the results of CHROMA to be evaluated in 
November 2017.84 Eculizumab (Soliris, Alexion Pharmaceuticals, New Haven, USA) is 
a humanized monoclonal antibody targeting complement 5 (C5). Eculizumab has been 
approved for the treatment of paroxysmal nocturnal hemoglobinuria. In a phase II clinical 
trial in AMD (COMPLETE, NCT00935883), systemically administered eculizumab was well-
tolerated, however, it did not decrease the growth rate of geographic atrophy significantly.85 
Another drug targeting C5 is Zimura (Ophtotech, USA), a chemically synthesized aptamer. 
This drug is currently in phase II/III trial (NCT02686658). Tesidolumab (LFG316, Novartis, 
Basel, Switzerland/MorphoSys, Planegg, Germany) is a human monoclonal antibody also 
targeting C5. The phase II clinical trial has been completed (NCT015275000); however, 
the results have not yet been published. Currently, another phase II trial is ongoing which 
analyzes CLG561 (Novartis, Basel, Switzerland), a human antibody Fab that neutralizes 
properdin, as monotherapy or in combination with tesidolumab (NCT02515942). Finally, the 
first gene therapy tested for GA treatment is HMR59 (AAVCAGsCD59, Hemera Biosciences 
Inc., Newton, USA), and its safety is currently being evaluated in a phase I clinical trial 
(NCT03144999). This therapy consists of a single injection of an adeno-associated virus that 
transfects the retinal cells, leading to expression of a soluble form of MAC-inhibitory protein 
(MAC-IP), also named CD59 (Figure 4B).
These therapies may not work equally in all AMD patients, and may be more effective in 
AMD patients in which the complement system is most over-activated. Identification of 
genetic variants as biomarkers for complement activation in AMD may be useful for 
selecting patients for complement inhibiting therapies.
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2  Genetic association studies for understanding 
complex traits
Genetic association studies are used to study multifactorial traits and to assess whether 
one or more genetic variants co-occur with a trait more often than would be expected by 
chance.86 Genetic association studies allow the identification of risk factors and can give 
insights into the biological mechanisms underlying a trait.18,87 An association between 
a genetic variant and a trait indicates a direct or indirect relationship. In the latter case, 
the associated variant is a marker for the causal variant as they are, to some degree, 
co-inherited. The indirect associations are usually weaker than the direct associations, 
however, can be useful to identify causal genes.88
There are two different strategies for performing association studies: the (targeted) 
candidate gene approach, and the (untargeted) genome-wide approach. In the candidate 
gene approach, genetic variants within a pre-specified gene or group of genes are analyzed. 
The variants chosen for analysis can be also pre-specified. This type of analysis is based 
on a hypothesis, and therefore, based on a priori knowledge of the gene’s function and the 
investigated trait.89 In contrast, genome-wide association studies (GWAS) explore variants 
distributed genome-wide and therefore entail a hypothesis-free approach.90 GWAS typically 
analyze common variants, however, analysis of single rare variants in the same manner 
has little statistical power due to the low allele frequencies. In order to overcome this 
limitation, rare variants can be grouped by gene, and the burden of rare genetic variation 
in each gene can be evaluated, increasing in this way the statistical power.91 One of the 
most important considerations in genetic association analysis is to avoid confounding 
due to population stratification; differences in allele frequencies across populations and 
differences in phenotype prevalence can lead to spurious results.90
3  Pharmacogenetics and precision medicine for 
AMD
3.1 Potential impact of pharmacogenetics 
Precision medicine aims to improve healthcare through individualized selection of treatment 
options, taking into account each patient’s characteristics and individual needs. The field 
of precision medicine has moved forward rapidly in the last decades thanks to association 
studies, which have identified genetic markers that predict response to treatment in 
many different diseases.92 Genetic screening prior to treatment is now increasingly being 
implemented in the healthcare system.93-95 A prime example is the oncology field, where, 
for instance, genetic variants in the DPYD gene are highly recommended to be screened to 
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avoid toxicity from fluoropyrimidine drugs.96 Other examples include the anti-coagulant 
warfarin, for which a GWAS successfully identified genetic variants with an effect on the 
maintenance dose,97 and genotype-guided prescription has been established to improve 
safety and effectiveness, and to reduce healthcare costs.98-100
3.2  First steps in the use of genetic biomarkers for precision 
medicine for AMD: where are we now and what is needed?
The use of dietary supplements has been proven to be effective in reducing the progression 
to late AMD and several groups have investigated whether the response is variable 
depending on the CFH rs1061170 and ARMS2 rs10490924 genotypes. At the beginning 
of this thesis, there was a discrepancy in the results of such studies and therefore not 
a clear biomarker.101-103 More comprehensive genetic studies are needed but it has not 
been the purpose of this thesis, however, the studies on this topic have been analyzed and 
compared in the discussion section (chapter 4, section 1.1).
The only available therapy to treat AMD symptoms is anti-VEGF injections for the CNV 
form, however, as mentioned in section 1.6.2, treatment response is highly variable among 
CNV patients. Identification of pharmacogenetic associations for AMD is highly relevant 
as they may help understand the causes underlying this variability, can be used for anti-
VEGF therapy planning and can help selecting patients for new therapy options. Before the 
start of this thesis work, several genetic variants such as rs1061170 in CFH, rs10490924 in 
ARMS2, rs699947 in VEGFA and rs4576072 in KDR had been identified in candidate gene 
studies, which suggested a role for genetic variation in treatment response, however, a 
systematic analysis of the 52 AMD-associated variants had not been performed yet.104-
127 One GWAS had been carried out which did not identify any statistically significant 
association, however, this study was very limited in sample size (n=65). Additionally, the 
role of rare genetic variants, which may have stronger effects on treatment response, had 
not been explored yet.128 As a consequence, more comprehensive association analyses 
were needed in order to find genetic biomarkers for treatment response to anti-VEGF 
therapy in CNV. 
For the treatment of advanced GA, complement inhibiting therapies are currently under 
development, but these will most probably not be equally effective in all AMD patients. 
Genetic variants that reflect complement activation in AMD patients could be used as 
biomarkers for patient selection in complement inhibiting therapies. At the start of this 
thesis work, three studies had analyzed the association of AMD variants with systemic 
complement activation measurements.48,50,52 Those studies had successfully identify 
variants in the CFH, CFB/C2, C3 and ARMS2 genes associated with systemic measurements 
of complement activation such as C3a, C5a, Ba and the C3d/C3 ratio. These results 
suggested that genetic variants could be useful biomarkers of complement activation 
in AMD. However, a comprehensive analysis of the genetic influence on complement 
activation had not yet been performed, nor had the 52 AMD-associated variants been 
comprehensively analyzed yet.
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4 Aims and outline of this thesis
Taking first steps towards a personalized treatment for AMD patients, we sought to identify 
genetic factors associated with response to anti-VEGF therapy, and to identify genetic 
variants associated with complement activation in AMD. 
1 Genetic factors associated with response to anti-VEGF therapy in AMD
Chapter 2 describes the different approaches we have taken for the identification of genetic 
variants associated with treatment response to anti-VEGF therapy in CNV. Chapter 2.1 
describes a candidate gene study of the NRP1 gene, which identified rs2070296 as a new 
genetic variant associated with treatment response. Taking a hypothesis-free approach as 
a next step, we performed a GWAS study using pooled DNA in chapter 2.2. This study was 
performed in collaboration with the group of Prof. Baird from the Centre for Eye Research 
Australia, and lead to the identification of rs4910623 in the OR52B4 gene as a new SNP 
associated with treatment response. In chapter 2.3, leading a large collaborative study, 
we performed a large GWAS for treatment response. In this study we also evaluated 
previously reported associations and the 52 AMD-associated variants, which were not 
found to influence treatment outcome in our study. Additionally, we performed genome-
wide gene-based tests of rare variants and identified that rare variation in the C10ORF88 
and UNC93B1 genes seems to have a profound impact on treatment outcome.
2 Genetic factors associated with complement activation in AMD
Chapter 3 describes studies on the complement system, which can be considered a first 
step in order to identify the most suitable patients for therapies targeting the complement 
system. In chapter 3.1, we performed a GWAS on systemic complement activation levels 
in order to identify genetic variants that associate with complement activation levels. We 
identified two independent signals at the CFH/CFHR locus. The top SNPs for these loci 
were rs3753396 located in CFH and rs6685931 located in the complement factor H related 
4 (CFHR4) gene. The results of this study lead to further investigation of the role of FHR-4 
in AMD, which is described in chapter 3.2. The biochemical studies together with genetic 
analyses presented in this chapter support that FHR-4 is a new complement component 
involved in AMD, and represents a promising new target for treatment. 
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Abstract
Objective: The aim of the study was to investigate the role of single nucleotide 
polymorphisms (SNPs) located in the neuropilin-1 (NRP1) gene in treatment response to 
antivascular endothelial growth factor (VEGF) therapy for neovascular age-related macular 
degeneration (nvAMD).
 
Methods: Four SNPs in the NRP1 gene (rs2229935, rs2247383, rs2070296 and rs2804495) 
were genotyped in a study cohort of 377 nvAMD patients who received the loading dose of 
three monthly ranibizumab injections. Treatment response was assessed as the change in 
visual acuity after three monthly loading injections compared with baseline.
 
Results: SNP rs2070296 was associated with change in visual acuity after 3 months of 
treatment. Patients carrying the GA or AA genotypes performed significantly worse than 
individuals carrying the GG genotype (P=0.01). A cumulative effect of rs2070296 in the 
NRP1 gene and rs4576072 located in the VEGF receptor 2 (VEGFR2 or KDR) gene, previously 
associated with treatment response, was observed. Patients carrying two risk alleles 
performed significantly worse than patients carrying zero or one risk allele (P=0.03) and 
patients with more than two risk alleles responded even worse to the therapy (P=3x10-3). 
The combined effect of these two SNPs on the response was also seen after 6 and 12 
months of treatment.
 
Conclusion: This study suggests that genetic variation in NRP1, a key molecule in VEGFA-
driven neovascularization, influences treatment response to ranibizumab in nvAMD 
patients. The results of this study may be used to generate prediction models for treatment 
response, which in the future may help tailor medical care to individual needs.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness in the western 
world1. The neovascular, or wet, form of AMD (nvAMD) is the most aggressive, being 
responsible for around 90% of the vision loss caused by the disease2. 
The first choice therapy for nvAMD consists of intravitreal injections of antivascular 
endothelial growth factor (VEGF) drugs. Although this treatment has dramatically changed 
the prognosis of the disease with a significant mean improvement in visual acuity (VA)3, a 
high variability in response rates has been described. Approximately 10% of the treated 
patients do not respond to anti-VEGF therapy and still lose more than 15 Early Treatment 
Diabetic Retinopathy Study (ETDRS) letters 2 years after the start of treatment3,4, which is 
comparable to the natural course of the disease5. 
To date, several studies have suggested that genetic variants can influence this variability 
in treatment response6-16. These studies have mainly focused on single nucleotide 
polymorphisms (SNPs) located in AMD-associated loci, but common variants in VEGF 
family members, cytokines, and proteins involved in development and maintenance of the 
retinal vasculature have also been explored. Not all studies showed consistent results9,16, 
however, due to a high variability in study designs it is difficult to reliably compare the 
outcomes of these studies. Therefore, the relevance and basis of the genetic component of 
this diverse response to treatment still needs to be elucidated.
Recently, two SNPs in the VEGF receptor 2 (VEGFR2 or KDR) gene, which encodes the main 
receptor of VEGFA on vascular endothelial cells17, have been associated with better anti-
VEGF response rates12. Consequently, other molecules involved in this pathway are also 
potential candidates to influence treatment response. Neuropilin-1 (NRP1) is a coreceptor 
of VEGFA that binds to the predominant isoform, VEGFA
165
18, and forms a complex with 
VEGFR2, which enhances the transduction of downstream signaling19-22. Recent studies 
have implicated NRP1 signaling pathways in pathological neovascularization of the retina23 
and NRP1 has been described to be involved in VEGFA-mediated vascular leakage19. Indeed, 
NRP1 has been shown to affect the evolution of the choroidal neovascularization in AMD24 
and has been proposed as a new target molecule for AMD treatment25. Moreover, NRP1 
seems to play a role in the cancer prognosis when treated with anti-VEGF compounds26, 
which makes this molecule a compelling candidate for being involved in response variation.
This study aimed to determine whether genetic variants in the NRP1 gene influence 
treatment response to anti-VEGF therapy in patients with nvAMD.
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Patients and methods
Study population
The study cohort comprised 377 eyes of 377 treatment-naive patients aged 50 years or 
older with active choroidal neovascularization secondary to AMD. A total of 145 patients 
were treated at the Department of Ophthalmology of the Radboud University Medical Center, 
Nijmegen, the Netherlands, 182 at the University of Cologne, Germany; and the remaining 
50 patients at the McGill University Health Center, Montreal, Canada. The patients from the 
German and Dutch clinics were enrolled between 2008 and 2010 in the European Genetic 
Database (EUGENDA), a multicenter database for the clinical and molecular analysis of AMD.
The study was performed in accordance with the tenets of the Declaration of Helsinki (7th 
revision). Approval of the local ethics committee was obtained for all three centers and 
written informed consent was acquired from all participants. 
The diagnosis of active nvAMD was determined by retinal specialists based on ophthalmic 
examination, spectral-domain optical coherence tomography (OCT) (Spectralis HRA+OCT, 
Heidelberg Engineering, Heidelberg, Germany) or fluorescein angiography (FA) (Spectralis 
HRA+OCT, Heidelberg Engineering; or Imagenet, Topcon Corporation, Tokyo, Japan). 
Exclusion criteria included any previous ophthalmic surgery, except for cataract removal, 
and retinal disorders other than AMD. If both eyes received treatment, the first eye to 
receive treatment was chosen as the study eye. If treatment started simultaneously, the 
study eye was chosen randomly.
All patients were treated between 2007 and 2009 with three consecutive monthly 
intravitreal injections of 0.5 mg ranibizumab (Lucentis; Novartis Pharmaceuticals UK 
Limited, Surrey, UK). VA was assessed in all cases before treatment (baseline) and after 
the three loading monthly injections. After the loading dose, patients were followed up 
on a monthly basis and treated on a pro re nata regimen at the clinics of Nijmegen and 
Cologne. At the clinic of Montreal, the patients were further managed through a treat-and-
extend regimen. OCT, best-corrected VA, fundus examination and FA were used alone or 
in combination to evaluate the effectiveness of the treatment. Recurrence or persistence 
of the choroidal neovascularization was defined as fluid seen by OCT, loss of VA of five 
ETDRS letters or more, leakage seen on FA, or new macular hemorrhage or fluid. In 
case of persistence or recurrence of the choroidal neovascularization, patients received 
three consecutive monthly ranibizumab injections. If available, VA was collected after 6 
and 12 months of treatment. For 304 patients, Snellen VA measurements were collected 
retrospectively and 73 patients were followed up prospectively using ETDRS VA. Treatment 
response was defined as the change in VA after the three first months of treatment 
compared with baseline. Longterm treatment response was defined as the change in 
VA after 6 and 12 months of treatment. Age at first ranibizumab injection, sex and other 
baseline variables were collected using questionnaires or retrieved from the patient files.
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Genotyping
The SNPs rs2229935, rs2247383, rs2070296 and rs2804495 were selected from the major 
haploblocks of the NRP1 gene for genotyping (see Table, Supplemental digital content 1, 
http://links.lww.com/FPC/A912, which details the chromosomal location of the SNPs). 
Two SNPs, rs2070296 (p.Ala179=) and rs2229935 (p.Tyr422=), were located in the coding 
region of NRP1. 
Genotyping of the SNPs was performed using competitive allele-specific KASP genotyping 
chemistry (LGC, Hoddesdon, UK). Primers and probes were developed by LGC, (see Table, 
Supplemental digital content 1, http://links.lww.com/FPC/A912, which describes the 
probes used). Quality control of the genotyping assays was assessed using duplicate DNA 
samples in each run, achieving a concordance of 100% of the results. 
Sanger sequencing of exon 4 of the NRP1 gene (NM_003873.5) was performed in 11 
patients for which genotyping by KASPar of SNP rs2070296 was not successful. Primers 
were designed using Primer3 software27 (see Table, Supplemental digital content 1, http://
links.lww.com/FPC/A912, which describes the primers used). PCR was performed, and the 
amplicons were sequenced using an automated sequencer (BigDye Terminator, version 
3, 3730 DNA analyzer; Applied Biosystems; Waltham, Massachusetts, USA). Sequences 
were assembled and analyzed using ContigExpress (Vector NTI Advance, version 11.0, Life 
Technologies). 
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics for Windows, version 20.0 
(IBM Corp., Armonk, New York, USA). ETDRS and Snellen VA records were converted to the 
logarithm of minimal angle of resolution (logMAR) for the purpose of statistical analysis. 
Change in VA after 3, 6 and 12 months was calculated as the difference between VA at 
baseline and VA at the different time points.
Deviation of the genotype frequencies from those expected under Hardy-Weinberg 
equilibrium was assessed by means of a χ2 test. To determine the influence of the baseline 
variables on the change in VA after 3 months Spearman’s correlation was used for the 
continuous variables, and Kruskal-Wallis or Mann-Whitney U tests were performed for the 
categorical variables. 
The association of the different SNPs with the change in VA after 3, 6 and 12 months was 
assessed using Mann-Whitney U tests. Bonferroni’s procedure was applied to correct for 
four tests (P≤0.01 were considered statistically significant).
To analyze the combined effect of NRP1 rs2070296 and KDR rs4576072 on the change in 
VA after 3, 6 and 12 months, patients were combined into three groups of approximately 
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equal size (carriers of less than two risk alleles, of two risk alleles, or of more than two 
risk alleles), and a Mann-Whitney U test was performed. Only the patients who were 
successfully genotyped for rs4576072 in a previous study12 were included in the analysis 
(n=353). The rs4576072 major allele (T) has been reported to lead to a worse response to 
therapy12, therefore, this allele was considered the risk allele.
table 1		Characteristics	of	the	study	cohort.
Demographics
 Age at first injection (years), mean (SD) 77.11 (7.46)
 Female gender, n (%) 215 (57.0)
Disease history
Hypertension (n=259)a, n (%)b 154 (59.5)
Diabetes mellitus (n=259)a, n (%)b 47 (18.1)
Other environmental factors
BMI (kg/m2) (n=258)a, median (quartiles) 25.39 (23.52 - 28.49)
Ophthalmological details
Baseline VA (logMAR), median (quartiles) 0.543 (0.398 - 1.000)
Equivalent baseline VA (ETDRS letters)c, median (quartiles) 57.9 (35.0 - 65.1)
 Change in VA after 3 months (logMAR)d, median (quartiles) 0.097 (0.000 - 0.259)
Equivalent change in VA after 3 months (ETDRS letters)c,d, median (quartiles) 4.8 (0.0 - 12.2)
Change in VA after 6 months (logMAR)d, median (quartiles) (n=262) 0.090 (-0.097 - 0.223)
Equivalent change in VA after 6 months (ETDRS letters)c,d, median (quartiles) 4.5 (-4.9 - 11.2)
Change in VA after 12 months (logMAR)d, median (quartiles) (n=240) 0.040 (-0.192 - 0.204)
Equivalent change in VA after 12 months (ETDRS letters)c,d, median (quartiles) 2 (-9.6 - 10.2)
 Type of CNV (n=335)a
 Occult with no classic, n (%)b 199 (59.4)
 RAP, n (%)b 21 (6.3)
 Minimally classic, n (%)b 42 (12.5)
 Predominantly classic, n (%)b 73 (21.8)
 Lesion size (DA) (n=285)a
 <2, n (%)b 92 (32.3)
 2-4, n (%)b 91 (31.9)
 4-6, n (%)b 43 (15.1)
 >6, n (%)b 59 (20.7)
SD, standard deviation; n, number of patients; VA, visual acuity; logMAR, logarithm of the 
Minimum Angle of Resolution; ETDRS, Early Treatment Diabetic Retinopathy Study; CNV, choroidal 
neovascularization; RAP, retinal angiomatous proliferation; DA, disk areas.
a  For the remaining patients no data were available. 
b  Valid percentage.
c   ETDRS letters equivalents were calculated in the following manner:  
ETDRS letters = 85 – logMAR/0.02 for logMAR values.
d   Change in VA after 3, 6 and 12 months was calculated in the following manner:  
VA prior to treatment - VA after 3, 6 or 12 months of treatment.
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table 2			Association	of	genotypes	in	NRP1	with	response	to	ranibizumab	treatment.
SNP N (%) ΔVA after 3 months (logMAR), 
median (quartiles)a
P-valueb
rs2229935
CC 203 (57.2) 0.100 (0.000 - 0.301) Reference
CT 132 (37.2) 0.079 (0.000 - 0.198) 0.12
TT 20 (5.6) 0.085 (-0.075 - 0.273) 0.50
CT or TT 152 (42.8) 0.079 (0.000 - 0.198) 0.11
rs2247383
CC 123 (35.2) 0.097 (-0.077 - 0.273) Reference
CT 169 (48.4) 0.097 (0.000 - 0.242) 0.94
TT 57 (16.3) 0.090 (-0.064 - 0.238) 0.69
CT or TT 226 (64.8) 0.097 (0.000 - 0.242) 0.84
rs2070296
GG 270 (71.6) 0.100 (0.000 - 0.287) Reference
GA 98 (26.0) 0.079 (-0.097 - 0.195) 0.04
AA 9 (2.4) 0.000 (-0.097 - 0.040) 0.04
GA or AA 107 (28.4) 0.040 (-0.097 - 0.184) 0.01
rs2804495
TT 167 (49.1) 0.098 (0.000 - 0.240) Reference
TG 147 (43.2) 0.097 (0.000 - 0.273) 0.74
GG 26 (7.6) 0.138 (-0.088 - 0.300) 0.84
TG or GG 173 (50.9) 0.097 (0.000 - 0.279) 0.72
SNP, single nucleotide polymorphism; N, number; VA, visual acuity; logMAR=logarithm of the 
Minimum Angle of Resolution.
a   Change in VA after 3 months (logMAR) was calculated in the following manner:  
VA prior to treatment - VA after 3 months of treatment.
b   P-values were calculated using Mann-Whitney U tests.
Results
Demographics and ophthalmological details of the patients are described in Table 1. Older 
age at first injection (P=0.01), having a better baseline VA (P<10-3) and having diabetes 
mellitus (P=0.02) were associated with worse response after 3 months of treatment (see 
Table, Supplemental digital content 2, http://links.lww.com/FPC/A913, which describes 
the results of the association tests). The type of choroidal neovascularization showed 
a trend towards statistical significance (P=0.06). These baseline variables were not 
associated with the SNPs of interest (P>0.05, lowest P=0.22) (see Table, Supplemental 
digital content 3, http://links.lww.com/FPC/A914, which describes the results of the 
association tests).
Over 90% of patients were successfully genotyped for SNPs rs2229935, rs2247383, 
rs2070296 and rs2804495 (Table 2). None of the SNPs showed deviations from Hardy-
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Weinberg equilibrium in the study cohort (P=0.81, 0.93, 0.98 and 0.41 respectively). The 
GA or AA genotypes of SNP rs2070296 were found to be associated with a significantly 
reduced improvement in VA after 3 months (P=0.01) compared with the GG genotype, 
showing a linear trend for the three genotype groups (Fig. 1a). The SNPs rs2229935, 
rs2248383 and rs2804495 were not found to be associated with treatment response 
(Table 2). 
figure 1			Effect	of	genetic	variants	in	NRP1	and	KDR	on	response	to	ranibizumab	treatment	in	
nvAMD.	
Change in visual acuity after 3 months of ranibizumab treatment stratified by NRP1 rs2070296 
genotype. (A) Change in visual acuity after 3 months of ranibizumab treatment stratified by the 
number of risk alleles in NRP1 rs2070296 (B) and KDR rs4576075 (T).  
The median change in visual acuity for each group is depicted in both figures.
logMAR, logarithm of minimal angle of resolution; nvAMD, neovascular age-related macular 
degeneration; VA, visual acuity.
A combined analysis of NRP1 rs2070296 and the previously associated SNP rs4576072 in 
KDR12 revealed a decrease in the change in VA after 3 months depending on the number of 
risk alleles (Fig. 1b). Patients who carried two risk alleles responded significantly worse to 
therapy than did carriers of one or zero allele (median of 0.090 logMAR or 4.5 ETDRS letters 
gained vs. 0.196 logMAR or 10 ETDRS letters gained, P=0.03), and carriers of more than 2 
alleles had even worse response rates (median of 0.020 logMAR or 1 ETDRS letter gained, 
P=3x10-3) (Fig. 1B and Table 3).
Besides the variability in treatment regimens after the first loading injections, we evaluated 
whether the effect of rs2072096 in NRP1 remained significant after 6 and 12 months 
of treatment. This SNP was not associated with the change in VA after 6 and 12 months 
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(Table 4). However, the combined effect of this SNP in NRP1 and rs4576072 in the KDR 
gene did influence long term response (Fig. 2 and Table 5).
table 3 		Combined	effect	of	the	risk	alleles	in	NRP1	rs2070296	(A)	and	KDR	rs4576072	(T)	on	
response	to	ranibizumab	treatment.		
Number of risk alleles N (%) ΔVA after 3 months (logMAR), 
median (quartiles)a
P-valueb
<2 79 (22.4) 0.196 (0.000 – 0.321) Reference
2 201 (56.9) 0.090 (0.000 – 0.204) 0.03
>2 73 (20.7) 0.020 (-0.097 – 0.180) 3x10-3
N, number of patients; VA, visual acuity; logMAR, logarithm of the Minimum Angle of Resolution.
a   Change in VA after 3 months (logMAR) was calculated in the following manner:  
VA prior to treatment - VA after 3 months of treatment.
b  P-values were calculated using Mann-Whitney U tests.
 
figure 2			Effect	of	genetic	variants	 in	NRP1	and	KDR	on	 long	 term	response	 to	 ranibizumab	
treatment	in	nvAMD.
(A) Change in visual acuity after 6 months of ranibizumab treatment stratified by the number of risk 
alleles in NRP1 rs2070296 (A) and KDR rs4576075 (T). (B) Change in visual acuity after 12 months 
of ranibizumab treatment stratified by the number of risk alleles in NRP1 rs2070296 (A) and KDR 
rs4576075 (T).  
The median change in visual acuity for each group is depicted in both figures. 
logMAR, logarithm of minimal angle of resolution; nvAMD, neovascular age-related macular 
degeneration; VA, visual acuity.
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table 4			Association	of	genotypes	in	rs2070296	NRP1	with	long	term	response	to	ranibizumab	
treatment.
 
ΔVA after 6 months (logMAR) ΔVA after 12 months (logMAR)
SNP N (%) Median (quartiles)a P-valueb N (%) Median (quartiles)a P-valueb
rs2070296
GG 188 (71.8) 0.097 (-0.092 - 0.257) Reference 180 (75.0) 0.078 (-0.120 - 0.218) Reference
GA 67 (25.6) 0.040 (-0.080 - 0.194) 0.38 53 (22.1) 0.020 (-0.222 - 0.252) 0.64
AA 7 (2.7) 0.000 (-0.398 - 0.090) 0.21 7 (2.9) -0.097 (-0.400 - 0.100) 0.33
GA or AA 74 (28.2) 0.020 (-0.098 - 0.194) 0.25 60 (25.0) 0.010 (-0.222 - 0.203) 0.46
VA, visual acuity; logMAR = logarithm of the Minimum Angle of Resolution; SNP, single nucleotide 
polymorphism; N, number.
a   Change in VA after 6 or 12 months (logMAR) was calculated in the following manner: VA prior to 
treatment - VA after 6 or 12 months of treatment.
b  P-values were calculated using Mann-Whitney U tests.
 
 
table 5			Combined	effect	of	the	risk	alleles	in	NRP1	rs2070296	(A)	and	KDR	rs4576072	(T)	on	
long	term	response	to	ranibizumab	treatment.	
Number 
of risk 
alleles
N (%) ΔVA after 6 months 
(logMAR), median 
(quartiles)a
P-valueb N (%) ΔVA after 12 months 
(logMAR), median 
(quartiles)a
P-valueb
<2 57 (22.7) 0.164 (-0.010 - 0.301) Reference 47 (20.4) 0.100 (-0.079 - 0.301) Reference
2 140 (55.8) 0.031 (-0.097 – 0.203) 0.03 137 (59.7) 0.000 (-0.199 - 0.201) 0.03
>2 54 (21.5) 0.034 (-0.209 – 0.184) 0.04 46 (20.0) 0.000 (-0.325 - 0.200) 0.04
N, number of patients; VA, visual acuity; logMAR, logarithm of the Minimum Angle of Resolution.
a   Change in VA after 6 and 12 months (logMAR) was calculated in the following manner: VA prior to 
treatment - VA after 6 or 12 months of treatment.
b  P-values were calculated using Mann-Whitney U tests.
Discussion
We evaluated the role of four SNPs located in NRP1 (rs2229935, rs2247383, rs2070296 
and rs2804495) in response to anti-VEGF treatment. The SNP rs2070296 was found to be 
significantly associated with a fewer gain in letters. Depending on the genotype, patients 
showed a different response following an additive model in which the minor allele (A) leads 
to worse response to treatment. In median, the nine patients that carried the homozygous 
AA genotype didn’t improve their VA and performed five ETDRS letters (one line) worse 
than the homozygous GG group. As a recent study showed that most patients perceive one 
line of the ETDRS chart as an improvement28, this difference could be clinically relevant. 
This effect was not seen after 6 and 12 months of treatment. Nevertheless, the dilution of 
the effect seen in the change in VA after the loading dose of three ranibizumab injections, 
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could be due to variability in the treatment regime and progression of the disease, which 
makes the comparison of the long term response difficult. 
We defined treatment response as change in VA after three consecutive loading injections 
compared with baseline. VA is an important functional outcome measure, which is most 
relevant for patients, and therefore, it has been extensively used to evaluate treatment 
response in nvAMD7,12,29-36. Most patients achieve the largest change in VA after the three 
first monthly injections3 and this time interval can be predictive of long-term response37. 
Therefore, this finding not only expands the knowledge of the mechanisms that underlie 
the variability in the response, but also could be implemented in future prediction models. 
Despite that, we encourage the evaluation of the effect of this SNP using also anatomic 
features defined by OCT. The patients in our study cohort were treated between 2007 
and 2009, and at that time, OCT scans were not implemented routinely during treatment 
regimes.
Although our study detected a significant association of rs2070296 with anti-VEGF 
treatment response, further studies are required to confirm our findings and to determine 
whether this SNP or other genetic variants in NRP1 are driving the effect. A more extensive 
analysis of additional genetic variants in NRP1 could reveal other SNPs associated with 
variability in the response. Furthermore, examination of low frequency and rare variants 
could reveal variants with a higher impact on the trait and major clinical relevance. 
The NRP1 gene has also been implicated in treatment response to anti-VEGF therapy in 
cancer. A SNP in the 3’UTR of NRP1 has been associated with better progression-free 
survival in recurrent ovarian cancer treated with bevacizumab (Avastin; Genentech Inc., 
San Francisco, California, USA)38, an anti-VEGF drug also used off-label for the treatment 
of nvAMD. NRP1 is expressed in endothelial cells and upregulated in numerous tumor cell 
types39-48, which has been associated with poorer outcomes in several cancers such as 
breast cancer42, osteosarcoma46 and nasopharyngeal carcinoma48. Therefore, the interest in 
developing new therapies targeting NRP1 in cancer is increasing49. Moreover, an improved 
effect of an anti-VEGF drug combined with anti-NRP1 antibodies has been described in 
tumor treatment.50 In addition, NRP1 has been proposed as a potential biomarker for 
treatment response in advanced gastric cancer treated with bevacizumab26. In a recent 
study, Raimondi and colleagues described that NRP1 promotes angiogenesis in a VEGFR2/
VEGFA independent manner. In this novel mechanism, NRP1 forms a complex with ABL1 
that leads to the activation of paxillin in a fibronectin dependent manner which enhanced 
motility in vitro and angiogenesis in vivo. Moreover, in a mouse model of oxygen-induced 
retinopathy, treatment with imatinib (an ABL1 inhibitor used for the treatment of leukemia) 
reduced angiogenesis. Consequently, imatinib was proposed as a new therapy for nvAMD 
targeting NRP125. 
The wide range of response to anti-VEGF therapy observed in nvAMD patients has drawn 
much attention in the pharmacogenetic research field. The findings described in this study, 
together with the findings of Hermann et al.12 and Lotery et al.9, suggest that variants in 
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components of the neovascularization pathways play an important role in treatment 
response to anti-VEGF therapy in AMD. The study by Hermann et al. showed that rs4576072 
in KDR is associated with response after 12 months of treatment12. In the current study we 
demonstrated a significant cumulative effect of this SNP and SNP rs2070296 in NRP1 in 
the response to ranibizumab treatment after the three loading injections, and also after 
6 and 12 months of treatment. This finding is specifically interesting for the development 
of prediction models based on relevant clinical parameters, environmental and genetic 
factors, which would allow patients to be grouped for different regimen doses or therapies.
In summary, our findings suggest that genotyping of SNPs in NRP1, in combination with 
SNPs in other genes as KDR, could be used as a rapid preclinical tool for selection of the 
optimal treatment for individual patients, which besides anti-VEGF treatment could also 
involve targeting of NRP1. In the future, genetic testing of such variants may help to predict 
outcome of nvAMD treatment, and to tailor medical care to individual needs.
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Supplemental content
supplemental digital content table 1			Chromosomal	location	of	the	NRP1	SNPs	and	primers	
used	for	genotyping.
SNP Chromosomal location
(chr, bp)a
Primers KASPar sequencing Primers Sanger sequencing
rs2229935 10, 33510663 Primer Allele FAM (C): AGCTTACCTGT-
TATCTTGCAACCG
Primer Allele HEX (T): CAGCTTACCTGT-
TATCTTGCAACCA
Primer Common: GGGAAACTGG-
CATATCTATGAGATTTGAA
NA
rs2247383 10, 33489052 Primer Allele FAM (C): CAGAATTGGAG-
GGAGGCCAGG
Primer Allele HEX (T): CAGAATTGGAG-
GGAGGCCAGA
Primer Common: CCACTGGGAA-
CAGAACGCTAATGTA
NA
rs2070296 10, 33552695 Primer Allele FAM (A): CCAGGATA-
ATCTCTGACATCTTTGGT
Primer Allele HEX (G): CAGGATA-
ATCTCTGACATCTTTGGC
Primer Common: ATCCCAACAGCCTT-
GAATGCACTTATATT
Fw: CTGAACTTGACTTTCCATACCC
Rv: TGCTTTGTTTTCCAGTGTCC
rs2804495 10, 33612500 Primer Allele FAM (G): ACTACTAACTGC-
CCTAGATACCAG
Primer Allele HEX (T): CACTACTAACTG-
CCCTAGATACCAT
Primer Common: CTCTTCTCTGGTT-
GATTGGCCTGTA
NA
SNP, single nucleotide polymorphism; chr, chromosome; bp, base pair; NA = not applicable;  
Fw, forward; Rv, reverse.                                               
a  The chromosomal location is based on the assembly of February 2009 (GRCh37/hg19).51
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supplemental digital content table 2			Influence	of	the	baseline	variables	on	response	to	
ranibizumab	treatment.	
    
ΔVA after 3 months (logMAR)a
 P-valueb Correlation coefficient/ median (quartiles)
Demographics
 Age at first injection 0.01 -0.130
 Gender 0.38 Female: 0.079 (0.000 - 0.222)
Male: 0.100 (-0.020 - 0.300)
Disease history
Hypertension (n=259)c 0.91 Yes: 0.104 (0.000 - 0.250)
No: 0.079 (0.000 - 0.301)
Diabetes mellitus (n=259)c 0.02 Yes: 0.000 (-0.204 - 0.176)
No: 0.107 (0.000 - 0.301)
Other environmental factors
BMI (kg/m2) (n=258)c 0.22 -0.077
Ophthalmological details
 Baseline VA (logMAR) <10-3 0.195
 Change in VA after 3 months (logMAR) NA NA
 Type of CNV (n=335)c 0.06 Occult with no classic: 0.097 (0.000 - 0.204)
RAP: 0.107 (-0.048 - 0.301)
Minimally classic: 0.000 (-0.099 - 0.176)
Predominantly classic: 0.100 (0.045 – 0.311)
 Lesion size (DA) (n=285)c 0.23 <2: 0.100 (-0.015 – 0.296)
2-4: 0.090 (0.000 – 0.222)
4-6: 0.100 (0.000 – 0.300)
>6: 0.000 (-0.097 – 0.176)
VA, visual acuity; logMAR = logarithm of the Minimum Angle of Resolution; NA, not applicable; n, 
number of patients; CNV, choroidal neovascularization; RAP, retinal angiomatous proliferation; DA, 
disk areas.
a   Change in VA after 3 months (logMAR) was calculated in the following manner: VA prior to 
treatment - VA after 3 months of treatment.
b   P-values were calculated using Spearman correlations for the independent continuous variables 
and Kruskal-Wallis tests or Mann-Whitney U tests for the categorical variables.
c  For the remaining patients no data were available.
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supplemental digital content table 3			Influence	of	NRP1	SNPs	on	potential	confounding	
factors.
Potential confounding factors of ΔVA after 3 months (logMAR)
 Age at first injection 
(years)
Baseline VA  
(logMAR)
Diabetes mellitus Type of CNV
 P-valuea P-valuea P-valuea P-valuea
rs2229935 0.23 0.23 0.38 0.22
rs2247383 0.89 0.30 0.37 0.93
rs2070296 0.50 0.34 0.30 0.30
rs2804495 0.85 0.47 0.79 0.39
VA, visual acuity; logMAR, logarithm of the Minimum Angle of Resolution; CNV, choroidal 
neovascularization.
a   P-values were calculated using Kruskal-Wallis tests for continuous outcome variables and test for 
categorical outcome variables.
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Abstract
Pooled DNA based GWAS to determine genetic association of SNPs with visual acuity (VA) 
outcome in anti-vascular endothelial growth factor (anti-VEGF) treated neovascular age-
related macular degeneration (nAMD) patients. We performed pooled DNA based GWAS 
on 285 anti-VEGF treated nAMD patients using high density Illumina 4.3M array. Primary 
outcome was change in VA in Early Treatment Diabetic Retinopathy Study (ETDRS) letters 
after 6 months of anti-VEGF treatment (patients who lost ≥5 ETDRS letters classified as non-
responders and all remaining classified as responders). GWAS analysis identified 44 SNPs 
of interest: 37 with strong evidence of association (p<9x10-8), 2 in drug resistance genes 
(p<5x10-6) and 5 nonsynonymous changes (p<1x10-4). In the validation phase, individual 
genotyping of 44 variants showed three SNPs (rs4910623 p=5.6x10-5, rs323085 p=6.5x10-4 
and rs10198937 p=1.30x10-3) remained associated with VA response at 6 months. SNP 
rs4910623 also associated with treatment response at 3 months (p=1.5x10-3). Replication 
of these three SNPs in 376 patients revealed association of rs4910623 with poor VA 
response after 3 and 6 months of treatment (p=2.4x10-3 and p=3.5x10-2, respectively). 
Meta-analysis of both cohorts (673 samples) confirmed association of rs4910623 with 
poor VA response after 3 months (p=1.2x10-5) and 6 months (p=9.3x10-6) of treatment in 
nAMD patients.
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Background
Age-related macular degeneration (AMD) is a common complex progressive neuro-
degenerative disease in the elderly, which can lead to irreversible severe vision loss1. Vision 
is threatened when AMD advances to its late sequelae of either geographic atrophy (GA) 
or choroidal neovascularization (CNV) also known as nAMD2. One of the most important 
regulators of the neovascularization process is vascular endothelial growth factor A 
(VEGF-A)3. Currently, the most effective treatment for nAMD is inhibition of VEGF through 
the use of recombinant, humanised anti-VEGF monoclonal antibodies such as ranibizumab 
(Lucentis), aflibercept (Eylea) or off-label bevacizumab (Avastin). These drugs have been 
shown in multiple studies4-8 to be efficacious in improving vision, but a varying response 
to anti-VEGF treatment has been observed. Approximately 10% of patients showed no 
improvement in visual acuity (VA) (loss of > 15 ETDRS letters), and exhibited a continuous 
decline in VA over two years of treatment similar to that previously reported for both 
ANCHOR and MARINA trials5,6. This range of variable VA response may in part be explained 
by genetic predisposition. 
It is well established that genetic factors are associated with risk of developing AMD9. 
Several of the genes associated with AMD are also genes encoding components of the 
neovascularization pathway and have previously been investigated in variation to anti-
VEGF treatment response studies8,10-12. However, conflicting findings have been reported 
thus far.
The current study aimed to investigate associations with genetic variants in a hypothesis-
free manner using a genome-wide association study (GWAS). We investigated whether 
genetic factors influencing ranibizumab treatment outcomes in nAMD patients could 
be identified through the initial use of a GWAS pooling strategy followed by a technical 
validation and subsequent replication in an independent cohort.
Results 
The objective of this study was to investigate whether genetic variants could be identified 
that might influence the treatment outcome after anti-VEGF treatment in nAMD patients. 
The demographic characteristics of patients of the Melbourne discovery cohort and 
the replication cohort are shown in Table 1. A total of 297 patients from the Melbourne 
discovery cohort (285 individuals used initially in the pooled GWAS, plus an additional 
12 ranibizumab-treated AMD patients were included, giving a total of 297 individuals) 
and 376 patients from the replication cohort met the study inclusion criteria with a mean 
age of 79.2 years and 77.1 years, respectively. A mean baseline VA (at the time of first 
injection) of 51 ETDRS letters was observed in the Melbourne discovery cohort and 52.6 
ETDRS letters in the replication cohort (Table 1). In the Melbourne discovery cohort, sex, 
smoking, type of lesion, size of CNV and number of injections up to 6 months of treatment, 
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showed no significant association with change in VA at 3 and 6 months of treatment 
(p>0.05). Baseline VA showed a consistent negative association with change in VA at 3 and 
6 months (p<0.001) in both the Melbourne and replication cohort. In addition, age at the 
time of nAMD treatment was associated with change in VA at 3 months (p<0.001) but not at 
6 months in the replication cohort (p>0.05) (Supplementary Table S1). Both the discovery 
and replication cohort have similar demographic and clinical characteristics except for the 
size of the CNV. 
table 1			Patient	demographics	and	clinical	characteristics	of	the	Melbourne	discovery	cohort	
and	the	replication	cohorts
Discovery Cohort
(Melbourne) (n=297)
Replication Cohort 
(Nijmegen/Cologne/Montreal) 
(n=376)
Sex
   Female 181 (60.9%) 214 (56.9%)
Male 116 (39.1%) 162 (43.1%)
Age (years), mean±SD
Range
79.2±7.1
(53-102)
77.1±7.4
(53-97)
Baseline Visual Acuity (ETDRS letters),
mean ±SD
Range
51.0±17.5
(2-88)
52.6±18.0∞
(1-85)
Type of lesion
Predominantly Classic
Non-Predominantly Classic
Missing Data
 
23%
77%
11% 
19.4%
69.7%
10.9%
*+Size of CNV
< 2 optic-disc area
> 2 Optic-disc area
Missing Data
44% 
29%
27%
24.5%
51.3%
24.2%
Number of Injections at 6 months, 
mean ±SD 4.7 ± 1.3 NA
^Number of Responders/Non-responders
                         3 Month
                          6 Month
84%/16%
79%/21%
82%/18%
76%/24%
SD = Standard Deviation, ETDRS = Early Treatment Diabetic Retinopathy Study, *In the discovery 
cohort, one optic-disc area is equal to 2.54 mm2, based on an optic disc diameter of 1.8mm,  
+ In the replication cohort optic disc measurement is based on each patient optic disc area, NA 
= Not available, ^Non-responders classified as those who showed loss of ≥5 EDTRS letters VA 
from baseline; all remaining patients were classified as responders. ∞ 303 Snellen visual acuity 
values were first converted into approximate ETDRS letters using a chart that has all three 
measurement to read the equivalent number of ETDRS letters. It is based on formula ETDRS letters = 
85-((-(logSnellen))/0.02)40.
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figure 1			Manhattan	plot	of	SNPs	tested	in	a	pooled	GWAS	for	response	to	anti-VEGF	
treatment.
The X-axis indicates the chromosomal position of the SNPs and the Y-axis shows their corresponding 
P-value (-log
10
). The red line indicates the threshold for genome-wide significance (p<5x10-8) and the 
blue line indicates the threshold for suggestive association (p<1x10-5).
First Phase – Genome wide association Study
First phase results from the pooled GWAS are shown in a Manhattan plot in Figure 1. 
A total of 44 SNPs from the pooled GWAS were selected for technical validation through 
independent individual genotyping on the basis of a genome-wide significant p-value 
(37 SNPs, p<9x10-8), SNPs in genes involved in drug resistance response (‘pharmagenes’) 
(2 SNPs, p<5x10-6) and SNPs leading to a missense change in a coding region of a gene (5 
SNPs, p<1x10-4) (Table 2). 
Second Phase – Validation 
In the second phase, all 44 SNPs from the first phase were genotyped in 297 patients (the 
same cohort as in phase 1 but with the addition of 12 extra patient samples who became 
available between the time of phase1 and phase2). This individual genotyping confirmed 
the 3 SNPs (rs4910623, rs323085, rs10158937) to be significantly (p<0.05) associated 
with response at 6 months of ranibizumab treatment after Bonferroni correction for 44 
independent tests. SNP rs4910623 showed the highest significance (p=5.7x10-5), in which 
the ‘G’ risk allele led to a worse response (OR=2.58 [95% CI=1.63-4.10]). While the C allele 
of both rs323085 and rs10158937 (p=6.5x10-4 and p=1.30x10-3, respectively) appeared 
protective (OR=0.16 [95% CI= 0.06-0.46] and OR=0.32 [95% CI=0.17-0.65], respectively) 
(Table 3).
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)
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table 2			Selected	SNPs	from	the	pooled	GWAS	comparing	responders	and	non-responders	
at	6	months	ranibuzimab	treatment	and	validation	results	using	an	independent	
genotyping	technique	in	the	Melbourne	discovery	cohort
SNP Chr. Position+ Gene Effect 
Allele
Pooled GWAS Technical Replication 
Pooled GWAS SNPs reaching P ≤ 9x10-8 P-Value OR  P-Value OR(95% CI)
rs4910623 11 4389639 OR52B4 G 3.69x10-9 3.14 5.65x10-5 2.58 (1.63-4.10)
rs323085 18 49290621 LOC100287225 C 3.29x10-8 0.22 6.53x10-4 0.16 (0.06-0.46)
rs10158937 1 66144876 LEPR C 5.36x10-8 0.28 1.30x10-3 0.32 (0.17-0.65)
rs2475779 5 157541895 CLINT1 T 1.59x10-9 0.29 1.36x10-6 0.40 (0.23-0.70)
rs59741976 3 74593662 CNTN3 T 2.65x10-8 0.32 1.84x10-3 0.31 (0.15-0.65)
rs4655583 1 66155407 LEPR A 1.37x10-8 0.28 2.38x10-3 0.34 (0.17-0.69)
rs7857431 9 132529504 PTGES T 3.36x10-8 0.25 4.58x10-6 0.12 (0.03-0.53)
rs794009 4 40139719 N4BP2 A 6.91x10-8 0.35 5.47x10-3 0.40 (0.22-0.77)
rs10234065 7 19547138 TWISTNB T 1.37x10-8 0.31 5.61x10-3 0.13 (0.03-0.56)
rs1447830 3 74613171 CNTN3 T 7.56x10-9 0.30 5.63x10-3 0.35 (0.17-0.74)
rs2110470 7 19509870 TWISTNB A 3.35x10-8 0.35 5.65x10-6 0.40 (0.21-0.77)
rs1892535 1 66097181 LEPR T 6.50x10-8 0.31 6.50x10-3 0.38 (0.19-0.77)
rs1573317 18 382268 COLEC12 T 1.11x10-9 0.27 7.60x10-3 0.36 (0.18-0.77)
rs13154178 5 42828101 SEPP1 A 2.09x10-8 0.36 8.20x10-3 0.49 (0.30-0.83)
rs4909963 11 11119228 GALNTL4 T 9.85x10-9 0.24 8.32x10-3 0.20 (0.06-0.67)
rs79966776 3 74582701 CNTN3 A 1.61x10-8 0.32 9.72x10-3 0.42 (0.22-0.81)
rs510549 3 111700305 ABHD10 T 1.60x10-9 0.34 1.07x10-2 0.53 (0.33-0.87)
rs6917419 6 27243480 PRSS16 T 3.80x10-8 0.33 1.41x10-2 0.32 (0.13-0.80)
 rs12117294 1 209814879 LAMB3 T 1.89x10-8 0.34 1.84x10-2 0.46 (0.25-0.88)
rs10767060 11 23468443 LOC100500938 T 8.72x10-8 0.38 2.23x10-2 0.58 (0.37-093)
rs17770298 9 101208288 GABBR2 A 7.44x10-9 0.18 2.40x10-2 0.19 (0.05-081)
rs11131078 3 7548067 GRM7 T 3.23x10-9 0.13 2.63x10-2 0.58 (0.37-0.94)
rs292998 5 58032485 RAB3C G 3.86x10-9 0.38 2.94x10-2 0.61 (0.39-0.95)
rs772433 2 7838257 LOC339788 A 5.06x10-8 0.36 4.24x10-2 0.62 (0.40-0.98)
rs3806586 2 128433897 LIMS2 T 1.16x10-9 0.26 4.96x10-2 0.52 (0.28-1.00)
rs9644866 9 2290590 SMARCA2 T 3.72x10-9 0.17 5.60x10-2 0.63 (0.40-1.01)
rs10050214 4 78733015 CNOT6L T 4.22x10-8 0.38 6.35x10-2 0.40 (0.28-1.04)
rs12638297 3 29748169 RBMS3 T 4.29x10-8 0.31 6.40x10-2 0.50 (0.25-1.04)
rs4449299 3 14598965 GRIP2 A 5.50x10-8 0.39 8.79x10-2 0.64 (0.39-1.07)
rs1353892 12 90716019 C12orf37 T 1.06x10-9 0.34 9.71x10-2 0.67 (0.42-1.07)
rs659910 11 131769454 NTM T 1.27x10-8 0.39 1.67x10-1 0.71 (1.00-1.03)
rs10141328 14 96752555 ATG2B C 7.78x10-8 0.16 1.90x10-1 0.73 (0.47-1.16)
rs9323992 14 98649816 C14orf64 T 4.59x10-8 0.38 5.14x10-1 0.84 (0.50-1.41)
rs7432690 3 77450363 ROBO2 T 9.91x10-10 0.14 6.81x10-1 1.09 (0.72-1.67)
rs141659302 11 128802177 TP53AIP1 T 3.79x10-8 0.41 9.99x10-1 0.74 (0.00-0.00)
rs7320683 13 71787948 DACH1 A 5.38x10-8 2.86 1.00 1 (-)
rs291477 3 73807858 PDZRN3 G 1.85x10-10 2.91 1.00 1 (-)
Pooled GWAS SNPs in known pharmagenes showing suggestive significance
rs3804938 3 7550294 GRM7 C 1.35x10-7 0.13 1.01x10-2 0.54 (0.34-0.87)
rs4148732 7 87234049 ABCB1 G 2.72x10-6 0.22 1.00x10-3 0.08 (0.02-0.38)
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For technical replication P values were calculated using logistic regression adjusted for baseline 
visual acuity, OR = odds ratio, SNP: single nucleotide polymorphism, Chr: chromosome, BP: 
base pair position on chromosome. SNPs that remained significantly associated after Bonferroni 
correction for multiple testing are highlighted in bold.+ Representing position from phase 3 1000G 
CEU reference panel.  
table 3			Genotypic	distribution	and	allele	frequency	of	rs4910623,	rs323085	and	rs10158937	
and	association	with	VA	response	at	six	and	three	months	of	anti-VEGF	treatment	in	
the	Melbourne	discovery	cohort
Definition of response was the same as in the pooled GWAS: Non-responders are patients who lost 
≥ 5 ETDRS letters and the remainder were classified as responders P-Value: Calculated using logistic 
regression adjusted for baseline visual acuity, OR = odd ratio, representing trend per copy effect of 
risk or minor allele on VA outcome, highlighted in bold for each SNP, CI: Confidence Interval,  
* Genotype frequency A1A1/A1A2/A2A2, +Allele frequency A1/A2.
 
Since a loading dose of three monthly injections is prescribed to all patients, we determined 
if the effect of these three selected SNPs in treatment outcome could be seen at this time 
point. The G allele of rs4910623 showed an association with worse outcome at three 
months of treatment (p=1.5x10-3, OR=2.23 [95% CI=1.36-3.66]).
SNP rs10158937 also showed an association with the C allele leading to a better response 
after 3 months (p=9.0x10-3, OR=0.36 [95% CI=0.17-0.77]), consistent with the six months 
result. However rs323085 did not show significant association at three months (Table 3).
Pooled GWAS SNPs leading to a missense change in gene
rs3877899 5 42801268 SEPP1 A 9.02x10-7 0.36 1.15x10-3 0.34 (0.18-0.66)
rs34677 5 33998768 AMACR T 3.22x10-5 0.35 3.0x10-3 0.26 (0.11-064)
rs3784588 15 31294654 TRPM1 T 4.73x10-5 0.27 9.96x10-1 0.04 (1.00-1.03)
rs17659179 18 47511113 MYO5B A 8.20x10-5 0.28 4.75x10-2 0.29 (0.09-0.99)
rs17673268 9 368128 DOCK8 T 1.54x10-5 0.41 2.44x10-1 0.63 (1.00-1.03)
6 Month 
SNP A1 A2 Genotype frequency * Allele frequency + P-Value OR 95% CI
Responders Non-responders Responders Non-Responders
rs4910623 G A 0.23/0.52/0.25 0.54/0.36/0.10 0.49/0.51 0.72/0.28 5.7x10-5 2.58 (1.63-4.10)
rs323085 C T 0.30/0.28/0.69 0/0.70/0.93 0.17/0.83 0.03/0.97 6.5x10-4 0.16 (0.06-0.46)
rs10158937 C A 0.06/0.33/0.61 0/0.17/0.83 0.23/0.77 0.08/0.92 1.3x10-3 0.32 (0.17-0.65)
3 Month
rs4910623 G A 0.25/0.51/0.24 0.52/0.37/0.11 0.51/0.49 0.71/0.29 1.5x10-3 2.23 (1.36-3.66)
rs323085 C T 0.02/0.25/0.73 0.02/0.22/0.76 0.14/0.86 0.13/0.87 0.81 0.92 (0.47-1.81)
rs10158937 C A 0.06/0.33/0.62 0.02/0.13/0.85 0.22/0.78 0.09/0.91 9.0x10-3 0.36 (0.17-0.77)
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Third Phase – Replication
In the third phase, we analysed the association of the three SNPs with treatment outcome 
in a replication cohort of European descent, consisting of 215 ranibizumab-treated AMD 
patients following pro re nata treatment protocol. The effect of rs4910623 replicated at six 
months of treatment (p=3.5x10-2, OR=1.71 [95% CI=1.04-2.80]). At the 3 month treatment 
time point all replication patients were included in the analysis (n = 376) as they were all 
treated in a similar manner to the discovery cohort. The effect of this SNP on treatment 
response was also similar at this time point (p=2.4x10-3, OR=1.8 [95% CI=1.24-2.71]). 
SNPs rs323085 and rs10158937 were not associated with treatment response in the 
replication cohort (Table 4).
table 4			Genotypic	distribution	and	allele	frequency	of	rs4910623,	rs323085	and	rs10158937	
and	association	with	VA	response	at	six	and	three	months	of	anti-VEGF	treatment	in	
the	replication	cohort
Definition of response was the same as in the pooled GWAS: Non-responders are patients who have 
lost ≥ 5 ETDRS letters and the remainder were classified as responders P-Value: Calculated using 
logistic regression adjusted for baseline visual acuity and age, OR = odd ratio, representing trend 
per copy effect of risk or minor allele on VA outcome, highlighted in bold for each SNP, CI: Confidence 
Interval, * Genotype frequency A1A1/A1A2/A2A2, + Allele frequency A1/A2.++ In replication cohort pr 
re nata treated patients included n = 215.
 
The frequency of rs4910623 risk allele (G) in the Melbourne discovery cohort was 71% and 
72% for the non-responder group (3 and 6 months respectively) in comparison to 51% and 
49% in the responders group (3 and 6 months, respectively) (Table 3). A similar change 
in allele frequency was also seen in the replication cohort with the frequency of the risk 
allele G being 62% and 38% in the non-responder group compared to 48% and 52% in 
the responders group (3 and 6 months (pro re nata patients), respectively) (Table 4). The 
overall distribution of change in VA corresponding to each genotype of rs4910623 in both 
cohorts is shown in Figure 2. 
6 Month 
SNP A1 A2 Genotype frequency * Allele frequency + P-Value OR 95% CI
Responders Non-responders Responders Non-Responders
rs4910623 G A 0.24/0.48/0.28 0.34/0.54/0.12 0.48/0.52 0.62/0.38 3.5x10-2 1.71(1.04-2.80)
rs323085 C T 0.02/0.25/0.74 0.00/0.21/0.79 0.14/0.86 0.10/0.90 0.46 0.74(0.34-1.63)
rs10158937 C A 0.05/0.32/0.63 0.02/0.30/0.67 0.21/0.79 0.17/0.83 0.58 0.84(0.45-1.57)
3 Month
rs4910623 G A 0.22/0.50/0.28 0.39/0.46/0.15 0.47/0.53 0.62/0.38 2.4x10-3 1.83 (1.24–2.71)
rs323085 C T 0.03/0.24/0.73 0/0.23/0.77 0.15/0.85 0.11/0.89 0.34 0.74 (0.50–1.33)
rs10158937 C A 0.04/0.32/0.64 0.06/0.35/0.59 0.20/0.80 0.23/0.77 0.25 1.31 (0.83-2.06)
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figure 2			Mean	change	in	visual	acuity	(VA)	after	three	and	also	the	six	month	time	period	
(pro	re	nata	treated	only)	of	treatment	stratified	by	rs4910623	genotype	for	the	
Melbourne	discovery	and	replication	cohorts.
Vertical lines represent the standard error (SE) of the mean change in VA.
Meta-Analysis
A meta-analysis of SNP rs4910623 in both the Melbourne discovery cohort and the 
replication cohort showed differences in allele distribution between responders and non-
responders at 3 months (p=1.21x10-5) and 6 months (p=9.3x10-6) of treatment (only pro 
re nata patients from the replication cohort were included) indicating the influence of 
rs4910623 on outcome of ranibizumab treatment in AMD patients (Table 5).
table 5			Meta-analysis	of	the	Melbourne	discovery	cohort	and	the	replication	cohort	for	SNP	
rs4910623	at	3	and	6	months	of	ranibizumab	treatment	in	AMD	patients
Meta-analysis was performed using METAL.* At 6 month only pro re nata treated patient were 
included from replication cohort.	
Meta-Analysis 
  3 Month 6 Month*
SNP Gene A1 A2 P-Value N  Direction Z score P-Value  N Direction Z score  
rs4910623 OR52B4 G A 1.2x10-5 673 ++ 4.37 9.3x10-6 512    ++ 4.43
Melbourne discovery cohort Replication cohort
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Discussion
We sought to identify genetic variants that influence the ranibizumab treatment response 
in AMD. Using a pooled DNA GWAS approach, we identified SNP rs4910623 in the promoter 
region of the OR52B4 gene as being associated with a worse response to ranibizumab 
treatment. The association was validated in the same cohort through individual genotyping 
and confirmed in an independent replication cohort of AMD patients of European descent. 
Individuals carrying the risk allele G did not respond as well to ranibizumab treatment 
in either cohort after 3 or 6 months of treatment compared to those with the A allele. In 
the replication cohort we observed significant association of rs4910623 with change in 
VA in patients on pro re nata treatment regimen at 6 months. However, 47 patients from 
Montreal were not included in this analysis as they followed a treat-and-extend regimen. 
We undertook an additional sensitivity analysis where these 47 patients were included 
back into the 6 month analysis time point to provide a total of 262 patients. A similar 
trend for association of the G allele of rs4910623 was seen (p=4.6x10-2, OR=1.53 [95% 
CI=1.00-2.30]). As this group consisted of only 47 patients it was too small to draw any 
conclusive conclusions about whether this treatment protocol significantly affected the 
association of the G allele of rs4910623 with change in VA. In the meta-analysis we found 
significant association of rs4910623 patients with change in VA at both 3 and 6 months 
of treatment.
Two other SNPs, rs323085 and rs10158937, located 202 kb 3’ of LOC100287225 and 
42 kb at 3’ of LEPR gene respectively, did not remain associated with change in VA after 
replication. The inconsistency in the results for these two SNPs could indicate that they are 
false positive findings.
The baseline characteristics of both the Melbourne discovery and replication cohort did 
not reveal significant association with change in VA except for the baseline VA in both the 
discovery and replication cohort at 3 and 6 months of treatment. Baseline VA is negatively 
associated with change in VA, thus lower baseline VA will lead to a greater VA gain after 
treatment and vice versa. Therefore our findings are in agreement with the ANCHOR and 
MARINA trials where higher VA at baseline was associated with a smaller gain in VA at 
12 and 24 months of treatment, respectively13. This in-turn reflects a floor and ceiling 
effect of baseline VA14. Based on definition of response in our study it may have floor 
effect of baseline VA where individuals with higher baseline VA will have limited chance to 
gain vision after the treatment and vice versa. On the other hand, the baseline VA is also 
reported as one of the predictors of treatment outcome for ranibizumab15. To overcome 
these potential issues we incorporated baseline VA as a covariate into our analysis. 
However, there was a difference in baseline CNV size in the discovery and replication 
cohort. This is probably due to differences in measurements between the cohorts with 
the Melbourne discovery cohort being based on one optic-disc area is equal to 2.54 mm2, 
using an optic disc diameter of 1.8 mm whereas the replication cohort was based on each 
patient’s optic disc area.
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Using the HaploReg database16, SNP rs4910623 is predicted to alter the GATA and TCF4 
regulatory motifs 22 bp upstream of the OR52B4 gene. We also analysed the surrounding 
variants within its linkage disequilibrium (LD) block from the 1000 Genomes Project (r2 
= 0.8, 250 Kb). A number of the identified SNPs in this LD block are predicted to alter 
transcriptional binding sites (Supplementary Table S3). Thus, this region may play an 
important role in transcriptional regulation of this gene. 
The OR52B4 protein (Q8NGK2, UniprotKB accession number) consists of 314 amino acids 
(aa) and is a member of the G-coupled protein receptor (GPCR) family, which is located in 
the plasma membrane of the cell. Interestingly we find the conserved domain of Q8NGK217 
is a 7-transmembrane domain (7tm) region which is highly conserved with the 7tm_4 
super family domain of all the olfactory receptors (33-321 aa) and also the 7tm_1 domain 
of the 7 transmembrane receptor (rhodopsin family) (43-294 aa) as indicated using the 
NCBI Conserved Domain Database (CCD) (http://www.ncbi.nlm.nih.gov/Structure/cdd/
wrpsb.cgi?seqinput=NP_001005161.2). Rhodopsin is also member of GPCR family and 
it functions to capture photons of light and trigger the intra-cellular photo-transduction 
cascade, forming the molecular basis of vision18. GPCRs are highly selective and expressed 
in specific tissues and cells, making them particularly important as potential drug targets 
as >50% of therapeutic agents in the market target these receptors19.
To assess expression of the OR52B4 gene in human eye tissue, we used online resource: 
“The Ocular Tissue Database”20. Expression of the OR52B4 gene was present in the retina, 
optic nerve and choroid (Supplementary Table S4). The identification of olfactory gene 
expression in the eye is relatively new, but not surprising, as recently published expression 
profiling of a number of olfactory receptors (olfr) in mouse cornea, retina and choroid21. Their 
analysis of eye tissue expression confirmed the presence of many olfr, with one of them, 
olfr547 representing a homolog of the human OR52B4 gene (85% identity). Interestingly, 
olfr547 is a close relative of olfr78, which has recently been shown to function in regulation 
of blood pressure in smooth muscle cells22,23. Expression of genes in the olfr pathway in 
mouse ocular tissues is mediated by the olfaction specific Gα protein, localised in the 
nuclear layer of the retina and previously thought to be only expressed in the olfactory 
epithelium21. Moreover, olfactory genes have been shown to be associated with cancer 
and other blood diseases, suggesting expression and function of olfactory proteins in a 
number of different pathways23-25. Interestingly, another olfactory receptor (OR10J5) was 
recently reported by Kim and colleagues26 to control cell migration and phosphorylation 
of signaling during angiogenesis in mice. However the functional role of OR52B4 gene in 
angiogenesis needs to be elucidated and it has so far not previously been reported to be 
associated with pharmacogenetic response to AMD. 
Previous studies investigating genetic factors in anti-VEGF treatment outcome have 
assessed known AMD risk-associated genes and genes encoding components of the 
neovascularization pathway8,10-12. However, most of these studies have produced variable 
results; for example, the Y402H variant in the CFH gene has been associated with poor VA 
outcome in some studies but in other studies has been reported to show no association 
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with VA. Similarly, inconsistent results of association were reported for ARMS2/HTRA111,27. 
Our pooled GWAS findings did not identify genome-wide significance for SNPs in the 
previously associated known AMD risk genes CFH, VEGF-A, HTRA1/ARMS2 (Supplementary 
Table S5). These findings are in agreement with our previous study28 and the CATT study, 
the largest current cohort in which major AMD risk alleles have been investigated for 
treatment outcome following treatment with bevacizumab, where no association with the 
CFH, VEGF, VEGFR2 and HTRA1/ARMS2 genes was identified with anti-VEGF treatment 
response11,12. To date, only one prior GWAS has been undertaken to identify genetic risk 
factors for treatment response to AMD. That study was conducted on 65 patients and 
reported the SNP rs7607942 near the ERBB4 gene to be associated with poor VA outcome 
after 6 months of treatment, although this SNP did not reach genome-wide significance 
(uncorrected p=6.692x10-6)29. Major drawbacks of that study were the small sample size 
and lack of replication of the reported association in an independent ranibizumab-treated 
AMD cohort. We did not find any association of this SNP in the current study (p>0.05).
We chose to use a pooled DNA GWAS strategy to investigate response to anti-VEGF 
treatment in AMD as this provided a cost-effective and efficient approach to identify 
genetic associations23,30-33. We were able to technically validate ~70% of the 44 SNPs that 
were identified in the pooling strategy at a nominal significance level. Whilst most SNPs 
replicated, the level of significance of the SNPs diminished following technical validation. 
Possible explanations for the diminished significance may be due to experimental error 
during pool construction, array-specific errors resulting from the use of a limited number of 
arrays per pool, variation in allele frequency due to small sample size in some of the pools, 
allele-specific bias skewing the results for some SNPs, and/or small differences in the set 
of samples used in the validation stage34,35. 
For the replication cohort, the number of injections at 6 month of treatment was not 
available, however it is interesting to note that a variation in treatment regime through 
change in number of injections between 3 and 6 months does not appear to ameliorate the 
genetic effect seen in the current study. However, after individual genotyping, replication and 
meta-analysis, SNP rs4910623 remained associated with worse functional outcome (change 
in VA) after the anti-VEGF treatment in AMD. Currently there is much interest in the role of 
anatomical features such as fluid clearance as a measure of treatment response. However, 
it was not considered in this analysis but this would be useful to examine in the future as to 
whether this SNP also affects fluid clearance and central macular thickness (CMT) on OCT 
following anti-VEGF treatment. To our knowledge, SNP rs4910623 and the 2 other SNPs 
associated with good response in the discovery phase have not previously been reported as 
associated with anti-VEGF treatment outcome in any type of cancer, thus it will be interesting 
to investigate the role of these SNPs in cancer following anti-VEGF treatment. Furthermore, 
much work needs to be undertaken to examine the biological basis of this phenomenon as 
well as the functional role of OR52B4 gene in models of angiogenesis, such studies could 
lead to the development of other therapies for AMD patients that can be used as an adjunct 
to existing treatment. This, in turn, offers the prospect of personalising treatment, based 
on genotype and opens up the route for exploring other drug treatment opportunities. In 
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conclusion, we report for the first time a pooled DNA based GWAS on pharmacogenetic 
response to ranibizumab treatment in AMD that identifies association of variant rs4910623 
in the OR52B4 gene. This finding was replicated in an independent replication cohort, 
suggesting that this gene may be involved in the response to anti-VEGF treatments in AMD 
patients of European decent. Finally, our data suggests that the SNP rs4910623 could be 
used as a diagnostic genetic marker before anti VEGF treatments for AMD. 
Methods
Patient Recruitment and Data Collection 
Melbourne Discovery Cohort 
The study was approved by the Human Research and Ethics Committee of the Royal 
Victorian Eye and Ear Hospital (RVEEH) and performed in accordance to the tenets of 
the Declaration of Helsinki (7th revision). Written informed consent was obtained for all 
study participants before participation. Patients were included in the study when they 
were >50 years of age, presented with an active sub-foveal CNV secondary to AMD, and 
received intravitreal anti-VEGF injections. Neovascularization was confirmed by fundus 
photography (Canon CR6-45NM; Canon Saitama, Japan), fundus fluorescein angiography 
(FFA) using IMAGEnet 2000 (Topcon Corporation, Tokyo, Japan), and optical coherence 
tomography (OCT) with Stratus OCT version 5.0.1 (Carl Zeiss Meditec, Dublin, CA) or Cirrus 
HD-OCT version 6.0.0.599 (Carl Zeiss Meditec). Exclusion criteria were nAMD associated 
with non-AMD conditions such as degenerative myopia, angioid streaks and hereditary 
retinal disorders. In addition bilateral nAMD patients who had different VA response 
between both eyes and treatment with either laser photocoagulation or photodynamic 
therapy before anti-VEGF treatment as previously reported were also excluded36. Initially 
a total of 315 nAMD patients were retrospectively recruited from the medical retinal clinic 
of the RVEEH. A total of 297 patients meet the eligibility criteria consisting of 277 patients 
with unilateral nAMD and 20 patients with bilateral nAMD who had the same (either gain 
or loss) VA response in both eyes. A total of 18 bilateral patients did not meet the eligibility 
criteria because they had differing VA response in both eyes.
VA was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 
4-metre distance at each visit. The majority of nAMD patients were treated with monthly 
ranibizumab injections (Lucentis; Novartis Pharma AG, Basel, Switzerland) for 3 months 
of initial dosing except for 27 (9.0%) patients who first received a single injection of 
bevacizumab (Avastin; Roche, Basel, Switzerland) who then went on to receive normal 
dosing using ranibizumab. After 3 monthly injections, pro re nata treatment regimen were 
adopted for follow-up injections, that was based on evaluation by a retinal specialist, who 
considered loss of VA ≥ 5 EDTRS letters, the presence of fluid on an OCT scan or presence 
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of chronic or new retinal haemorrhage as criteria for treatment. Data on demographics and 
clinical history (including VA and treatment regimens) were collected for all participating 
patients.
Replication Cohort
Ethical approval for the replication cohort was obtained from the local ethic committees of 
the Radboud university medical center, University of Cologne, and McGill University Health 
Centre. Written informed consent was acquired from all participants. 
The replication cohort consisted of 376 treatment naïve patients of European descent 
with choroidal neovascularization secondary to AMD. Patients were diagnosed by retinal 
specialists based on ophthalmic examination, spectral-domain OCT (Spectralis HRA+OCT, 
Heidelberg Engineering, Heidelberg, Germany) or fluorescein angiography (FA) (Spectralis 
HRA+OCT, Heidelberg Engineering, Heidelberg, Germany; or Imagenet, Topcon Corporation, 
Tokyo, Japan). All included patients were over the age of 50 years, had not undergone any 
previous ophthalmic surgery, except for cataract removal, and did not have other retinal 
disorders besides AMD. 
A total of 144 patients were treated at the Department of Ophthalmology of the Radboud 
university medical centre, Nijmegen, the Netherlands and 182 at the University of Cologne, 
Germany. These patients were included in the European Genetic Database (EUGENDA), 
a multicenter database for the clinical and molecular analysis of AMD. The remaining 
50 patients were treated at the McGill University Health Center, Montreal, Canada. All 
patients received the loading dose of three consecutive monthly intravitreal injections of 
0.5 mg ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland). Afterwards, they 
were followed up monthly and treated on a pro re nata regimen at the clinics of Nijmegen 
and Cologne and on a treat-and-extend regimen at the clinic of Montreal. In Nijmegen 
and Cologne (pro re nata regimen), in cases of persistence or recurrence of choroidal 
neovascularization, which was defined as loss of VA of ≥ 5 ETDRS letters, leakage seen 
on FA, fluid seen by OCT, or new macular hemorrhage or fluid, three consecutive monthly 
ranibizumab injections were administered. VA was assessed before treatment and after the 
three loading injections for all patients. VA was also recorded after 6 months of treatment 
for 262 patients. For 303 patients, Snellen VA measurements were recorded retrospectively 
and 73 patients were followed up prospectively using ETDRS VA. Baseline variables were 
collected using questionnaires or retrieved from the patient files. One eye was selected per 
patient; if both eyes received treatment, the first eye treated was selected and if treatment 
started simultaneously, the study eye was chosen randomly.
First phase – Pooled DNA Based GWAS in the Melbourne Discovery Cohort
In the first phase of the study, a GWAS using a DNA pooling approach was conducted 
(Macgregor et al.37). A peripheral blood sample was collected from each patient and DNA 
was extracted (Qiagen, Victoria, Australia). Genomic DNA was quantified by Nanodrop 
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Specrophotometer (Thermo Scientific) for a DNA concentration ≥175ng/µl. A total of 285 
samples were selected for the pooling cohort (12 samples were excluded due to a low 
DNA concentration required for pooling). Each pool was given a unique ID number, based 
on presenting VA. Non-responders from each pool were classified as those who showed 
loss of ≥5 EDTRS letters VA following 6 months of ranibizumab treatment and all remaining 
patients were classified as responders. Six equimolar DNA pools were generated with a 
pool size varying from 9 to 133 samples (Supplementary Table S2). An equal amount of 
DNA from each sample (varying from 0.2µg to 0.6µg) was added to the appropriate pool, 
with a minimum volume of 5µl per sample to reduce pipetting errors at low volume. Pooled 
genomic DNAs were assayed using an Illumina Human Omni5-Quad Bead Chip that captured 
4.3 million SNP markers. We randomised the pooled samples on the genotyping arrays to 
avoid spurious associations that may arise from array position. Approximately 4,600 indels 
or copy number variants were removed from the analyses. We applied stringent quality 
control (QC) as previously described (Lu et al.38). Briefly, we excluded SNPs with minor allele 
frequency (MAF) <1% from the reference panel of CEU (Utah residents with ancestry from 
northern and western Europe) samples in the 1000 Genome Project. Thus, the number of 
SNPs was reduced to 2.5 million. Further QC criteria for excluding SNPs from the analysis 
were: 1) SNPs with more than 10% negative probe scores; 2) a sum of the mean raw red 
and green intensity values less than 1200 for each array (to ensure calibration); 3) SNPs 
with a small number of expected probes in pools (SNPs with MAF between 1-5% required 
at least half of the expected number of probes, and SNPs with MAF > 5% required at least a 
third; the expected number of probes was calculated as the average number of probes per 
pool per SNP multiplied by the number of samples in each pool); 4) non-autosomal SNPs; 
5) SNPs where the variance of the estimated allele frequency was significantly different 
between all pools. After applying these QC filters, a total of 1,940,408 SNPs were retained 
for further analysis. A GWAS was carried out between responders and non-responders from 
three different baseline VA categories and then results were combined in a meta-analysis, 
which included 225 responders and 60 non-responders.
Second Phase – Technical Replication in the Melbourne Discovery Cohort
In the second phase, the most interesting associations found in the pooled DNA GWAS 
were validated by undertaking individual genotyping of the original 285 samples, plus 
the inclusion of the additional 12 patient samples that subsequently became available 
whose initial concentration was not enough for the pooling GWAS. These samples were 
genotyped individually for 44 SNPs using the MassArray platform (Agena Bioscience, San 
Diego, CA) and performed as previously described36.
Third Phase – Replication in an Independent Cohort of European Descent
In the third phase of the study, SNPs that showed association (p<0.05 after correction 
for multiple testing) in the second phase of the study were analysed in an independent 
ranibizumab-treated AMD cohort of European descent. DNA was extracted and quantified 
in Nijmegen, the Netherlands. Subsequently, DNA samples of a total of 376 AMD patients 
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were genotyped in Melbourne using the MassArray platform (Agena Bioscience, San Diego, 
CA) as previously described36.
Statistical analysis 
Linear regression was undertaken to assess the role of non-genetic factors (potential 
cofounders), including age, sex, smoking status, CNV size, lesion type, number of injections 
and baseline VA, on the dependent variable “change in VA” at 3 and 6 months respectively. 
The GWAS of pooled DNA was undertaken at the Queensland Institute of Medical Research 
(QIMR) as previously described37. A customised pipeline developed at QIMR was used 
for data analysis37,38. Briefly, a GWAS was run within each pool comparison, i.e. a linear 
model based approach was used for association between SNP and allele frequency 
difference in responder compared to non-responder pools accounting for pooling errors. 
A meta-analysis was performed summarising the GWAS results from the multiple pool 
comparisons, weighted by inverse variances. Finally, we applied post-analysis checks to 
the meta-analysis results in order to reduce the chance of false positive findings, filtering 
any SNP that had results from only one of the multiple pool comparisons and those with 
large discrepancies in association results of the SNP itself and its proxies. 
For individual genotyping data, logistic regression was used to assess differences in allele 
frequency between the responder and non-responder groups (defined in the same manner 
as for the GWAS) and adjusted for baseline VA in the discovery cohort and baseline VA and 
age at first injection in the replication cohort. In this replication cohort, different treatment 
regimens were administered after the 3 initial monthly injections. Therefore, we stratified 
the analysis for the replication cohort into two groups; pro re nata and treat-and-extend. 
These groups consisted of 215 pro re nata (Nijmegen and Cologne) and 47 treat-and-
extend (Montreal) patients respectively. Results are reported as odds ratios (OR), 95% 
confidence intervals (95% CI) and p value with statistical significance being defined as 
p <0.05 following Bonferroni correction for multiple testing. For the analyses, the statistical 
software Plink V1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/) and SPSS IBM SPSS 
Statistics for Windows, version 20.0 (IBM Corp., Armonk, New York, USA) were used. To 
prevent any possible confounding, the analyses performed in the both the Melbourne 
discovery and the replication cohort were corrected for baseline VA. 
Meta-analysis of the discovery and replication cohorts was performed using Metal 
software39. For 3 month meta-analysis all the patients from Melbourne discovery and the 
replication cohort were included because they all were treated with 3 initial doses of anti-
VEGF injections while for the 6 months analysis we considered the fact that the Melbourne 
discovery cohort was treated using a pro re nata strategy. Therefore, we included only the 
215 pro re nata treated patients from Nijmegen and Cologne and excluded the 47 patients 
from Montreal who were treated with a treat-and-extend regimen.
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Supplementary material
table s1			Analysis	of	the	influence	of	demographic	and	clinical	variables	on	the	change	in	VA	
after	3	and	6	month	of	anti-VEGF	treatment	in	the	Melbourne	discovery	cohort	and	
the	replication	Cohort
P-value calculated using a linear regression test for change in VA and non-genetic covariates, β: 
coefficient of the linear regression, CI: confidence Interval, SE: Standard Error, VA: Visual Acuity, CNV: 
Choroidal Neovascularization.
table s2			Design	of	DNA	pools,	pool	comparisons	and	meta-analysis	in	pooled	GWAS	in	the	
Melbourne	discovery	cohort	(1st	phase	of	study)
Different pool sizes lead to differences in pooling variance; thus pools were combined to have 
similar sizes (responders checked for association against non-responders). Mean age (at time of first 
treatment with anti-VEGF). SD=standard deviation. vs.=versus.
Melbourne Discovery Cohort Replication Cohort
3 Months  6 Months 3 Months  6 Months
Characteristics P-Value β (CI 95%) SE P-Value β (CI 95%) SE P-Value β (CI 95%) SE P-Value β (CI 95%) SE
Gender (Male vs 
Female)
0.86 -0.26 (-2.7-2.1) 
0.93
0.84 -0.311(-3.4- 
2.84)1.58
0.89 0.33 (-1.13 - 
4.78) 2.26
0.33 2.78 (-2.88 – 
8.45) 2.86
Age 0.27 -1.10 (-0.2-
0.05) 0.10
0.45 -0.07(-0.2- 
0.13)0.10
<0.01 -0.42 (-0.70 - 
-0.13) 0.14
0.06 -0.37 (-0.75 – 
0.11) 0.19
Baseline VA <0.001 -0.24 (-0.3 
-0.17) 0.03
<0.001 -0.32 (-0.32 
to -0.15)0.04
0.001 -0.21 (-0.33 - 
-0.09) 0.06
0.04 -0.18 (-0.35 –  
- 0.007) 0.09
Smoking 0.71 0.53 (-1.9-2.9) 
1.48
0.42 1.27(-1.84 
4.38) 1.58
0.33 2.21 (-2.29 - 
6.71) 2.28
0.37 2.61 (-3.14 – 
8.36) 2.90
Type of lesion 0.30 2.1 (-1.2-5.5) 
2.0
0.45 -1.74(-6.2 to 
2.78)2.2
0.63 1.23 (-3.87 – 
6.33) 2.58
0.50 -2.21 (-8.68 – 
4.27) 3.27
Size of CNV 0.91 0.18 (-2.8-3.2) 
1.83
0.53 -1.27(-5.2 to 
2.73)2.0
0.12 -0.48 (-1.08 – 
0.133) 0.31
0.08 -0.71 (-1.51 - 
0.09) 0.41
Number of 
injections
- - 0.25 -3.4(-5.9 to 
-1.9)0.71
- - - -
Pool ID 
(responder)
Presenting VA 
ETDRS Letters
Pool 
size
Male/Female n (%) Mean age ± 
SD (years)
Pool ID (non- 
responders)
Presenting VA 
ETDRS Letters
Pool 
size
Male/Female
N (%)
Mean age ± 
SD (years)
1 = 36 -69 133 48(17.0)/85(29.9) 78.9±6.3 VS 2 =36 -69 44 21(7.4)/23(8.0) 79.0±8.6
3 ≤ 35 46 23(8.0)/23(8.0) 79.9±7.0 4 ≤ 35 7 1(0.3)/6(2.1) 80.8±7.6
5 ≥ 70 46 19(6.6)/27(9.5) 79.8±7.7 6 ≥ 70 9 3(1.1)/6(2.1) 80.7±8.0
Meta-analysis of pool comparisons Responder/Non-responders
 1, 3,5 vs.  2,4,6 (225 individuals)/ (60 individuals)
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table s3			HaploReg	database	showing	variants	located	within	predicted	regulatory	regions	
and	in	LD	(r2	>	0.8)	with	rs4910623	(+/-	250Kb)
HaploReg http://www.broadinstitute.org/mammals/haploreg/haploreg.php
table s4			The	Ocular	Tissue	Database	shows	expression	of	the	OR52B4	gene	in	adult	human	
eye	tissues
1  Expression of genes in the Ocular Tissue Database (https://genome.uiowa.edu/otdb/) is 
represented as an Affymetrix Probe Logarithmic Intensity Error (PLIER) number. RPE: retinal pigment 
epithelium
table s5			Pooled	GWAS	association	of	previously	associated	known	AMD	risk	genes	with	
change	in	VA	at	6	month	of	anti-VEGF	treatment	in	Melbourne	discovery	cohort
+SNPs in high LD with rs11200638 (r2>0.8). *SNP in high LD with rs1061170 (r2=1)
Chr pos 
(hg19)
LD(r²) LD(D’) Variant Ref Alt EUR 
(freq)
Motifs Changed RefSeq Genes Functional 
Annotation 
11 4372783 0.87 0.96 rs4910613 A C 0.49 - 16kb 3’ of OR52B4 -
11 4377981 0.94 0.98 rs10835954 C T 0.5 Pou5f1 11kb 3’ of OR52B4 -
11 4387760 0.99 1 rs12293167 G T 0.5 5 altered motifs 731bp 3’ of OR52B4 -
11 4389587 1 1 rs7929171 G C 0.51 DMRT1,DMRT4,LUN-1 OR52B4 5’-UTR
11 4389639 1 1 rs4910623 G A 0.51 GATA,TCF4 22bp 5’ of OR52B4 -
11 4395551 0.91 -0.98 rs1895914 C T 0.51 Nkx2,Sox 5.9kb 5’ of OR52B4 -
11 4396029 0.92 -0.99 rs12575038 T C 0.51 TR4 6.4kb 5’ of OR52B4 -
11 4399936 0.88 -0.99 rs7124081 A C 0.52 CEBPB 6.2kb 3’ of TRIM21
Seq 
name
start stop strand Probe Id GENE 1PLEIR Score in different tissues of Eye
Choroid & 
RPE
Optic nerve Optic nerve 
head
Retina
chr11 4388614 4391330 - 3360136 OR52B4 17.3781 22.4866 22.9475 25.5724
GENE            SNP P-value
VEGF-A
rs699946 0.24
rs3025000 0.04
ARMS2
   rs10490924 0.85
HTRA1
rs2284665+ 0.09
rs932275+ 0.06
CFH
rs3753394       0.54
rs800292 0.33
rs1065489 0.23
rs7529589* 0.55
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Abstract
Importance: Visual acuity (VA) outcome differs considerably among neovascular age-related 
macular degeneration (nAMD) patients treated with anti-VEGF drugs. 
Objective: The purpose of this study was to identify genetic factors associated with variability 
in the response to anti-VEGF therapy for nAMD. Identification of pharmacogenetic associations 
may help to understand the mechanisms underlying this variability, as well as to pave the way 
for personalized treatment in nAMD.
Design: Cohort study.
Setting: Multicenter. 
Participants: 2,058 nAMD patients (678 were included in the discovery phase, and 1,380 in 
the replication phase).
Main Outcome(s) and Measure(s): VA change after the loading dose of three monthly anti-
VEGF injections.
Results: The mean age at baseline for all patients included in the study was 78 years (SD=7.4), 
and 58.8% of the patients were of female sex. The mean baseline VA was 51.3 Early Treatment 
Diabetic Retinopathy Study (ETDRS) letters (SD=20.3), and the mean change in VA after the 
loading dose of 3 monthly injections was a gain of 5.1 ETDRS letters (SD=13.9). Genome-
wide single variant analyses of common variants revealed five independent loci that reached 
a P-value<10-5. After replication and meta-analysis of the lead variants, rs12138564 located in 
the CCT3 gene remained nominally associated with a better treatment outcome (P=1.38x10-5, 
β=0.034, SE(β)=0.008). Genome-wide gene-based analyses of rare variants showed genome-
wide significant associations for the C10orf88 and UNC93B1 genes (P=4.22x10-7 and 
P=6.09x10-7, respectively), in both cases leading to a worse treatment outcome. Patients 
carrying rare variants in the C10orf88 gene lost a mean of 30.6 ETDRS letters after treatment, 
and patients carrying rare variants in UNC93B1 lost a mean 26.5 ETDRS letters after treatment.
Conclusions and relevance: Our results suggest that rare protein-altering variants in the 
C10orf88 and UNC93B1 genes are associated with worse response to anti-VEGF therapy for 
nAMD. There was a limited contribution of common genetic variants to variability in nAMD 
treatment response with a nominal association of rs12138564 in CCT3 with better treatment 
outcome. This study for the first time identified a role for rare genetic variation in treatment 
response of nAMD, which may be used to adapt treatment strategies to individual needs.
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Introduction
Advanced age-related macular degeneration (AMD) is a leading cause of blindness in 
the elderly1,2. The most vision-impairing type of advanced AMD is the neovascular form 
(nAMD), which is responsible for the majority of the visual acuity (VA) loss caused by this 
disease3. In nAMD, the proliferation of aberrant new blood vessels leads to severe scarring 
of the central retina4. Currently, the most effective treatment for nAMD is intravitreal 
injections of anti-vascular endothelial growth factor (VEGF) antibodies5,6. Although this 
treatment has resulted in dramatic improvements in VA for many nAMD patients, a high 
degree of variability in response to these drugs has been observed. In fact, around 10% 
of the nAMD patients show a decline in VA of at least 15 letters on the Early Treatment 
Diabetic Retinopathy Study (ETDRS) letter chart despite treatment5-7.
Early identification of patients with poor treatment response is a critical step in optimizing 
AMD treatment. Patients classified as non-responders based on an absence of VA 
improvement after anti-VEGF injections, may indeed have better outcomes with higher 
frequency of dosing along with regular monitoring8. Also, alternative therapies with the 
potential for longer action are currently being developed for nAMD9, and it is possible 
that other therapeutic options will become available for patients who do not achieve 
improvements in vision with current strategies. Therefore, establishing which factors are 
involved in treatment response variability could aid in the stratification of patients for the 
best treatment regime or therapeutic option10.
Several studies have shown that clinical and epidemiological factors associated with 
disease severity before treatment can influence the anti-VEGF treatment outcome11. 
Genetic factors have also been indicated to affect treatment outcome in nAMD patients, 
although contradictory results have been reported12. Anti-VEGF treatment seemed to be 
less effective in nAMD patients carrying the AMD risk variant rs1061170 (p.Y402H) in 
the CFH gene in a meta-analysis of 13 different studies13. In addition, other studies have 
reported pharmacogenetic associations with other AMD-associated variants, variants 
involved in the VEGF neovascularization pathway and variants in other genes12,14-31. 
However, pharmacogenetic analysis in randomized controlled trials such as the CATT and 
IVAN studies did not reveal any associations with genetic variants32-36.
The pharmacogenetic studies reported so far focus on a limited amount of variants or are 
limited in sample size and therefore statistical power12,14-33. Moreover, these studies have 
been restricted to the analysis of common variants. Rare variants, which may have stronger 
effects and can pinpoint underlying mechanisms by identifying the gene involved, have not 
yet been explored37,38. Consequently, larger and more comprehensive genetic studies are 
needed, targeting both common and rare variation in the genome.
Employing the resources of the International AMD Genomics Consortium (IAMDGC) and 
additional nAMD cohorts treated with anti-VEGF, we performed a multicenter genome-wide 
association study in order to: 1) evaluate in a hypothesis-free approach the association 
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of common genetic variants with VA treatment response to anti-VEGF therapy for nAMD, 
and 2) evaluate for the first time the cumulative effect of rare protein-altering variants on 
VA treatment response to anti-VEGF therapy for nAMD. Identification of pharmacogenetic 
associations is of great relevance in the AMD field, as they can help to identify underlying 
causal genes and thus mechanisms, suggest potential new drug targets, and can be used 
as robust biomarkers for precision medicine.
Methods
Study cohorts
Patients for both the discovery and replication cohorts of this study were recruited from 
multiple clinics, as detailed in Table 1. The discovery cohort included nAMD patients who 
were evaluated as part of the International AMD Genomics Consortium (IAMDGC) project39. 
All groups collected data according to Declaration of Helsinki principles. Study participants 
provided informed consent, and protocols were reviewed and approved by local ethics 
committees.
Inclusion criteria for all study center patients were defined as neovascularization secondary 
to AMD confirmed by fluorescein angiogram or optical coherence tomography, age greater 
or equal to 50 years, and a loading dose of three consecutive injections of bevacizumab 
(Hoffmann-La Roche, Basel, Switzerland) or ranzibizumab (Hoffmann-La Roche, Basel, 
Switzerland / Novartis Basel, Switzerland) therapy at monthly intervals (± two weeks). We 
excluded eyes with other retinal morbidities such as myopia greater than 8 diopters, ocular 
surgery during follow-up or in the two months prior to treatment, previous treatment for 
neovascular disease, macular hole, staphyloma, or a VA lower than 2.3 logMAR (0 ETDRS 
letters). Information about gender, age at first injection, as well as baseline VA before 
anti-VEGF treatment and after three monthly injections (± two weeks) was collected. VA 
was collected in ETDRS letters or Snellen and was transformed into logMAR for analysis. 
Influence of the variables age and baseline VA on the change in VA after 3 months was 
assessed including these variables in a general linear model.
Exome array genotyping and quality control
DNA samples from patients included in the discovery cohort were uniformly genotyped 
with a custom-modified HumanCoreExome array (Illumina) by the IAMDGC, at the 
Center for Inherited Disease Research (CIDR). Genotype quality control and imputation 
was performed by the IAMDGC, as has been previously detailed39. Imputation provided 
information on 28,930,739 variants. Principal components analysis (PCA) was performed 
and only European-descent individuals, based on the PCA, were included in the analysis. 
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Informative PCA eigenvalues were additionally used as covariates to adjust for population 
stratification. Identity-by-descent analysis was performed and samples with a relatedness 
score (PI-HAT)>0.25 were excluded.
Treatment outcome measurement
The outcome measure was a functional response defined as the change in visual acuity 
after treatment (ΔVA), which was defined as the initial VA before treatment subtracted 
from the final VA after three anti-VEGF injections. The logMAR VA values for the initial and 
final visual acuity distributions were evaluated for normal distribution amongst each study 
cohort, and outliers (defined as mean+3*standard deviation) were adapted to mean±2*SD. 
Genome-wide analyses of common variant
Variants with imputation quality score (R2) less than 0.6 and minor allele frequency (MAF)<0.05 
were excluded from the common variant analysis. Genome-wide single variant association 
analyses using the ΔVA as the testing variable were performed including the first two ancestry 
principal components (PC1, PC2), baseline VA and age at first injection as a covariates. 
Common variants (MAF≥0.05) were tested via a quantitative linear regression model (linear-
Wald testing) using the q.lm package in the EPACTS software (http://genome.sph.umich.
edu/wiki/EPACTS). In order to account for inter-cohort heterogeneity, the analyses were 
performed separately in the five discovery cohorts and covariate-adjusted estimates of the 
genetic effects were subsequently combined in a meta-analysis, which comprised a total of 
678 unrelated European descent nAMD patients. Meta-analysis was performed with METAL40 
based on effect size estimates, and standard errors per cohort. Genomic control was applied 
and if lambda was greater than 1, adjustments were made for the inflation factor per cohort. 
A threshold for suggestively associated variants from the discovery cohort was set at P=10-5. 
Final results were visualized using Manhattan and Q-Q plots generated with the R package 
qqman (https://cran.r-project.org/web/packages/qqman/index.html). Locus Zoom was 
used to visualize the LD structure block in each associated locus (http://locuszoom.org/)41.
Genotyping and association analyses in replication cohorts
The lead variants of the loci that reached the threshold for suggestive significance 
(P-value<10-5) were selected for genotyping in independent replication cohorts. These 
were rs241692 (chr3:60,410,187), rs12138564 (chr1:156,291,600), rs13002976 
(chr2:10,678,538), rs242939 (chr17:43,895,579), and rs2237435 (chr7:41,731,053).
Genotyping in the replication phase was performed using KASP technology (LGC Group, 
Middlesex, United Kingdom) and the MassARRAYiPlex technology (Agena Bioscience, San 
Diego, CA, USA. All variants fell within Hardy-Weinberg equilibrium measures.
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The association analysis in the replication cohort was performed with EPACTS in the 
same manner as the discovery cohort, except for the inclusion of PCA components as 
covariates. The results of all cohorts were combined in a meta analysis based on effect size 
estimates and standard errors. Subsequently, an overall meta-analysis of the discovery 
and replication phase was performed in the same manner (11 cohorts, n=2,058). Meta-
analyses were performed using the software METAL40.
Gene-based analysis of rare variants
We performed gene based analyses using the optimal unified sequence kernel association 
test, SKAT-O42, as implemented in EPACTS(http://genome.sph.umich.edu/wiki/EPACTS). 
When the majority of variants in a gene are associated with a trait and the effects are in the 
same direction, the burden test is most powerful, in contrast, SKAT is most powerful when 
most of the variants are not associated and the effects are in different directions. We used 
the SKAT-O test as it maximizes power compared to the traditional burden test and SKAT 
maintaining the power in both scenarios42. Rare and low frequency (MAF<0.05) protein-
altering variants (missense, nonsense or affecting canonical splice sites) were included in 
the analysis. Imputed variants were only included if imputation quality (R2) was ≥0.8. As in 
the single variant analysis for common variants, only non-related individuals of European 
descent were included in the analysis. Association tests were adjusted for age, baseline 
VA and the first two ancestry principal components, and a sensitivity analysis adjusting for 
ten ancestry principal components was additionally performed. The summary statistics for 
each single variant were extracted from a comparable single variant analysis using EPACTS 
(http://genome.sph.umich.edu/wiki/EPACTS).
Results
Characteristics of the study cohorts
We collected demographic and VA treatment response information for 2,058 nAMD 
patients who received anti-VEGF therapy. In the discovery phase, 678 patients of five 
different cohorts were genotyped with exome arrays by the IAMDGC39 and used for 
genome-wide association analyses on common and rare variants. In the replication phase, 
1,380 individuals from six different cohorts were genotyped for common variants identified 
in the discovery study.
Demographics and clinical parameters of the study cohorts are described in Table 1. The 
mean change in VA after the loading dose of 3 monthly injections for all patients included 
in the study was 0.101 logMAR (logarithm of the minimum angle of resolution), which 
corresponded to a gain of 5.1 ETDRS letters, and varied per cohort (Table 1). Age and visual 
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acuity at baseline have been the factors most consistently described as influencing change 
in VA after anti-VEGF treatment43-46. This was also true for the total patient population 
and in the majority of the individual cohorts (eTable 1). Therefore, these variables were 
included as covariates in all our subsequent analyses.
Genome-wide association analyses of common variants identify 
a nominal association of rs12138564 in the CCT3 gene with better 
response to anti-VEGF therapy in nAMD
In the discovery phase, we performed genome-wide single-variant association analyses on 
the change in VA after 3 monthly anti-VEGF injections. Linear regression models adjusted 
for age, baseline VA and the first two ancestry principal components were conducted on 
6,089,769 quality-controlled common variants (minor allele frequency, MAF≥0.05).
We identified a total of 111 variants that reached a suggestive significance level 
(P-value<10-5) (Figure 1A). The overall genomic inflation factor was very low (λ = 1.01), 
implying no confounding effect of the population’s genetic structure on the association 
analyses (eFigure 1). Consecutive conditional analysis revealed that these variants 
were distributed across five different loci, for which the lead variants were rs12138564, 
rs13002976, rs241692, rs2237435 and rs242939. The results for these variants are 
described in Table 2, and the details of the associations per cohort are presented in 
eTable 2.
In the replication phase, the lead variants of the five associated loci were analyzed in six 
independent anti-VEGF treated nAMD patient cohorts, which comprised a total of 1,380 
patients. SNP rs12138564 on chromosome 1 was nominally associated with functional 
treatment response in the replication phase, showing the same direction of effect as in 
the discovery phase (P
replication
=0.029, β=0.019, SE(β)=0.009) (Table 2). This association 
was mainly driven by the cohort of St. James’s University Hospital, Leeds (P
Leeds
=0.028, 
β=0.044, SE(β)=0.020) as no association was observed for this variant in any of the other 
five replication cohorts (eTable 2). The other four lead variants did not show an association 
in the replication phase.
The results of the discovery and replication phase were combined in an overall meta-
analysis of eleven cohorts, including 2,058 nAMD patients (Table 2, eTable 2). The 
association of SNP rs12138564 with functional treatment response remained nominally 
significant, showing a positive effect of the minor allele on treatment outcome 
(P
meta
=1.38x10-5, β=0.034, SE(β)=0.008) (Table 2, eTable 2). SNP rs12138564 is located in 
intron 8 of the Chaperonin Containing TCP1 Subunit 3 (CCT3) gene (Figure 1B). The other 
four lead variants did not replicate and their association was lost after the meta-analysis of 
the discovery and replication cohorts (Table 2, eTable 2).
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figure 1			Single-variant	association	analyses	of	common	variants	on	response	to	anti-VEGF	
therapy	in	neovascular	AMD
A) Genome-wide single-variant association analysis for common variants in a discovery cohort of 678 
nAMD patients identified five loci reaching suggestive significance. The Manhattan plot illustrates 
the -log(P-values) of each individual SNP tested for association. The horizontal blue line indicates 
the threshold considered for suggestive significance (P-value<10-5). B) Locus track plot showing a 
detailed view of the chromosome 1 locus with rs12138564 in the CCT3 gene as the lead SNP shown 
with a purple rhombus. The linkage disequilibrium (LD) structure of the area was constructed 
with this SNP as reference. C) Change in VA after 3 months of anti-VEGF treatment stratified by 
rs12138564 genotype in the discovery and replication cohorts. The homozygous genotype for the 
reference allele (GG) showed a mean improvement in VA of 0.079 logMAR or approximately 4 ETDRS 
letters, whereas the heterozygous GT group showed a mean improvement in VA of 0.118 LogMAR 
or approximately 6 ETDRS letters (P=8x10-3), and the homozygous TT group an improvement 0.150 
logMAR or approximately 7.5 ETDRS letters (P=2x10-3).
VA = visual acuity, logMAR = logarithm of the minimum angle of resolution.
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figure 2			Gene-based	analysis	of	rare	variants	on	response	to	anti-VEGF	therapy	in	
neovascular	AMD
A) Manhattan plot illustrating the -log(P-values) of each gene analyzed in the SKAT-O 
gene-based test of rare variants. The red line indicates the genome-wide significance level 
(P<3.38x10-6=0.05/14,788). A genome-wide significant burden of rare protein-altering variants in the 
C10orf88 and UNC93B1 genes was associated with worse response to anti-VEGF therapy.  
B) Change in VA after 3 months of anti-VEGF treatment stratified by non-carriers of rare variants and 
carriers of rare variants in C10orf88 and UNC93B1. Horizontal lines indicate the mean change in VA 
after 3 months of anti-VEGF treatment per group. Carriers of rare variants in C10orf88 who did not 
carry rare variants in UNC93B1 were included in the SKAT-O test of UNC93B1 as non-carriers and vice 
versa. Non-carriers gained on average 0.109 logMAR or 5.5 ETDRS letters of VA after treatment, while 
carriers of rare variants in C10orf88 lost 0.609 logMAR or 30.6 ETDRS letters and carriers of rare 
variants in UNC93B1 lost 0.529 logMAR or 26.5 ETDRS letters on average.
VA = visual acuity, logMAR = logarithm of the minimum angle of resolution.
 
Next, we analyzed the genotypic effects of SNP rs12138564 on change in VA in the 
discovery and replication cohorts combined. The heterozygous GT genotype group 
showed an increased improvement in VA after anti-VEGF treatment compared to the 
reference GG genotype group (P=8x10-3), and the homozygous TT group showed the 
largest improvement (P=2x10-3). The homozygous genotype for the reference allele (GG) 
showed a mean improvement in VA of 0.079 logMAR or approximately 4 ETDRS letters, 
whereas the heterozygous GT group showed a mean improvement in VA of 0.118 LogMAR 
or approximately 6 ETDRS letters, and the homozygous TT group an improvement 0.150 
logMAR or approximately 7.5 ETDRS letters (Figure 1C).
Additionally, variants shown to be associated with treatment response in previous 
studies12,14-31 were extracted from the GWAS results. No variants reached genome-wide 
significance, nor were they suggestively associated (P-value<0.05/18=0.003) with 
functional treatment response in this study (eTable 3). We also determined whether 
the 52 AMD-associated variants reported by the largest AMD case-control GWAS study 
performed so far39 were associated with functional treatment outcome. Out of the 52 
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AMD-associated variants, 47 were present in one or more of our study cohorts but none 
of these were found to be associated with VA response at either suggestive significance 
(P-value<0.05/47=0.001) nor at the genome-wide significance level (eTable 4).
Gene-based analysis identifies a burden of rare variants in the 
C10Orf88 and UNC93B1 genes associated with worse response to 
anti-VEGF therapy in nAMD
Using the rare variation content of the IAMDGC exome array, we analyzed the cumulative 
effect of rare protein-altering variants on nAMD functional treatment response. The analysis 
was performed on the 678 patients of European descent genotyped with exome arrays. 
We performed SKAT-O42 gene-based tests of quality controlled variants with a MAF<0.05. 
A total of 58,414 protein-altering variants classified as missense (leading to an amino 
acid change), nonsense (introducing a stop codon) or affecting canonical splice sites were 
included in the analysis. These variants were distributed in a total of 14,788 genes. The 
association analyses were adjusted for age, baseline VA and the first two ancestry principal 
components.
We identified two genes associated with VA treatment response at a genome-wide 
significance level (P-value<3.38x10-6=0.05/14,788): chromosome 10 open reading frame 
88 (C10orf88, P=4.22x10-7) and unc-93 homolog B1 (UNC93B1, P=6.09x10-7) (Table 3, 
Figure 2A). Sensitivity analysis was carried out adjusting for eight additional ancestry 
principal components, and yielded comparable results (C10orf88, P=2.24x10-7; UNC93B1, 
P=1.65x10-7). Patients who did not carry a rare variant in either C10orf88 or UNC93B1 
gained on average 0.109 logMAR or 5.5 ETDRS letters of VA after treatment. In contrast, the 
mean change in VA after treatment for the carriers of rare variants in C10orf88 was a loss 
of 0.609 logMAR or 30.6 ETDRS letters. The carriers of rare variants in UNC93B1 showed 
a substantial decrease in VA after treatment as well, losing 0.529 logMAR or 26.5 ETDRS 
letters on average (Figure 2B).
table 3			Gene-based	analysis	of	rare	variants	on	response	to	anti-VEGF	therapy	in	neovascular	
AMD
Gene Chromosome Chromosomal positiona N rare variants RAC P-value
C10orf88 10 124,692,082 – 124,712,511 3 7 4.22x10-7
UNC93B1 11 67,765,163 – 67,770,499 2 14 6.09x10-7
N = number, RAC = rare allele count
aChromosome and chromosomal position according to the NCBI RefSeq hg19 human genome 
reference assembly. 
 
All variants included in the burden tests for these two genes had a high imputation quality 
score (R2) of 1. For C10orf88, three rare protein-altering variants were included in the 
test; two of them leading to an amino acid change (c.412G>A; p.Glu138Lys and c.827T>C; 
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p.Ile276Thr) and one variant introducing a stop codon (c.1258C>T; p.Gln420*). The 
p.Glu138Lys and p.Ile276Thr variants individually showed a nominal association with worse 
response to treatment (P=4.96x10-4 and P=2.33x10-5, respectively). The variant p.Gln420* 
was present in only one individual and did not show an association at the single variant level 
(P=0.120). The variants p.Glu138Lys and p.Gln420* had a CADD score >20, which indicates 
that they are among the 1% most deleterious substitutions in the genome (eTable 5).
Two variants contributed to the burden of the UNC93B1 gene, both leading to an amino 
acid change (c.385C>A; p.Leu129Ile and c.626C>T; p.Pro209Leu). Both variants individually 
showed a nominal association with worse response to treatment (P=3.33x10-7 for 
p.Leu129Ile and P=4.21x10-7 for p.Pro209Leu), and had an assigned CADD score >20 (eTable 
5). These two variants are in high linkage disequilibrium (r2~_1), and were simultaneously 
present in 7 individuals, all belonging to the Hadassah-Hebrew University Medical Center 
cohort from Jerusalem.
Finally, we extracted the results of the genes in which a burden of rare variation has been 
shown in AMD (CFH, CFI, TIMP3 and SLC16A8) from the gene-based analysis39. A suggestive 
association (P-value<0.05/4=0.013) was found for SLC16A8 (P=0.007) (eTable 6); while 
none of the genes reached the genome-wide significance level.
Discussion
We have undertaken the largest multicenter pharmacogenetic cohort study of nAMD 
patients reported so far, and performed for the first time both a genome-wide single variant 
analysis for common variants and a gene-based analysis for the cumulative effect of rare 
variants.
We evaluated the role of genetic variation on primary functional response: change in VA 
after the loading dose of three monthly injections. We aimed to understand the genetic 
component of the variability in functional response because VA is the most relevant outcome 
measure for patients as it directly influences their quality of life47. Whether our findings on 
the functional response can be related to an anatomical response, commonly defined as 
the change in central macular thickness or retinal fluid clearance as measured by optical 
coherence tomography, remains to be further investigated48. We chose the time interval of 
3 months, as three loading injections are administered widely in contrast to the follow-up 
treatment, which is variable per clinic and will impact on VA outcomes49. The majority of 
patients show the most improvement in their VA after the three first monthly injections5, 
and this time interval can thus be predictive of a longer-term response15. Moreover, long-
term treatment response, is likely to be affected by non-adherence to treatment protocols. 
As there is no consensus in the definition of a functional non-response, we analyzed the 
trait in a continuous manner. This type of exploratory analysis represents the full spectrum 
of the patient population and may facilitate comparison and interpretation of study results. 
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We investigated the treatment response to bevacizumab or ranzibizumab therapy in a 
combined analysis. The CATT50,51 and IVAN52,53 clinical trials have demonstrated similar 
outcomes after bevacizumab treatment compared to those after ranibizumab treatment, 
and therefore the factors underlying the treatment response variability may be similar. 
In order to increase our statistical power, we combined results from both treatments in a 
unique analysis.
The heritability of treatment response to anti-VEGF in nAMD is unknown and difficult 
to estimate with our sample size. Nevertheless, our study had 80% power to detect 
common variants of moderate effects, explaining at least 6.2% of the variance in 
treatment response54. However, no single-variant associations were found at genome-wide 
significance level, suggesting a limited effect of individual common variants on treatment 
outcome.
Our genome-wide single variant association analysis of common variants identified the 
variant rs12138564, located in intron 8 of the CCT3 gene, to be nominally associated with 
treatment response after replication analysis, and therefore, this variant may merit further 
investigation in alternative cohorts. 
We did not find any of the previously reported variants12,14-31 to be associated with functional 
response at a genome-wide level nor at suggestive significance level (P-value<0.003). 
This may be due to differences between the studies in response definition and patient 
population in terms of disease stage and other environmental factors, or due to spurious 
findings. However, our results support the notion that none of the previously identified 
genetic markers, individually, are strong determinants of overall functional treatment 
response. Furthermore, we also did not find a genome-wide nor a suggestive association 
(P-value <0.001) for any of the 52 AMD-associated variants reported in the largest AMD 
GWAS performed so far39.
The rare variant burden test revealed two genes associated with primary functional 
response at a genome-wide level: C10orf88 and UNC93B1. The function of C10orf88 is 
still uncharacterized and therefore the biological link to treatment response in nAMD is 
unclear. It has been suggested that common variants in C10orf88 are associated with 
vitamin D levels, although it cannot be excluded that the effect might be driven by the 
neighbouring gene ACADSB (acyl-Coenzyme A dehydrogenase)55. Additionally, C10orf88 
is expressed at low levels in the retina and RPE/choroid56. UNC93B1 is involved in the 
innate and adaptive immune response by regulating toll-like receptor (TLR) signaling57,58. 
Regulation of the TLR and their subsequent signaling pathways has been found to be 
associated with AMD in apoptotic response59, as well as with activation of microglia 
leading to retinal inflammation60. TLRs are found on retinal and choroidal vasculature61, 
and interact with CD46, known to be associated with regulation of the complement immune 
system. Dysregulation in TLR signaling and the complement system may contribute to the 
pathogenesis of AMD62-64. Therefore, the identification of rare genetic variation in UNC93B 
in our study may point towards an immune component in treatment response in AMD. Of 
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note, the UNC93B variants driving the effect in the SKAT-O test were only found in patients 
belonging to the Jerusalem cohort. This is in line with the higher allele frequency found for 
the Jewish population as compared to the non-Finish European population in the Ashkenazi 
Genome Consortium and ExAC databases65,66, and therefore, this finding may be related to 
the genetic nature of that specific population.
Carriers of rare variants in the C10orf88 and UNC93B genes lost on average 6 and 5 lines 
of vision in the ETDRS letter chart respectively. The effect of rare variants in VA outcome 
after treatment was thus very large, making these findings potentially relevant for the 
clinical practice67. Interestingly, when analyzing the genes with a burden of rare variants 
associated with AMD39, we found a suggestive association (P-value<0.013) with functional 
treatment outcome for the gene SLC16A8.
Conclusions
Our multicenter GWAS suggests that the variability in primary functional treatment 
outcome in nAMD is probably not explained by large effects of individual common variants. 
We identified a common variant in the CCT3 gene nominally associated with functional 
primary response to anti-VEGF therapy for nAMD. However, rare genetic variants seem to 
have large effects on treatment outcome, as a burden of rare protein-altering variants in 
the C10orf88 and UNC93B1 genes was associated with worse VA treatment response. This 
suggests that rare genetic variants might be used as biomarkers for VA response in nAMD, 
and may allow patients to be stratified for different regimen doses or therapies. 
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etable 5			Rare	protein-altering	variants	in	C10orf88	and	UNC93B1	included	in	the	gene-based	
analysis	
Gene Varianta Protein change Imputation 
quality (R2)
CADD scoreb RAC Single vari-
ant P-value
β (SE)
C10orf88
 
c.412G>A p.Glu138Lys 1 24.6 3 4.96x10-4 -0.618 (0.177)
c.827T>C p.Ile276Thr 1 0.038 3 2.33x10-5 -0.749 (0.176)
c.1258C>T p.Gln420* 1 38 1 0.120 <0
UNC93B1 c.385C>A p.Leu129Ile 1 24.9 7 3.33x10-7 -0.606 (0.118)
c.626C>T p.Pro209Leu 1 25.6 7 4.21x10-7 -0.596 (0.117)
RAC = Rare allele count, SE = Standard error
a   Positions according to the NCBI RefSeq hg19 human genome reference assembly. 
b   The CADD score refers to the PHRED-like scaled C-score for which ≥20 indicates that the variant is 
predicted to be in the 1% most deleterious substitutions in the human genome.
etable 6		Gene-based	analysis	of	rare	variants	in	genes	previously	associated	with	AMD
Gene Chromosome Chromosomal positiona N rare variants RAC P-value
CFH 1 196,621,252-196,716,375 14 40 0.541
CFI 4 110,662,068-110,723,117 10 26 0.026
TIMP3 22 33,198,100-33,255,356 2 4 0.163
SLC16A8 22 38,474,406-38,478,804 5 21 0.007
N = number, RAC = rare allele count
a  Chromosome and chromosomal position according to the NCBI RefSeq hg19 human
efigure 1		Q-Q	plot	of	the	single-variant	association	analysis	of	response	to	anti-VEGF	therapy	
in	neovascular	AMD
Shown as black dots are the observed P-values (-log
10
(p)) compared to those expected under the null 
hypothesis.
In the meta-analysis, adjustment for the inflation factor of the different cohorts was conducted 
when λ>1 (University Hospital of Cologne cohort λ=1.020, Hadassah-Hebrew UMC cohort λ=0.99, 
Radboud umc cohort λ=1.001, Centre for Eye Research Australia cohort λ=1.005 and Centre for 
Vision Research cohort λ=1.005).
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Abstract
Purpose: To identify genetic variants associated with complement activation, which could 
help to select age-related macular degeneration (AMD) patients for complement inhibiting 
therapies.
Design: Genome-wide association study (GWAS) followed by replication and meta-analysis.
Participants: 2,245 AMD patients and controls.
Methods: A GWAS on serum C3d/C3 levels was performed in 1,548 AMD patients and 
controls. After genotype imputation and quality control, 9,972,920 variants were included in 
the analysis. For replication and meta-analysis, 697 additional individuals were genotyped 
for the lead SNPs in the associated signals. A model for complement activation including 
the identified genetic and non-genetic factors was built, and the variance explained was 
estimated. Haplotype analysis was performed for eight SNPs across the CFH/CFHR locus. 
Association with AMD was performed for the variants and haplotypes found to influence 
complement activation. 
Main Outcome Measure: Normalized C3d/C3 levels as a measure of systemic complement 
activation.
Results: Associations with complement activation were identified at the CFH/CFHR locus. 
Complement activation was independently associated with rs3753396 located in CFH 
(P
discovery
=1.09x10-15, P
meta
=3.66x10-21, β=0.141, SE=0.015) and rs6685931 located in CFHR4 
(P
discovery
=8.18x10-7, P
meta
=6.32x10-8, β=0.054, SE=0.010). A model including age, AMD 
disease status, body mass index, triglycerides, rs3753396, rs6685931, and previously 
identified SNPs, explained 18.7% of the variability in complement activation. Haplotype 
analysis revealed three haplotypes (H1-2 and H6 containing rs6685931, and H3 containing 
rs3753396) associated with complement activation. Haplotypes H3 and H6 conferred 
stronger effects on complement activation compared to the single variants (P=2.53x10-14, 
β=0.183, SE=0.024 and P=4.28x10-4, β=0.144, SE=0.041 respectively). Association 
analyses with AMD revealed that SNP rs6685931 and haplotype H1-2 containing rs6685931 
associated with a risk for AMD development, while SNP rs3753396 and haplotypes H3 and 
H6 were not associated with AMD.
Conclusions: SNP rs3753396 in CFH and SNP rs6685931 in CFHR4 are associated with 
systemic complement activation levels. The stronger effects of haplotypes H3 and H6 on 
complement activation suggest that other variants at the CFH/CFHR locus also influence 
this trait. SNP rs6685931 in CFHR4, and its linked haplotype H1-2, conferred also a risk for 
AMD development, and therefore could be used to identify AMD patients that would benefit 
most from complement inhibiting therapies.
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 Background
The complement system is an integral part of our innate immunity. Its best known 
physiological functions are host defense against foreign intruders and homeostasis 
maintenance.1 It consists of more than 30 plasma proteins and cellular components that 
interact in proteolytic cascades for an efficient and rapid activation leading to inflammation, 
opsonization and targeted cytolysis.2
The complement system can be activated by three different pathways: the classical 
pathway (CP), the lectin pathway (LP) and the alternative pathway (AP). The CP is activated 
by antibody-antigen complexes and the LP by lectin or ficolin binding to carbohydrates, 
both on the surfaces of pathogens. In contrast, the AP is constitutively activated at a low 
level in a process known as tick-over.3
All three pathways lead to the formation of C3 convertases that catalyze a proteolytic 
cleavage of complement component 3 (C3) into the potent anaphylatoxin C3a, and C3b, an 
opsonization molecule that can be further cleaved into C3d. C3b can also bind the cleaved 
form of factor B (FB, Bb) to form the AP C3 convertase (C3bBb) that will cleave more C3, 
initiating an amplification loop. Downstream in the cascade C5 convertases are formed, 
initiating the terminal pathway with the subsequent formation of additional activation 
products as well as the membrane-attack complex (MAC) that is responsible for cytolysis.4
The complement system can be rapidly amplified and therefore several inhibitory proteins 
such as complement factor H (FH) and complement factor I (FI) are in place regulating 
complement activity.4
Deregulation and deficiencies of the complement system have been reported to be 
associated with numerous inflammatory, autoimmune, neurodegenerative and infectious 
disorders.5 A prime example of a multifactorial disease associated with a deregulation of 
the complement system is age-related macular degeneration (AMD). AMD is characterized 
by a progressive degeneration of the central retina, and is responsible for the majority of 
vision loss in the elderly with a pooled prevalence of 8.9 %.6,7 AMD entails a major health 
problem as in 2020, the number of people affected by a form of this disease is projected at 
196 million, raising to 288 million in 2040.8 Several lines of evidence point towards an over-
activation of the complement system in AMD, mainly through a dysregulation of the AP. 
Multiple genetic variants in or near complement genes (CFH, C3, CFI, C2/CFB locus and C9) 
have been strongly associated with AMD.9,10 Moreover, complement components have been 
described in drusen, the hallmark of the disease,11-14 and complement activation fragments 
in plasma/serum such as Ba, C3a, C3d and C5a have been found to be significantly elevated 
in AMD patients compared to controls.15-21 Currently, there is no treatment available for the 
majority of AMD cases, nor is there an effective means to halt AMD progression. Therefore, 
therapies for AMD, as well as for other diseases involving complement deregulation, are 
being developed aiming to inhibit or lower complement activation.22-24
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Systemic complement activation levels demonstrate considerable variation among 
individuals.16-20 As a consequence, patients who have higher levels of complement activation 
may benefit more than others from the upcoming therapies. A better understanding 
of the factors that influence complement activation would facilitate the selection of the 
most suitable patients for complement inhibiting therapies. Genetic markers are robust 
biomarkers that could be included in prediction models for complement activation. 
Several studies have previously evaluated the effect of genetic variation on complement 
activity; however, these studies were restricted to a limited number of single nucleotide 
polymorphisms (SNPs).16-19,21,25
The aim of this study was to perform the first genome-wide association study (GWAS) 
on systemic complement activation levels. Identification of genetic variants explaining 
complement activation levels will contribute to a better understanding of the molecular 
mechanisms of complement related diseases, will pinpoint potential drug targets, and will 
facilitate the selection of patients for complement inhibiting therapies. 
Results
Characteristics of the study cohorts
We evaluated the association of genetic variants with systemic complement activation 
levels through a GWAS in a discovery cohort of 1,548 individuals, followed by replication in 
an independent cohort of 697 individuals. For both cohorts, demographics and information 
about AMD disease status, body mass index (BMI), triglycerides and high-density 
lipoprotein (HDL)-cholesterol was collected (Table 1).
table 1		Demographics	and	other	characteristics	of	the	discovery	and	replication	cohorts
Discovery cohort (n=1,548) Replication cohort (n=697)
Complement activation ln(c3d/c3), mean (SD) 1.459 (0.407) 1.464 (0.398)
Age, mean (SD) 73.2 (7.8) 73.3 (7.7)
Sex (female), % 60 58.8
AMD disease status (control), (%) 53.7 37.4
BMI kg/m2, median (quartiles) 25 (23 – 28) 25 (23 – 28)
Triglycerides mmol/l, median (quartiles) 1.620 (1.170 - 2.220) 1.620 (1.165 - 2.210)
HDL cholesterol mmol/l, mean (SD) 1.489 (0.377) 1.478 (0.403)
Clinic (Radboud university medical center), % 53.5 63
BMI=Body mass index, HDL=High-density lipoprotein, SD=standard deviation.
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table 2			General	linear	model	for	systemic	complement	activation	levels	including	
environmental	factors
 β SE (β) P-value R2
Age (years) 0.003 0.001 0.002 0.010
Sex (female) -0.025 0.018 0.155 0
Disease status (AMD) 0.074 0.017 6.700x10-5 0.013
BMI (kg/m2) -0.012 0.002 8.635x10-8 0.034
Triglycerides (mmol/l) -0.130 0.010 5.723x10-39 0.101
HDL cholesterol (mmol/l) 0.015 0.026 0.545 0.024
Clinic (University Hospital of Cologne) -0.064 0.016 6.800x10-5 0.005
BMI=Body mass index, HDL=High-density lipoprotein, SE=standard error. 
R2=0.141 (adjusted R2=0.138).
 
Higher complement activation levels were associated independently with older age, 
AMD disease status, lower BMI and lower triglycerides levels as previously described.21,26 
Differences were also observed between the sample collection clinics (Table 2, available 
at www.aaojournal.org). Therefore, these factors were included as covariates in all 
consecutive analyses.
GWAS identifies two independent signals at the CFH/CFHR locus to 
be associated with systemic complement activation
We carried out a GWAS of normalized C3d/C3 levels as a measure of systemic complement 
activation. Following quality control, a total of 1,548 individuals and 9,972,920 variants 
were included in the analysis. The study had >80% of power to detect common variants 
(minor allele frequency ≥5%) explaining ≥2.6% of variance in complement activation levels.
A total of 280 variants reached genome-wide significance (Manhattan plot Fig. 1a, QQplot 
Fig. 2 (available at www.aaojournal.org), λ
GC
=0.999). All variants, except for one, were 
located on chromosome 1 at the CFH/CFHR locus (chr1:196.643.724-197.061.086). The 
only variant outside of this locus was located on chromosome 6 near the PSORS1C1 gene, 
but could not be verified by Sanger sequencing. SNP rs3753396 (c.2016A>G, p.Gln672Gln) 
located in exon 14 of the complement factor H (CFH) gene showed the strongest association 
with complement activation levels (P=1.09x10-15, β=0.145, SE=0.018, Table 3, locus zoom 
depicted in Fig. 1b).
Conditional analysis on the lead SNP revealed a second independent signal with a P 
value close to genome-wide significance for which the strongest associated variant was 
rs6685931. This SNP was also located at the CFH/CFHR locus, specifically in intron 1 (c.59-
4315T>C) of the complement factor H related 4 (CFHR4) gene (P=8.18x10-7, β=0.068, 
SE=0.014, Table 3, locus zoom depicted in Fig. 1c).
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figure 1		GWAS	identifies	two	independent	signals	at	the	CFH/CFHR	locus	associated	with	
systemic	complement	activation	levels
(A) Manhattan plot illustrating the P-values of each individual SNP tested for association with systemic 
complement activation. The red horizontal line indicates the threshold considered for genome-wide 
significance (P=5x10-8). (B) Locus zoom plot showing a detailed view of the chromosome 1 signal. 
The lead SNP rs3753396, is located in the CFH gene. SNPs are colored based on their LD estimate (r2) 
to the lead SNP. (C) Locus zoom plot showing a detailed view of the signal on chromosome 1 after 
conditioning the association analysis for rs3753396. Here, the lead SNP rs6685931, is located in the 
CFHR4 gene. SNPs are colored based on their LD estimate (r2) to the lead SNP.
Variants shown to be associated with complement activation fragments in previous studies 
were extracted from the GWAS results.17,18 SNP rs800292 in CFH, and the two SNPs in 
linkage disequilibrium rs4151667 in CFB and rs9332739 in C2 were nominally associated 
with systemic complement activation levels in the current study, showing the same 
direction of the effect. SNP rs2230199 in C3 and SNP rs10490924 in ARMS2 could not be 
replicated (Table 4, available at www.aaojournal.org).
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figure 2		Q-Q	plot	of	the	GWAS	on	systemic	complement	activation	levels	
Shown as black dots are the observed P-values (-log
10
(P)). Lack of population stratification was 
confirmed by a genomic inflation factor (λ) for the trend of 0.999.
Replication in an independent cohort confirms the effect of 
rs3753396 in CFH and rs6685931 in CFHR4 on systemic complement 
activation
Replication analysis of rs3753396 in CFH and rs6685931 in CFHR4 in an independent 
cohort of 697 study participants confirmed both variants to be significantly associated 
with systemic complement activation levels (rs3753396: P=1.39x10-6, β=0.131, SE=0.027, 
rs6685931: P= 8.62x10-3, β= 0.038, SE=0.014, Table 3). Subsequent meta-analysis showed 
associations for both rs3753396 (P=3.66x10-21, β=0.141, SE=0.015) and rs6685931 
(P=6.32x10-8, β=0.054, SE=0.010), confirming that two independent signals at the CFH/
CFHR locus are associated with higher complement activation levels (Table 3). Sensitivity 
analyses adjusting for AMD disease status showed comparable results (Table 5, available 
at www.aaojournal.org), and neither an interaction between clinic and the identified SNPs 
(P
rs3753396 x clinic
=0.436, P
rs6685931
 
x clinic
=0.676), nor an interaction between AMD status and the 
identified SNPs (P
rs3753396 x AMD
 status=0.557, P
rs6685931 x AMD
 status=0.658) was detected.
Next, mean complement activation levels in the genotype groups of rs373396 and 
rs6685931 were analyzed. For rs3753396 in CFH, the heterozygous AG genotype group 
showed higher complement activation levels compared to the reference AA genotype 
group (P=6.23x10-18, β=0.152, SE=0.018), and for the homozygous GG group these levels 
were even higher (P=2.39x10-7, β=0.267, SE=0.052, Fig. 3a). In the case of rs6685931 in 
CFHR4, a similar effect was observed: the heterozygous TC genotype group had higher 
complement activation levels than the reference TT genotype (P=10-3, β=0.063, SE=0.019) 
and for the homozygous CC group the levels were even higher (P=3.62x10-7, β=0.118, 
SE=0.023, Fig. 3b). Analysis of the cumulative effect of both SNPs showed that the main 
effect on systemic complement activation levels is driven by rs3753396 in CFH, and 
rs6685931 in CFHR4 introduces additional variation to the rs3753396 genotypes (Fig. 3c).
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figure 3			Systemic	complement	activation	levels	stratified	by	rs3753396	and	rs6685931	
genotypes:	rs6685931	introduces	additional	variation	on	the	main	effect	of	rs3753396
The Y axes represent the ln-transformed C3d/C3 as a measure of systemic complement activation. 
Horizontal bars indicate the mean values for each genotype group. The complement-raising alleles for 
both SNPs are indicated in red. Association analyses included the 2,245 individuals from the discovery 
and the replication cohorts. (A) Distribution of complement activation levels for each genotype of 
rs3753396 in CFH. (B) Distribution of complement activation levels for each genotype of rs6685931 in 
CFHR4. P-values were calculated adjusting the model for rs3753396. (C) Distribution of complement 
activation levels over the genotype combinations of rs3753396 in CFH and rs6685931 in CFHR4.
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A model of genetic and non-genetic variables explains 18.7% of the 
variability in complement activation
General linear models were built in order to determine how much of the variation could be 
explained by factors found to be associated with systemic complement activation. 
A model including only non-genetic factors (age, AMD disease status, BMI and triglycerides) 
explained 12.6% of the variability in systemic complement activation. With the addition of 
SNP rs3753396 to the model, 16.3% of the variability could be explained, and by including 
SNP rs6685931, a total of 17.3% was explained. We additionally incorporated SNPs 
associated with complement activation fragments in a previous study that replicated in our 
GWAS: rs800292 in CFH and rs9332739 in C2.18 Only rs9332739 remained independently 
associated with systemic complement activation levels, and the variance explained by the 
model rose to 18.7% (adjusted R2, Table 6).
table 6			A	model	of	genetic	and	non-genetic	variables	explains	18.7%	of	the	variability	in	
systemic	complement	activation
β SE (β) P-value
CFH rs3753396                          AG 0.196 0.023 8.772x10-17
GG 0.330 0.066 6.461x10-7
CFHR4 rs6685931                             TC 0.070 0.024 0.003
CC 0.125 0.033 1.620x10-4
CFH rs800292                             GA -0.011 0.023 0.639
AA 0.027 0.046 0.555
C2 rs9332739                             GC -0.185 0.034 4.674x10-8
CC 0.168 0.213 0.431
Age (years) 0.004 0.001 0.005
Disease status (AMD) 0.035 0.020 0.089
BMI (kg/m2) -0.012 0.003 2x10-6
Triglycerides (mmol/l) -0.131 0.011 1.177x10-33
BMI=Body mass index, SE= Standard error.
R2=0.193 (adjusted R2=0.187). The model included the 1,548 individuals of the discovery phase.
Haplotypes across the CFH/CFHR locus have stronger effects on 
systemic complement activation levels compared to individual 
variants
In order to assess whether more variants at the CFH/CFHR locus influence systemic 
complement activation, and to determine the cumulative effect of several variants on the 
same haplotype, we evaluated the effect of distinct haplotypes across the CFH/CFHR locus 
on systemic complement activation.
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table 7			Association	of	haplotypes	across	the	CFH/CFHR	locus	with	systemic	complement	
activation	levels	
Haplotype Alleles 
CFH rs3753396 – CFHR4 rs6685931
HF β SE (β) P-value
H2 A-T 0.18 Reference Reference Reference
H1-2 A-C 0.36 0.062 0.019 1.148x10-3
H3 G-T 0.14 0.183 0.024 2.531x10-14
H4 A-T 0.10 0.013 0.026 0.607
H5 A-T 0.04 -0.058 0.038 0.128
H1-1 A-T 0.03 -0.053 0.043 0.218
H6 A-C 0.03 0.144 0.041 4.823x10-4
H7 A-C 0.03 0.060 0.046 0.192
H8 A-T 0.03 -0.007 0.048 0.890
HF=Haplotype frequency, SE=Standard error.
Haplotype association analyses with AMD were performed on the 1,548 individuals of the discovery 
cohort. Haplotypes are coded as in Hageman et al., 2005. If two different sub-haplotypes based 
on the extra allele in SNP rs6685931 were found, the Hageman haplotypes were recoded as 1 or 2. 
Alleles associated with higher complement levels are underlined. The reference haplotype was set to 
the most common haplotype not carrying any complement-raising allele for rs3753396 or rs6685931.
table 8		Predicted	haplotypes	across	the	CFH/CFHR	locus
*SNPs in linkage disequilibrium (r2=1). †SNPs in linkage disequilibrium (r2=1).
Haplotypes are coded as in Hageman et al., 2005. If two different sub-haplotypes based on the extra 
allele in SNP rs6685931 were found, the Hageman haplotypes were recoded as 1 or 2.
Haplotype rs3753394 rs529825* rs800292* rs3766404 rs1061170 rs203674 rs3753396† rs1065489† rs6685931
H1-2 
(rs6685931-C)
C G G T C G A G C
H2 C A A T T T A G T
H3 T G G T T T G T T
H4 C G G C T T A G T
H5 T G G T T T A G T
H1-1 
(rs6685931-T)
C G G T C G A G T
H6 T G G T T G A G C
H7 T G G T C G A G C
H8 T G G C T T A G T
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table 9			Association	of	complement-raising	SNPs	and	haplotypes	with	AMD:	SNP	rs6685931	
and	haplotype	H1-2	confer	a	risk	for	AMD
OR CI P-value
SNP rs3753396 1.031 0.839 - 1.223 0.756
SNP rs6685931 1.631 1.489 - 1.772 5.889x10-12
Haplotype H3 1.015 0.911 - 1.130 0.795
Haplotype H6 0.828 0.637 - 1.075 0.135
Haplotype H1-2 1.318 1.223 - 1.420 1.382x10-12
OR=Odds ratio, CI=Confidence interval.
Single variant and haplotype association analyses with AMD were performed on the 1,548 
individuals of the discovery cohort. Haplotype analyses were based on X2 tests that compared the 
frequency of the analyzed haplotypes in cases vs. controls.
 
Haplotypes previously described for AMD already included rs3753396, the lead variant 
associated in the GWAS,27 and were expanded by adding rs668593, the second independent 
signal. In total, seven SNPs across the CFH/CFHR locus yielded nine different haplotypes 
with a predicted population frequency higher than 1% (Table 7, Table 8 available at www.
aaojournal.org).
Association with systemic complement activation levels revealed haplotypes with 
stronger effects on complement activation compared to the single SNPs identified in the 
GWAS. Haplotypes H1-2, H3 and H6 were associated with higher systemic complement 
activation levels. Haplotype H3 carrying the complement-raising allele of rs3753396 (G) 
had a stronger effect on complement activation levels (P=2.53x10-14, β=0.183, SE=0.024) 
compared to the complement-raising allele of rs3753396 in the single variant analysis 
(β=0.141, SE=0.015). Haplotypes H1-2 and H6 both carried the complement-raising allele 
for rs6685931 (C). Haplotype H6 showed a stronger effect on complement activation levels 
(P=4.82x10-4, β=0.144 SE=0.041) compared to the single variant analysis for rs6685931 
(β=0.054, SE=0.010) (Table 7, Table 8 available at www.aaojournal.org).
SNP rs6685931 in CFHR4 and haplotype H1-2 confer a risk for AMD 
In order to identify genetic biomarkers that are relevant in the context of disease, we 
explored whether the SNPs and haplotypes associated with systemic complement 
activation levels associate also with AMD.
SNP rs3753396 in CFH was not associated with AMD (P=0.76). In contrast, the complement-
raising allele of rs6685931 in CFHR4 (C) was associated with an increased risk for AMD 
(P=5.89x10-12, OR=1.631 CI=1.489-1.772) (Table 9). These results are in concordance 
with the largest GWAS on AMD reported to date (rs3753396: P=3x10-3; rs6685931: 
P=1.02x10-495, OR>1).9
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figure 4 		Complement	activation	levels	stratified	by	common	haplotypes	across	the	CFH/
CFHR4	locus:	the	AMD	risk	haplotype	H1-2	shows	high	complement	activation	
levels,	and	the	non-AMD-associated	H3-1	haplotype	shows	the	highest
Horizontal bars indicate the mean values for each haplotype carrier group. Haplotype carriers 
included in the graph had a posterior probability higher than 0.75. The haplotype group colors 
indicate the association with AMD: orange=protective, blue=risk conferring, grey=not associated. 
Association analyses were carried out on the 1,548 patients genotyped with exome-array.
table 10		Association	of	the	52	AMD	variants	with	systemic	complement	activation	levels
Variant* AMD risk-
increasing 
allele 
Locus name AF† β † SE (β) † P-value† P-value†‡
rs10922109 C CFH 0.629 0.089 0.013 5.389x10-11 1.406x10-9
rs570618 T CFH 0.421 -0.002 0.013 0.876 0.629
rs121913059§ T CFH - - - - -
rs148553336 T CFH 0.995 -0.128 0.097 0.186 0.219
rs187328863 T CFH 0.042 0.028 0.036 0.445 0.668
rs61818925 G CFH(CFHR3/CFHR1) 0.637 0.015 0.015 0.306 0.187
rs35292876 T CFH 0.016 0.031 0.052 0.550 0.648
rs191281603 G CFH 0.01 0.041 0.088 0.639 0.578
rs11884770 C COL4A3 0.738 -0.022 0.015 0.146 0.176
rs62247658 C ADAMTS9-AS2 0.417 0.007 0.013 0.616 0.475
rs140647181 C COL8A1 0.018 -0.092 0.057 0.109 0.106
rs55975637 A COL8A1 0.129 -0.015 0.020 0.473 0.427
rs10033900 T CFI 0.495 0.004 0.014 0.762 0.664
rs141853578 T CFI 0.003 0.292 0.133 0.028 0.042
rs62358361 T C9 0.014 0.025 0.057 0.668 0.742
rs114092250 G PRLR/SPEF2 0.975 -0.046 0.045 0.300 0.297
rs116503776 G C2/CFB/SKIV2L 0.872 0.059 0.020 0.003 0.005
rs144629244 A C2/CFB/SKIV2L 0.010 0.067 0.065 0.300 0.360
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AF= Allele frequency, SE= Standard error.
*Location of the SNP as in Fritsche et al., 2016, †Refers to the AMD risk-increasing allele, ‡Analysis 
adjusted for AMD disease status, §Variant not found in the study cohort. 
In agreement with the single variant analysis of CFH rs3753396, the haplotype H3 that gave 
the highest risk for higher systemic complement activation was not associated with AMD 
(P=0.80). Haplotype H6 carries the CFHR4 rs6685931 complement-raising allele (C) but did 
not reach significance in the association with AMD (P=0.14); however the frequency of H6 
was relatively low (3%). Haplotype H1-2, the most common haplotype carrying the CFHR4 
rs6685931 complement-raising allele (C), showed a strong risk-conferring association with 
AMD (P=1.38x10-12, OR=1.318 CI=1.223-1.420) (Table 9, Fig. 4).
rs114254831 G C2/CFB/SKIV2L 0.242 -0.01 0.015 0.508 0.426
rs181705462 T C2/CFB/SKIV2L 0.008 -0.008 0.075 0.921 0.877
rs943080 T VEGFA 0.510 -0.026 0.013 0.056 0.075
rs1142 T KMT2E/SRPK2 0.371 0.002 0.014 0.883 0.948
rs7803454 T PILRB/PILRA 0.184 -0.01 0.017 0.574 0.484
rs79037040 T TNFRSF10A 0.518 0.011 0.013 0.411 0.338
rs10781182 T MIR6130/RORB 0.301 -0.008 0.015 0.594 0.701
rs71507014 G TRPM3 0.421 -0.005 0.014 0.732 0.724
rs1626340 G TGFBR1 0.793 -0.009 0.017 0.598 0.468
rs2740488 A ABCA1 0.740 -0.009 0.015 0.555 0.403
rs12357257 A ARHGAP21 0.238 -0.001 0.016 0.927 0.915
rs3750846 C ARMS2/HTRA1 0.297 0.01 0.014 0.468 0.866
rs3138141 A RDH5/CD63 0.210 0.046 0.021 0.030 0.045
rs61941274 A ACAD10 0.013 0.003 0.072 0.971 0.980
rs9564692 C B3GALTL 0.727 -0.008 0.015 0.618 0.506
rs61985136 T RAD51B 0.619 0.007 0.014 0.620 0.541
rs2842339 G RAD51B 0.095 0 0.023 0.994 0.975
rs2043085 T LIPC 0.616 0.029 0.014 0.036 0.039
rs2070895 G LIPC 0.800 -0.03 0.017 0.071 0.062
rs5817082 C CETP 0.745 0.017 0.016 0.284 0.402
rs17231506 T CETP 0.326 -0.001 0.014 0.924 0.723
rs72802342 C CTRB2/CTRB1 0.929 0.003 0.028 0.914 0.932
rs11080055 C TMEM97/VTN 0.503 0.015 0.013 0.246 0.206
rs6565597 T NPLOC4/TSPAN10 0.391 0.003 0.015 0.824 0.862
rs2230199 G C3 0.224 -0.034 0.017 0.044 0.060
rs147859257 G C3 0.006 0.098 0.089 0.270 0.385
rs12019136 G C3(NRTN/FUT6) 0.958 -0.012 0.035 0.740 0.689
rs67538026 C CNN2 0.556 0.001 0.015 0.960 0.900
rs429358 T APOE 0.883 0.022 0.021 0.311 0.294
rs73036519 G APOE(EXOC3L2/MARK4) 0.697 0.012 0.015 0.453 0.477
rs142450006 TTTTC MMP9 0.858 0.009 0.020 0.667 0.705
rs201459901 T C20orf85 0.948 -0.024 0.030 0.425 0.444
rs5754227 T SYN3/TIMP3 0.871 -0.003 0.020 0.895 0.796
rs8135665 T SLC16A8 0.210 0.003 0.016 0.853 0.973
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Finally, we determined whether other AMD-associated variants are associated with 
systemic complement activation levels. For this purpose, we extracted the 52 AMD-
associated variants reported in the largest AMD study performed so far from the GWAS 
on complement activation levels.9 However, no variants outside of the CFH/CFHR locus 
were found to be associated with systemic complement activation levels at the genome-
wide significance level, nor at a suggestive significance level of P<0.05/52=0.001 (Table 
10, available at www.aaojournal.org). Interestingly, a risk score based on the 52 AMD 
risk-conferring alleles associated with higher levels of complement activation (P=0.043, 
β=0.004, SE(β)=0.002). A similar risk score including only the variants located in or 
near complement genes was more strongly associated with higher levels of complement 
activation (P=0.022, β=0.009, SE(β)=0.004). This complement risk score included three 
nominally associated variants: two common variants located in the CFH and C2/CFB/
SKIV2L loci: rs10922109 and rs116503776 respectively, and a rare variant located in the 
CFI gene: rs141853578 or p.Gly119Arg. However, the effects of these genetic risk scores 
are smaller compared to the single variant effects in the model for systemic complement 
activation described in Table 6.
Discussion
We conducted a GWAS on systemic complement activation levels, evaluating for the first 
time in an unbiased approach the genetic risk factors involved in the activation of this 
essential component of the immune system. We identified and replicated two common 
variants, rs3753396 and rs6685931, that lead to higher systemic complement activation 
levels independently of age, sex, AMD disease status, triglycerides and body mass index. 
These two variants were included in a model for systemic complement activation, which 
explained 18.7% of its variability.
SNP rs3753396 (c.2016A>G, p.Gln672Gln) is a coding, synonymous variant located in exon 
14 of the CFH gene, and therefore this variant, or the linked causal variant(s), may regulate 
complement activation levels through FH. Factor H is a key negative regulator of the AP and 
the amplification loop of the complement cascade, which is expressed constitutively in 
the liver and locally by other cell types, such as retinal pigment epithelial and endothelial 
cells.28-30 Evidence to support the theory that rs3753396 exerts an effect on complement 
activation through FH comes from genetic studies on other diseases. SNP rs3753396 has 
been reported to be associated with atypical hemolytic uremic syndrome (aHUS), known 
to be caused by mutations in CFH.31,32 Moreover, reduced susceptibility to meningococcal 
disease has also been associated with rs3753396. Meningococcal disease is caused by 
Neisseria meningitides, which binds FH to avoid complement-mediated killing.33 SNP 
rs3753396 is in linkage disequilibrium (LD) with rs1065489, also located in CFH (c.2808G>T, 
p.Glu936Asp), which was proposed to be the causal variant for meningococcal disease 
based on in-silico pathogenicity predictions.34 
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SNP rs6685931 (c.59-4315T>C) is located in intron 1 of the CFHR4 gene. Factor H related-4 
(FHR-4) is a glycoprotein that, in contrast to the attenuating effects of FH, seems to promote 
complement activation. It binds the complement fluid-phase C3b and forms an additional 
AP C3 convertase (CFHR4-C3bBb), which is less susceptible to FH-mediated decay.35 
However, since rs6685931 is in high LD (r2>0.8) with several variants located in the CFH 
gene, either FH or FHR-4 could be responsible for the effects observed on complement 
activation.
We analyzed the association of genetic variants with systemic complement activation 
levels in a hypothesis-free manner. The results indicate that with our study design, the 
genetic variants with the largest effect on complement activation levels are rs3753396 and 
rs668593, located at the CFH/CFHR locus. Moreover, other previously associated variants 
in CFH and C2/CFB could be replicated.18 Haplotype analysis at the CFH/CFHR locus 
revealed two haplotypes with stronger effects on complement activation levels compared 
to the individual SNPs. These findings suggest that additional variants at the CFH/CFHR 
locus play a role in the activation of the complement system. Indeed, several rare coding 
variants in the CFH gene have been shown to lead to increased complement activity.10 
Genetic variants in other genes that influence systemic complement activation levels 
may be uncovered with larger sample sizes which would allow for the detection of rarer 
variants and smaller effects. A compelling rare variant candidate which may merit further 
investigation is CFI rs141853578 (p.Gly119Arg), which was found nominally significant in 
our study. This variant has been previously associated with lower FI levels in plasma, and a 
lower ability to degrade C3d on the cell surface and C3b in the fluid phase.36
In this study, AMD was associated with systemic complement activation, which is an 
agreement with previous reports.15-18,20 In our analysis, rs6685931 in CFHR4 was associated 
with both systemic complement activation and AMD. Haplotype analyses were in line 
with these results; we observed that the complement-raising allele of SNP rs6685931 (C) 
was located mainly on the H1-2 haplotype, which associated with a higher risk for AMD 
development. Thus, this SNP and its linked haplotype could serve as a robust biomarker for 
complement activation in the context of AMD, and could be used to identify AMD patients 
that would benefit most from complement inhibiting therapies.
We noted that the rare haplotype H6 (with a frequency of 3%), also containing rs6685931, 
had a larger effect on complement activation levels compared to the single variant 
rs6685931. However, haplotype H6 was not significantly associated with AMD probably 
due to statistical power limitations. Studies with larger cohort sizes may clarify the role of 
the H6 haplotype in AMD, and may identify other rare haplotypes that associate with AMD 
and have larger effects on complement activation levels.
Strikingly, the genetic variant that was most strongly associated with systemic complement 
activation, rs3753396 in CFH, and its main haplotype (H3) did not associate with AMD. 
SNP rs3753396 and haplotype H3 have been, however, described to confer risk for aHUS 
development. aHUS is a complement system related disease that leads to systemic 
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thrombotic microangiopathy and renal endothelial injury.32,37 This finding suggests that the 
effect of the haplotypes might be different systemically compared to the AMD disease site, 
possibly through a tissue-specific effect of the genetic variants. Consequently, systemic 
complement activation may not always reflect complement activation in the disease tissue 
and, therefore, it may not be the most appropriate measure for AMD studies. Genetic 
biomarkers such as SNP rs6685931 and haplotype H1-2 are a robust markers that, together 
with the C3d/C3 ratio, could serve as biomarkers for complement activity studies in AMD. 
This is supported by a recent study demonstrating that complement activation levels in 
aqueous humor are higher than in plasma samples of AMD patients.38 As a consequence, 
the effect of rs6685931 and H1-2 on local complement activation might be even larger than 
the effect seen on systemic levels.
Our results could also further the understanding of other complement-related diseases, 
as well as be used in the context of personalized medicine involving FH supplementation 
therapy and other complement-targeting therapies.39-41 Besides Neisseria meningitidis, a 
number of bacteria, fungi, parasites and viruses bind FH in order to avoid elimination by the 
alternative pathway of complement system.42 Also, some cancer cells express FH in order 
to avoid being targeted by the immune system.43-45 Other FH related diseases for which our 
results may be of interest include HUS, aHUS, encephalomyelitis, atherosclerosis, insulin 
resistance, IgA nephropathy, Alzheimer’s disease, cisplatin nephropathy as well as severe 
dengue, for which variants in the CFH gene have been shown to be protective.46
In conclusion, we have identified two common variants located at the CFH/CFHR locus, 
rs3753396 and rs668593, which strongly influence systemic complement activation levels. 
Moreover, our haplotype studies suggest that other genetic variants in the CFH/CFHR locus 
influence systemic complement activation. Genetic and non-genetic factors identified 
in this and other studies explain up to 18.7% of the variability in systemic complement 
activation levels. The common variant rs6685931 in CFHR4, and its associated haplotype 
H1-2, could be used, together with other environmental factors as well as rare genetic 
variants, to select AMD patients that would benefit from complement inhibiting therapies.
Methods
Study population
In this study, we included 2,245 participants from the European Genetic Database 
(EUGENDA, www.eugenda.org). EUGENDA is a multicenter database for the clinical and 
molecular analysis of AMD collected at the Radboud University medical center in Nijmegen 
and at the University Hospital of Cologne. The study participants were separated in two 
cohorts: a discovery cohort who comprised 1,548 individuals and a replication cohort of 
697 individuals.
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The study was performed in accordance with the tenets of the Declaration of Helsinki (7th 
revision) and the Medical Research Involving Human Subjects Act (WMO). Approval of the 
local ethics committee of both University hospitals was obtained and written informed 
consents were acquired from all participants. All the individuals included in the study 
agreed to the performed serum measurements and genotyping. All participants were of 
European descent and over the age of 50 years. AMD and control status were assigned 
by multimodal image grading according to the standard protocol of the Cologne Image 
Reading Center (CIRCL) by certified graders. Age, gender, height and weight were obtained 
by standardized interviewer-assisted questionnaires.
Serum complement and lipid measurements
Serum was obtained by a standard coagulation/centrifugation protocol, and within 1 hour 
after collection the samples were stored at –80°C.
Triglycerides and HDL cholesterol were measured using standard procedures by a 
clinical chemistry laboratory (Architect Analyzer, Abbott Diagnostics Hoofddorp, The 
Netherlands). Complement component C3 was assessed by radial immunodiffusion (or 
Mancini method) using mono specific polyclonal rabbit antisera, and C3d was measured by 
rocket electrophoresis, as previously described.21 C3d is a fragment of C3 generated upon 
activation of the system and, therefore, a direct measurement of complement turnover.4 
Moreover, C3d has the longest half life of all C3 split products.47 The C3d/C3 ratio is a 
sensitive way of assessing the activation of the complement system independently of the 
baseline individual C3 concentration.48-50 The C3d/C3 ratio has been previously described 
to be a robust biomarker for complement activation in AMD studies.19 The different 
measurements were performed for all samples in a single assay.
Genotyping
Genomic DNA was extracted from peripheral blood samples using standard procedures. 
The discovery cohort was genotyped with a custom-designed HumanCoreExome array 
by Illumina within the International AMD Genetics Consortium (IAMDGC). All the details 
regarding the design of the array, annotation, imputation and quality control of the 
genotypic data have been previously described.9
Imputed lead variants in GWAS peaks that reached significance, rs6685931 and rs3130572, 
were confirmed by polymerase chain reaction and Sanger sequencing. SNP rs6685931 was 
evaluated in 12 individuals representing the three genotypes and a 100% of concordance 
with the imputed genotypes was achieved. SNP rs3130572 (chromosome 6) was located in 
a highly repetitive region and specific primers could not be designed, therefore, this SNP 
was excluded from further analysis.
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In the replication cohort, CFH rs3753396 and CFHR4 rs6685931 were genotyped using 
competitive allele-specific PCR assays according to the manufacturer instructions (KASP 
genotyping chemistry, LGC, Hoddesdon, UK).
Statistical analysis
Natural log transformation was applied to normalize the skewed distribution of C3d/C3 
measurements. A general linear model for ln(C3d/C3) including as independent variables 
the environmental factors collected was used to determine potential confounders. The 
R-squared and adjusted R-squared statistics were estimated for the model. Additionally, 
the R-squared statistic was estimated for each of the independent factors individually, 
performing separate models. Analyses were carried out using SPSS software version 20.0 
(IBM Software and Systems, Armonk, NY, USA).
A power calculation for the GWAS was performed using the Genetic power calculator.51 
Association tests in the GWAS and replication analyses were performed by means of a 
linear Wald test from EPACTS software (http://genome.sph.umich.edu/wiki/EPACTS) 
using allele dosages. Linear regression models adjusted for age, sex, BMI, triglycerides, 
clinic and the first two ancestry principal components were used. Manhattan and Q-Q 
plots were generated using the ‘qqman’ R package (version 0.1.2). The regional plots for 
chromosome 1, were generated using LocusZoom.52
Meta-analysis of fixed effects based on effect size estimates and standard errors was 
performed using METAL software (version 2-11-03-25).53
Evaluation of an interaction between the identified SNPs and clinic or AMD status was 
performed including an interaction parameter on the general linear model and assessing 
nominal significance.
Comparisons of systemic complement activation levels between the genotype groups 
were performed using a general linear model adjusted for age, BMI, triglycerides and clinic 
including both the discovery and the replication cohorts. SPSS software version 20.0 (IBM 
Software and Systems, Armonk, NY, USA) was used for these analyses.
In order to estimate how much of the variation in systemic complement activation could 
be explained by the identified factors, general linear models for systemic complement 
activation were performed using SPSS software version 20.0 (IBM Software and Systems, 
Armonk, NY, USA). Only the 1,548 individuals from the discovery cohort were included in 
order to accommodate the CFH rs800292 and C2 rs9332739 SNPs, which were not analyzed 
in the replication cohort. The adjusted R-squared statistic was estimated for the models.
Haplotype analysis was carried out on the 1,548 patients genotyped with exome-arrays 
using the haplo.glm function of the R library ‘haplo.stats’ (version 1.7.7). Analysis was 
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performed based on a general linear model adjusted for age, sex, BMI, triglycerides, clinic 
and the first two ancestry principal components.
Single variant and haplotype association analyses with AMD were performed on the 1,548 
individuals of the discovery cohort. Single variant analyses were performed using a Firth 
bias-corrected likelihood-ratio test with EPACTS software (http://genome.sph.umich.edu/
wiki/EPACTS). Haplotype analyses were based on X2 tests including haplotypes with a 
predicted probability ≥0.75 using SPSS software version 20.0 (IBM Software and Systems, 
Armonk, NY, USA).
Risk scores for AMD-associated variants were calculated as a sum of the number of AMD 
risk-increasing alleles. Two risk scores were calculated: the first risk score included the 
52 AMD-associated variants described in Fritsche et al., 2016, and the second risk score 
included the 19 variants located in or near complement genes out of these 52. The variants 
included in the complement risk score were: rs10922109, rs570618, rs121913059, 
rs148553336, rs187328863, rs61818925, rs35292876 and rs191281603 from the 
CFH locus; rs10033900 and rs141853578 from the CFI locus; rs62358361 from the C9 
locus; rs116503776, rs144629244, rs114254831 and rs181705462 from the C2/CFB/
SKIV2L locus; rs147859257 from the TMEM97/VTN locus; rs2230199, rs147859257 and 
rs12019136 from the C3 locus. The risk scores were included in linear models for ln(C3d/
C3) that included age, BMI, triglycerides and clinic as covariates, and the effect of the risk 
score was estimated. The 1,548 individuals of the discovery phase, genotyped with the 
HumanCoreExome array, were included in these analyses.
Figures including graphs were generated using Graphpad Prism 5.03 (GraphPad Software, 
La Jolla California USA). 
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Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly 
in the Western world. However, the exact mechanisms underlying this disease are not 
fully understood yet. An over-activation of the complement system has been proven to be 
involved in the pathogenesis of AMD. Genetic studies have identified variants spanning the 
CFH/CFHR locus to be associated with AMD development, but the effect of these variants on 
protein expression or function of Factor H (FH) or the Factor H related proteins remains to be 
determined. A recent genome-wide association study on systemic complement activation in 
AMD described a SNP located in the CFHR4 gene as the top associated variant. Therefore, we 
hypothesized that FHR-4 could be directly implicated in AMD pathogenesis. 
In this study, we show that FHR-4 accumulates in the choriocapillaris, partially diffuses 
through the Bruch’s membrane and can be detected in drusen. Additionally, FHR-4 activates 
the complement system by competing off FH and factor I binding to C3b. Whereas expression 
of FHR4 was not detected in the retinal pigment epithelium and choroid, evaluation 
of systemic FHR-4 shows elevated levels in advanced AMD cases compared to controls 
(β = 0.21, CI = 0.12 – 0.30, P = 7.1 x 10-6). Systemic FH levels, however, do not show any 
difference (P = 0.70). We also evaluated the AMD-associated variants at the CFH/CFHR 
locus for association with FHR-4 levels. The AMD-risk conferring alleles of rs10922109, 
rs187328863 and rs61818925 showed an association with increased FHR-4 levels 
independently of AMD status (P = 6.5 x 10-52, P = 2.7 x 10-5 and P = 8.2 x 10-18 respectively). 
The SNP rs570618, which is in high linkage disequilibrium with the p.Y402H variant, showed 
an association with lower FHR-4 levels (P = 2.5 x 10-14). Haplotype analysis of these variants 
revealed two haplotypes associated with AMD, which showed a protective effect (H2 and 
H3). The H2 and H3 haplotypes were also highly associated with decreasing FHR-4 levels, 
independently of AMD status (β = -0.46, CI = -0.52 – -0.39, P = 4.7 x 10-42 and β = -0.24, 
CI = -0.31 – -0.16, P = 1.2 x 10-9, respectively). A genome-wide association analysis on systemic 
FHR-4 levels revealed only the CFH/CFHR locus as significantly associated. Altogether, our 
findings suggest that FHR-4 is a new component of the complement cascade involved in the 
pathogenesis of AMD and a compelling new therapeutic target.
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Introduction
Age-related macular degeneration (AMD) is a highly prevalent cause of vision loss that 
is predicted to affect 196 million people worldwide by 20201. The condition results in 
destruction of the central retina, i.e. the macula, where initial changes occur in the retinal 
pigment epithelium/Bruch’s membrane (BrM)/choriocapillaris complex. In early AMD soft 
drusen are observed (Fig. 1a), which are accumulations of debris within BrM. Progress to 
late AMD is associated with visual loss and this can manifest as either geographic atrophy 
(commonly referred to as ‘dry’ AMD) or choroidal neovascularisation (or ‘wet’ AMD)2. 
AMD has a strong genetic basis and at least 34 genetic loci have been associated with this 
condition3. Several genes encoding components of the complement cascade are associated 
with AMD and the strongest effect is seen at the regulator of complement activation 
locus on chromosome 1 which encodes CFH and CFHR1-54,5. The CFH gene encodes both 
factor H (FH) and a smaller splice variant called factor H-like protein 1 (FHL-1)6,7. While FH 
is the main blood borne regulator of complement activation, FHL-1 predominates in the 
BrM and extracellular matrix (ECM) in between the vessels of the choriocapillaris, i.e. the 
intercapillary septa (Fig. 1a)4,8. The identification of rare coding variants in CFH implicated 
this gene in AMD9,10, but due to extensive linkage disequilibrium, the reason why common 
variants at the CFH/CFHR locus are associated with altered AMD risk remains elusive. 
Genetic variants located in the CFHR4 gene and haplotypes delineated by single nucleotide 
polymorphism (SNPs) within and downstream of CFHR4 have been shown to influence 
AMD disease risk11,12. Moreover, a genome-wide association study (GWAS) on systemic 
complement activation in the context of AMD has recently identified a variant in the CFHR4 
gene as the top SNP associated with higher systemic complement activation and a higher 
risk for AMD development (see chapter 3.1), which raises the possibility that this gene 
could be implicated in AMD. Furthermore, the factor H-related 4 (FHR-4) protein encoded 
by CFHR4, has been shown to promote complement activation by forming a platform for the 
assembly of alternative pathway C3 convertase13,14. Therefore, in this study we examined 
the role of FHR-4 in AMD.
Results
FHR-4 accumulation in the choriocapillaris drives complement 
activation
In order to assess whether FHR-4 localizes at the AMD disease site, immunohistochemistry 
experiments were performed on retinas of post-mortem donor eyes affected with AMD. 
Using a specific monoclonal antibody against FHR-4 (Extended data Fig. 1 and 2) we 
observed the protein accumulating in the choriocapillaris and Bruch’s membrane (BrM), 
particularly localizing to the intercapillary septa: the extracellular matrix (ECM) between 
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figure 1		Accumulation	of	FHR-4	in	the	eye	inhibits	C3b	breakdown.	
a) Schematic diagram showing anatomical structures in the macula including the retinal pigment 
epithelium (RPE), the underlying Bruch’s membrane (BrM), the choriocapillaris and the intercapillary 
septa (pillars of extracellular matrix that separate the fenestrated capillaries of the choriocapillaris); 
basement membranes are represented as black lines. Drusen, the hallmark lesions of early AMD, 
form within BrM, underneath the RPE basement membrane. b-c) Immunohistochemistry showing 
the localization of FHR-4 (yellow) which is particularly evident in the intercapillary septa of the 
choriocapillaris, but weak labeling is also seen within BrM: collagen IV staining is used to delineate 
basement membranes which define the inner and outer borders of BrM (red), DAPI labeling is in 
blue. d) FHR-4 is also localized in drusen. e) Both FHR-4 and C3/C3b localize in the intercapillary 
septa of the choriocapillaris (white arrow): scale bars 20µm. f) SPR analysis showing the binding 
of FHR-4 to immobilized C3b. g) Solid phase binding assays demonstrate that the binding of fluid 
phase FH or FHL-1 to immobilized C3b can be competed off with increasing concentrations of FHR-4. 
h) Measurement of factor H-like protein 1 (FHL-1) mediated breakdown of C3b by factor I (FI); in the 
presence of fixed concentrations of C3b and FI, increasing concentrations of FHL-1 result in increased 
breakdown of the C3b α-chain as measured by analyzing the intensity of Coomassie-blue stained 
bands following SDS-PAGE (Extended data Fig. 3). i) Optimal C3b breakdown conditions from (h) are 
repeated but now including increased concentrations of fluid-phase FHR-4, and an inhibition of FHL-
1/FI-mediated C3b α-chain breakdown is observed. j) Mean systemic levels of FHR-4 are higher in 
subjects with AMD compared to non-AMD controls.
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the fenestrated capillaries of the choriocapillaris (Fig. 1a-c). Weak staining for FHR-4 within 
BrM indicates that the protein can penetrate in some degree into the ECM (Fig. 1c), but 
diffusion experiments with BrM and purified protein indicated that it does not pass through 
completely (Extended data Fig. 3). In addition, staining of drusen showed immunoreactivity 
for FHR-4 (Fig. 1d). C3/C3b localized to the intercapillary septa of the choriocapillaris as well 
as FHR-4 (Fig. 1e). FHR-4 has previously been shown to bind C3b and form an alternative C3b 
convertase13,15. We confirmed that FHR-4 binds immobilized C3b (Fig. 1f ) and demonstrated 
that FHR-4 can compete off the binding of both negative regulators of complement activation 
FH and FHL-1 to immobilized C3b in solid-phase binding assays (Fig. 1g). 
Given that FHR-4 binds to C3b and out-competes the binding of FHL-1, the complement 
regulator responsible for protecting the intercapillary septa from aberrant complement 
activation4,8, we investigated whether FHR-4 could inhibit C3b breakdown mediated by FHL-1 
and FI, employing fluid-phase C3b breakdown assays where the cleavage of the C3b α-chain 
was used as a readout. Using conditions in which ~80% C3b α-chain breakdown is achieved 
in the absence of FHR-4, we found that adding increasing concentrations of FHR-4 resulted 
in a progressive inhibition of C3b α-chain breakdown; where only ~50% C3b breakdown 
occurred at a 2.5 molar excess of FHR-4 over FHL-1(Fig. 1h and i and Extended data Fig. 4). 
Systemic FHR-4 levels are elevated in advanced AMD cases
Next we investigated the source of FHR-4 observed in the intercapillary septa. Transcription 
of the CFHR4 gene was not detected in the RPE or in the choroid of human eyes (data not 
shown). Therefore, we concluded that the observed FHR-4 protein was derived from the 
systemic circulation and passed from the choriocapillaris into the surrounding ECM. Using 
a FHR-4 specific ELISA, we measured circulating FHR-4 concentration in a total of 484 
advanced AMD patients (with geographic atrophy and/or choroidal neovascularization) 
and 522 examined controls, collected within two independent AMD studies (Cambridge 
and EUGENDA, Table 1). Patients with AMD showed a significant elevation of FHR-4 levels 
compared to controls, both in each study separately (Table 1) and in the meta-analysis 
(overall sex- and age-adjusted: β = 0.21, CI = 0.12 – 0.30, P = 7.1 x 10-6; Table 1, Fig. 2), 
whilst there was no difference in FH levels between AMD patients and controls (overall sex- 
and age-adjusted β = 0.01, CI = -0.02 – 0.04, P = 0.70; Table 1, Fig. 1j). 
AMD-associated variants at the CFH/CFHR locus are associated 
with systemic FHR-4 levels
A recent large GWAS of AMD conducted by the International AMD Genomics Consortium 
reported 52 independently associated variants across 34 AMD risk loci, including 8 variants 
at the CFH/CFHR locus. We hypothesized that any of these 8 genetic variants (single or in 
combination) may be associated with systemic FHR-4 levels that in turn are increased in 
AMD patients. 
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One of the 8 variants is the highly penetrant rare variant p.R1210C. This variant was only 
present heterozygously in one individual belonging to the Cambridge cohort, and therefore 
was not included in the genetic association analyses. Out of the 7 evaluated variants, single-
SNP association analyses revealed a strong association with FHR-4 levels, independently 
of AMD status, for four variants: SNPs rs10922109 (β = -0.41, CI = -0.46 – -0.35, P = 6.5 
x 10-52), rs570618 (β = -0.21, CI = -0.27 – -0.16, P = 2.5 x 10-14), rs187328863 (β = 0.32, 
CI = 0.17 – 0.47, P = 2.7 x 10-5) and rs61818925 (β = -0.25, CI = -0.30 – -0.19, P = 8.2 x 
10-18). The AMD-risk alleles were associated with higher FHR-4 levels except rs570618, for 
which increasing disease risk allele G was associated with decreased FHR-4 levels. SNP 
rs148553336 showed only a nominally significant association with FHR-4 levels (β = 0.50, 
CI = 0.05 – 0.94, P = 0.028), which was not significant after correction for 7 tests and the 
other two SNPs, rs35292876 and rs191281603, were not associated (P = 0.053 and P = 
0.199, respectively, Table 2). 
Haplotype analysis at the CFH/CFHR locus reveals haplotypes 
strongly associated both with AMD and FHR-4 levels
In order to determine the cumulative effect of several variants on the same haplotype, 
we extracted the haplotypes formed by the 7 AMD-associated variants at the CFH/CFHR 
locus using the phased genotype data produced within the GWAS of the IAMDGC study3. 
Haplotype-based analyses were performed to assess the association of the observed 
haplotypes with AMD and with FHR-4 levels in each cohort separately, and corresponding 
results were meta-analysed. We observed 8 haplotypes with an overall frequency greater 
than 1% in the two cohorts combined (Table 3). Using the most common haplotype 
CTTCCGC (H1; 50% in cases, 32% in controls) as reference, we found two AMD protective 
haplotypes, CTGACTC (H2; OR = 0.36 , CI = 0.28-0.48, P = 3.0 x 10-13) and CTGACGC 
(H3; OR = 0.29, CI = 0.21-0.40, P = 6.5 x 10-14). Haplotypes H2 and H3 were also highly 
associated with decreasing FHR-4 levels, independently of AMD status (β = -0.46, CI = 
-0.52 – -0.39, P = 4.7 x 10-42; β = -0.24, CI = -0.31 – -0.16, P = 1.2 x 10-9, respectively). 
These two haplotypes contain the AMD protective and FHR-4 lowering allele A of the top 
IAMDGC SNP rs10922109. While both haplotypes differ from the reference H1 also for the 
presence of FHR-4 lowering allele G of rs570618 (i.e., the second top IAMDGC SNP), only 
H2 contains additionally the FHR-4 lowering allele T of rs61818925. In addition, two other 
haplotypes showed an association with FHR-4 despite not being associated with AMD: 
TTTCCGC (H6) and CTTCCTC (H7). The haplotype H6 showed an association with higher 
levels of FHR-4 (β = 0.28, CI = 0.15 – 0.41, P = 3.9 x 10-5). This haplotype differed from 
the reference haplotype on the presence of the FHR-4-raising allele T in rs187328863. The 
rarer haplotype H7 showed an association with lower FH4-levels (β = -0.34, CI = -0.57 – 
-0.10, P = 0.005), and differed from the reference haplotype on the presence of the FHR-4-
lowering allele T of rs61818925. The remaining haplotypes (H4, H5 and H8) did not show 
a significant association with FHR-4 levels after Bonferroni correction for multiple testing.
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No locus other than CFH/CFHR shows genome-wide level 
association with FHR-4 levels
To assess whether genetic variants associated with systemic FHR-4 levels exist at loci other 
than CFH/CFHR, we also performed a (hypothesis-free) GWAS for FHR-4 levels. The analysis 
was performed separately in the Cambridge and EUGENDA cohorts, and the results were 
combined in a meta-analysis. Genotype data on a total of 9,160,410 were available from 
the IAMDGC study for the 1,005 individuals included in this study.3 This analysis had 
>80% power to detect associations of genetic variants with a minor allele frequency ≥5% 
explaining ≥3.9% of variance in FHR-4 levels.
Through linear regression models adjusted for age, sex and the first two ancestry principal 
components, we identified a total of 701 variants that reached genome-wide significance 
(P < 5 x 10-8) (Fig. 2, Supplementary Fig. 5). These variants were all located on chromosome 
1 spanning the CFH/CFHR locus (chr1:196,240,335–197,275,153, according to the 
GRCh38 genome assembly). The top signals of association with FHR-4 levels were at SNPs 
rs7535263, rs10737680 and rs2274700 (β = -0.195, CI = -0.219 – -0.171, P = 1.4 x 10-55 
for all three variants). These variants are located in the CFH gene (rs7535263, intron 9, 
c.1337-519G>A; rs10737680, intron 9, c.1337-3410A>C; rs2274700, exon 10, p.Ala473=, 
Figure 2). Sensitivity analysis adjusting additionally for AMD status revealed comparable 
results with the same top three associated SNPs rs7535263, rs10737680 and rs2274700 
(P = 8.9 x 10-50 for all three variants; Fig. 2, Supplementary Fig. 5), and no other locus 
showed genome-wide significant associations. 
Discussion
In this study, we aimed to assess whether FHR-4 may play a role in AMD pathology. We 
found that FHR-4 localizes at the AMD disease site as it is present in drusen and in the BrM, 
specifically at the intercapillary septa. We did not detect FHR-4 expression in the RPE nor 
in the choroid, and the systemic circulation may be the source of the FHR-4 detected in 
the intercapillary septa. Systemic levels of FHR-4 were higher in AMD patients compared 
to controls; therefore FHR-4 levels could be used as a biomarker for the disease. This 
contrasts with the results for FH, for which differences in systemic levels between cases 
and controls were not detected. Several studies had previously evaluated systemic levels 
of FH and contradictory results had been published16-24. The largest studies performed so 
far were by Ansari et al., Silva et al. and Smailhodzic et al. Ansari et al. compared 382 cases 
vs. 201 controls and reported lower FH levels in AMD patients20. In contrast, Silva et al. 
analyzed 119 AMD patients and 152 controls and did not find a significant difference24 in FH 
levels and Smailhodzic et al. analyzed 197 AMD patients and 150 controls and did not find 
a significant difference either19. Our study did not find an association between systemic 
FH levels and AMD status, either in the separate cohorts nor in the meta-analysis, which 
included 484 AMD patients and 394 controls. Overall, our findings suggest that systemic 
levels of FHR-4 (and not of FH) may be an important source of inflammation for AMD25. 
genetic biomarkers for complement inhibiting therapies 147
The results of our genetic analysis suggest that the elevated FHR-4 levels found in AMD 
patients may be in part related to genetic variability. Four AMD-associated variants at 
the CFH/CFHR locus were found to be associated with FHR-4 levels independently of 
AMD status. The AMD-risk conferring allele for the variants rs10922109, rs187328863 
and rs61818925 showed increased FHR-4 levels. These SNPs locate in intron 15 of CFH, 
intron 12 of KCNT2 (upstream of CFH) and in an intergenic region (upstream of CFHR4) 
respectively. Contrary to what we expected, one of the variants, rs570618, associated with 
lower FHR-4 levels. However, this variant is in high linkage disequilibrium with rs1061170 
(p.Y402H) for which a damaging effect on FH function has been described26. To take into 
account the cumulative effect of these variants we carried out a haplotype analysis. 
Haplotypes H2 and H3 were protective for AMD and were associated with decreasing 
FHR-4 levels, independently of AMD status. 
In conclusion, the immunohistochemistry experiments on human retinas, systemic FHR-4 
measurements and genetic analyses presented in this study point towards a potential role 
of FHR-4 in AMD pathogenesis, through an increased activation of the complement system. 
As a consequence, inhibition of FHR-4 may represent a new therapeutic strategy for AMD.
Methods
Proteins and antibodies
Recombinant FHR-4 was made through the GenScript gene synthesis and protein 
expression service using their baculovirus-insect cell expression system, and was based 
on the published sequence for the FHR-4B variant of the CFHR4 gene (UniProt identifier 
Q92496-3): the protein was designed to include a N-terminal 6x His tag and TEV cleavage 
site (see Extended Fig. 1). Recombinant FHL-1 was expressed in HEK293 cells as described 
previously8. Commercially available purified complement proteins used include C3b (VWR 
International, Lutterworth, UK, catalogue no. 204860), FH (Sigma-Aldrich, catalogue no. 
C5813), and FI (VWR International, catalogue no. 341280). Commercially available antibody 
against collagen IV was used (catalogue no: 600-401-106S, 2B Scientific Ltd., Oxford, UK).
Generation of a FHR-4 monoclonal antibody 
Mice were immunised subcutaneously (sc) with recombinant FHR-4 (~30µg/mouse; 
supplied by SC) in complete Freund’s adjuvant; boosted 4 and 6 weeks later with FHR4 
(dose as above), in incomplete Freund’s adjuvant and test bled at 8 weeks. 
The titre of anti-FHR-4 antibody was assessed by screening sera from individual mice in a 
capture ELISA. 96-well microtiter plates were coated with recombinant FHR4 (0.2µg/well 
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in carbonate buffer pH9.6) for 1 hour at 37˚C, blocked in 1% BSA in PBS/tween, washed 
three times in PBS/tween and blotted dry. A doubling dilution of serum from each mouse 
(in duplicate; 1:100 - 1:256,000) was added to the wells and incubated for 1 hour at 37˚C. 
Wells were washed three times in PBS/tween, then HRP-labelled anti-mouse IgG (Jacksons) 
diluted 1:1000 in PBS/tween was added to each well and incubated for 1 hour at 37˚C. 
Wells were washed as above, blotted dry then OPD substrate added to each well. When 
colour had developed sufficiently, the reaction was stopped by adding an equal volume of 
10% H
2
SO
4
 to each well. Plates were read in an ELISA reader. Titre for a serum sample was 
the highest dilution giving an absorbance >2x background (non-immune serum at the same 
dilution). 
The mouse with the highest titre in the above assay was boosted intraperitoneally with 
FHR4 (30µg in PBS). The mouse was sacrificed 48 hours later and the spleen harvested 
aseptically.
Spleen cells were obtained by perfusion with RPMI in a sterile cabinet. Spleen cells were 
then fused with SP2 myeloma cells to generate hybridomas using a standard protocol. Cells 
were suspended in 100ml complete medium containing HAT (to select for hybridomas) and 
plated out, 100µl/well in 10 x 96-well flat-bottomed tissue culture plates that had been 
pre-conditioned by plating peritoneal macrophages 24 hours previously. Plates were 
placed in a 37˚C/5% CO
2
 incubator and left undisturbed for 14 days. 
Supernatant (50µl) was removed from each well and transferred to corresponding wells in 
a 96-well microtiter plate coated with FHR-4 as above; bound antibody was detected as 
above. Cells were harvested from wells that were positive in the screen, diluted to 10ml in 
complete medium containing HT, and re-cloned into macrophage-preconditioned 96-well 
plates.
After 10-14 days, wells containing visible clones were screened as above. Positive wells 
were simultaneously re-cloned and expanded to 24-well plates. 
Once stable clones had been obtained and expanded in sufficient scale, antibodies were 
purified either on protein G or by salt precipitation. Purified antibodies were tested in 
western blotting against recombinant FHR-4 and human serum. Non-competitive pairs of 
antibodies were identified for ELISA development. 
Human eye tissue
Post-mortem donor eyes were obtained from the Manchester Eye Bank at the Royal Eye 
Hospital (Manchester, UK), within 48 hours from the time of death, after removal of the 
corneas for transplantation; these were classified and curated as part of the Manchester 
Eye Tissue Repository (ETR). No organs/tissues were procured from prisoners. Our 
research adhered to the tenets of the Declaration of Helsinki and in all cases, there was 
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prior informed consent for the eye tissue to be used for research obtained and held by the 
Manchester Eye Bank, and guidelines established in the Human Tissue Act of 2004 (UK) 
were followed. Ethical approval for the use of tissue in these experiments was granted by 
the Manchester Eye Tissue Repository ethics committee (ref. 15/NW/0932).
Immunohistochemistry
Tissue sections (10 µm) were stained for the presence of endogenous FHR-4, collagen IV or 
C3/C3b as described previously8. Briefly, tissue sections were incubated with chilled (-20˚C) 
histological grade acetone (Sigma-Aldrich) and methanol (mixed 1:1) for 20 seconds before 
thorough washing with PBS. Tissue sections were blocked with 0.1% (w/v) BSA, 1% (v/v) 
goat serum, and 0.1% (v/v) Triton X-100 in PBS for 1 h at room temperature. After washing 
with PBS, tissue sections were incubated with Ab combinations of either 10 µg/ml of anti-
FHR-4 (clone 150: see above) mixed with 1 µg/ml Collagen IV rabbit polyclonal antibody, 
or anti-FHR-4 mixed with 1 µg/ml anti C3 rabbit polyclonal antibody (catalogue no: 21337-
1-AP, Proteintech Group, Inc, United States), for 16 h at 4°C. Sections were washed and 
biotinylated anti-mouse IgG (Catalogue No. BA_9200, Vector laboratories, Inc) diluted 
1:250 in PBS was applied for 1 hour to amplify the FHR-4 signal. Slides were subsequently 
washed and Alexa Fluor® 647 streptavidin (catalogue no: S32357, Invitrogen) diluted 
1:250 in PBS and Alexa Fluor® 488-conjugated goat anti-rabbit Ab (Invitrogen, USA) diluted 
1:500 in PBS were added for 2 h at room temperature. After washing DAPI was applied as 
a nuclear counterstain (at 0.3 mM for 5 min) prior to mounting with medium (Vectashield; 
H-1400, Vector Laboratories, Peterborough, UK) and application of a coverslip. 
In the case of blank control sections the exact same protocol was followed but PBS replaced 
the primary antibody. To test antibody specificity in immunohistochemistry pre-adsorption 
experiments were performed whereby 10-fold molar excess of pure recombinant FHR-4 
is premixed with the anti-FHR-4 Ab prior to application to the tissue sections. In all cases 
images were collected on a Zeiss Axioimager.D2 upright microscope using a 40x / 0.5 EC Plan-
neofluar and 100x / 0.5 EC Plan-neofluar objective and captured using a Coolsnap HQ2 camera 
(Photometrics) through Micromanager software v1.4.23. Specific band pass filter sets for 
DAPI, FITC and Cy5 were used to prevent bleed through from one channel to the next. Images 
were then processed and analysed using Fiji ImageJ (http://imagej.net/Fiji/Downloads). 
To prevent bleed-through of color from one channel to the next, specific band pass filter 
sets were used for DAPI, FITC, and Cy-5. All images were handled using ImageJ64 (version 
1.40g; http://rsb.info.nih.gov/ij). 
Surface plasmon resonance
The binding of FHR-4 to immobilised C3b was measured by surface plasmon resonance 
(SPR) using a Biacore 3000 (GE Healthcare). The sensor surfaces were prepared by 
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immobilizing human C3b onto the flow cells of a Biacore series S carboxymethylated 
dextran (CM5) sensor chip (GE Healthcare) using standard amine coupling and included 
blank flow cells were no C3b protein was present. Experiments were performed at 25°C and 
a flow rate of 15 µl/min in PBS with 0.05% surfactant P20. FHR-4 was injected in triplicate 
at concentration ranging from 1 to 100µg/ml. Samples were injected for 150 seconds and 
dissociated for another 200 seconds and the chip was regenerated between injections 
with 1M NaCl for 1 min before chip is re-equilibrated into PBS with 0.05% surfactant P20 
prior to the next injection. After subtraction of each response value from the blank cell, 
association and dissociation rate constants were determined by global data analysis. All 
curves were fitted using a 1:1 Langmuir association/dissociation model (BIAevaluation 
4.1; GE Healthcare).
Solid phase binding assays
Purified C3b was adsorbed onto the wells of microtiter plates (Nunc Maxisorb, Kastrup, 
Denmark) at 1µg/well in 100µl/well PBS for 16 h at room temperature. Plates were blocked 
for 90 minutes at 37°C with 300µl/well 1% (w/v) BSA in assay buffer (20mM HEPES, 
130mM NaCl, 0.05% (v/v) Tween-20, pH 7.3). This standard assay buffer (SAB) was used 
for all subsequent incubations, dilutions and washes and all steps were performed at room 
temperature. A constant concentration of 100nM is made for either FH or FHL-1 in SAB and 
increasing concentrations of FHR-4 are used as a competitor, up to 500nM. FH/FHR-4 and 
FHL-1/FHR-4 mixes are incubated with the immobilized C3b for 4 hours. After washing, 
bound FH or FHL-1 protein was detected by the addition of 100µl/well of 0.5µg/ml OX23 
antibody and incubated for 30 minutes followed by washing and a 30 minute incubation 
in 100µl of a 1:1000 dilution of AP-conjugated anti- mouse IgG (Sigma-Aldrich). Plates 
were developed using 100µl/well of a 1mg/ml disodium p-nitrophenylphosphate solution 
(Sigma-Aldrich) in 0.05 M Tris-HCl, 0.1 M NaCl, pH 9.3. The absorbance values at 405 nm 
were determined after 10 minutes of development at room temperature and corrected 
against blank wells (i.e., those with no immobilized C3b). 
Fluid phase C3b breakdown assays
The fluid phase cofactor activity of FHL-1 was measured by incubating purified FHL-1, C3b 
and FI together in a total volume of 20µl PBS for 15 minutes at 37°C. For each reaction 2µg 
C3b and 0.04µg FI were used with varying concentrations of FHL-1 ranging from 0.015µg to 
1µg per reaction. The assay was stopped with the addition of 5µl 5x SDS reducing sample 
buffer and boiling for 10 minutes at 100°C. Samples were run on a 4-12% NuPAGE Bis 
Tris gel at 200V for 60 minutes in order to maximise the separation of the C3b breakdown 
product bands (see Extended data Fig. 4). Molecular weight markers used were Novex 
Sharp pre-stained protein standards (3.5-260kDa, Cat. No. LC5800, Life Technologies, 
Paisley, UK). The density of the 68kDa iC3b product band was measured using ImageJ64 
(version 1.40g; rsb.info.nih.gov/ij) and used to track C3b breakdown efficiency of the FHL-1 
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proteins. For FHR-4 inhibition assays, the amount of FHL-1 used in the reaction is fixed 
at 1µg and increasing amounts of FHR-4 are added to create up to a 5-fold molar excess 
of FHR-4 over FHL-1. Otherwise the reactions are performed under the same condition as 
previously. In all cases averaged data from three separate experiments were used. 
Ussing chamber diffusion experiments
The macular region of enriched Bruch’s membrane isolated from donor eyes was mounted 
in an Ussing chamber (Harvard Apparatus, Hamden, CT). Once mounted, the 5-mm-diameter 
macular area was the only barrier between two identical compartments (see Extended Fig. 3a). 
Both sides of Bruch’s membrane were washed with 2 ml PBS for 5 min at room temperature. 
Fresh PBS was used in both the sample and diffusate chambers. To the sample chamber pure 
recombinant FHR-4, with a final concentration of 100µg/ml is added and the Ussing chamber 
was left at room temperature for 24 hours with gentle stirring in each compartment with 
magnetic stirrer bars to avoid generating gradients of diffusing protein. Samples from each 
chamber were analyzed on 4-12% NuPAGE Bis-Tris gels, run at 200V for 60 minutes. Either 
20µl samples straight from each chamber were missed with 5µl 5x SDS loading buffer and run 
or 100µl samples were taken and concentrated using StrataClean beads (Agilent Technologies, 
Cheadle, U.K) by mixing the beads with each 100µl sample for 5 minutes at room temperature 
before centrifugation and removal of the supernatant. Beads were then re-suspended in 20µl 
neat 5x SDS loading buffer and loaded directly to the gel. Gels were stained with Instant Blue 
stain (Expedeon, Harston, UK) for 60 min at room temperature, before washing and storage in 
MiliQ water. Molecular weight markers used were Blue Prestained Protein Standards, Broad 
Range (11-190kDa, New England BioLabs, Hitchin, UK, catalogue no. P7706S). Diffusion 
experiments were performed on three separate donor BrM.
FHR-4 measurements 
The levels of FHR-4 were measured using an optimised in-house sandwich ELISA. Nunc-
Immuno™ MaxiSorp™ 96-well plates were coated with 50µl/well of monoclonal anti-FHR4 
antibody 4E9 at 5µg/ml (in 0.1M carbonate buffer pH9.6). After incubating for 1 hour at 
37°C, the plates were blocked with 2% BSA in PBS + 0.1%Tween-20 (PBST) for 1 hour at 
room temperature. After 3 washes of PBST, 50µl/well of purified FHR-4 protein diluted in 
0.1% PBST was added in duplicate starting at 1µg/ml and serially diluted (1 in 2) down the 
plate. Test samples were added (50µl/well) in duplicate at a 1:40 dilution to the remaining 
wells, and plates were incubated at 37°C for 1.5 hours. After 3 washes in PBST, 50µl/well of 
1µg/ml of HRP-labelled anti-FHR-4 monoclonal antibody clone 17 was added and the plates 
were incubated for 1 hour at room temperature. After washing 3 times with PBST, 50µl/well 
of orthophenylenediamine (SIGMAFAST™ OPD, Sigma-Aldrich, UK) was added to develop 
the plates and the reaction was stopped after 5 minutes by adding an equal volume of 
10% sulphuric acid. Absorbance was measured in a plate reader at 492 nm and protein 
concentrations were interpolated from standard curves plotted using GraphPadPrism5. 
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Cambridge and EUGENDA study samples
The Cambridge AMD study is a case-control study of AMD with participants recruited 
from ophthalmic clinics in London, the southeast of England, and the northwest of 
England between 2001 and 200727. All patients had at least 1 eye affected by choroidal 
neovascularization (CNV) and/or geographic atrophy (GA). Patients were excluded if they 
had greater than 6 diopters of myopic refractive error or evidence of other inflammatory 
or retinovascular disease (such as retinal vessel occlusion, diabetic retinopathy, or 
chorioretinitis) that could contribute to the development of or confound the diagnosis of 
maculopathy. Almost all of the controls were spouses or partners of index patients, and 
the remainder were friends of patients. All participants described their race/ethnicity as 
white rather than other on a recruitment questionnaire. Participants were examined by an 
ophthalmologist and underwent color stereoscopic fundus photography of the macular 
region. Images were graded at the Reading Centre, Moorfields Eye Hospital, London, using 
the International Classification of Age-related Maculopathy and Macular Degeneration28. 
Blood samples were obtained at the time of interview; EDTA samples were obtained for 
DNA extraction, and lithium-heparin plasma samples stored at –80°C were later used for 
FHR-4/FH measurements. 
The European Genetic Database (EUGENDA) is a database for the clinical and molecular 
analysis of AMD. Patients from the EUGENDA cohort were recruited at the Department of 
Ophthalmology of the Radboud university medical center, Nijmegen, the Netherlands, and 
the University of Cologne, Germany. All the individuals were graded by classification of 
retinal images according to the standard protocol of the Cologne Image Reading Center 
by certified graders.29 Only patients graded as late AMD were included in the study. Serum 
samples were obtained by a standard coagulation/centrifugation protocol, and within 1 
hour after collection the samples were stored at –80°C. 
For both studies ethical approval was obtained from either national or local ethics 
committees and adhered to the tenets of the Declaration of Helsinki. All participants 
provided written informed consent to undergo the clinical examination and epidemiological 
data collection, and to provide a blood sample for biochemical and genetic analyses.
Genotype data
All Cambridge and EUGENDA individuals included in this study had been previously 
analyzed within a large GWAS of AMD carried out by the International AMD Genomics 
Consortium (IAMDGC) on 43,566 subjects (of which, 16,144 patients with advanced AMD 
and 17,832 control subjects of European ancestry)3. All DNA samples were genotyped with 
a custom-modified Illumina HumanCoreExome array at the Center for Inherited Disease 
Research (CIDR) and quality control and genotype imputation using the 1000 Genomes 
Project30 reference panel were performed by the IAMDGC as described previously3. A total 
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of 12,023,830 directly genotyped (439,350) or imputed (11,584,480) quality-controlled 
variants were available for single-variant genetic association analyses. Phased genotype 
data as inferred within the IAMDGC study3 were also available for haplotype-based 
association analyses.
Association analyses of FHR-4/FH levels, SNPs, haplotypes and 
AMD
Stata software, version 13.1 (StataCorp), and ipdmetan and mvmeta commands were used 
for conducting 2-stage, fixed-effects meta-analyses of the available individual participant 
data from the 2 cohorts (Cambridge and EUGENDA). Heterogeneity across studies was 
assessed using the I2 statistic. FHR-4 and FH levels were natural logarithmically transformed 
to ensure normality of the distribution. We assessed the association of late AMD status 
with FHR-4 and FH levels via Wald tests using linear regression models adjusted for age 
and sex. We also assessed the association of the 8 independently associated SNPs at the 
CFH/CFHR locus reported by the IAMDGC study3 (rs10922109, rs570618, rs121913059, 
rs148553336, rs187328863, rs61818925, rs35292876, rs191281603) with FHR-4 and FH 
levels via Wald tests on the SNP genotypes coded as 0, 1 and 2 according to the number 
of minor alleles using linear regression models adjusted for late AMD status. Finally, 
we extracted data for the haplotypes formed by those independently associated SNPs 
using the phased genotype data produced within the IAMDGC study3 and assessed the 
association of the observed haplotypes with AMD using logistic regression models and 
with FHR-4 and FH levels using linear regression models adjusted for late AMD status.
GWAS meta-analysis of FHR-4/FH levels
We carried out GWASs of (natural logarithmically transformed) FHR-4 and FH levels in each 
cohort (Cambridge and EUGENDA) using linear regression models adjusted for age, sex 
and the first two ancestry principal components (as estimated within the IAMDGC study3). 
The GWASes were carried out using EPACTS software (http://genome.sph.umich.edu/
wiki/EPACTS) and Wald tests were performed on the SNP genotypes coded as 0, 1 and 2 
according to the number of minor alleles for the directly typed variants or allele dosages for 
the imputed variants. Genomic control correction31 was applied if lambda was greater than 
1. Effect size estimates and standard errors of single variants seen in both cohorts were 
subsequently combined in a fixed-effect meta-analysis using METAL32. Manhattan and Q-Q 
plots were generated using the qqman R package (version 0.1.2) (https://cran.r-project.
org/web/packages/qqman/index.html). Sensitivity analyses adjusting the GWASes 
additionally for late AMD status were performed in an analogous manner.
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Extended data
HHHHHHGSSENLYFQGSSGQEVKPCDFPE IQHGGLY YKSLRRLYFPAAAGQSYSY	
YCDQNFVTPSGSYWDYIHCTQDGWSPTVPCLRTCSKSDIE IENGFISESSSIY ILNKE	
IQYKCKPGYATADGNSSGSITCLQNGWSAQPIC IKFCDMPVFENSRAKSNGMRFKL	
HDTLDYECYDGYE ISYGNTTGS IVCGEDGWSHFPTCYNSSEKCGPPPPISNGDTTS	
FLLKVYVPQSRVEYQCQSYYELQGSNYVTCSNGEWSEPPRCIHPCI ITEENMNKNN	
IQLKGKSDIKYYAKTGDTIEFMCKLGYNANTSVLSFQAVCREGIVEYPRCE
			
extended data figure 1		Sequence	of	FHR-4	recombinant	protein.
Recombinant FHR-4 gene synthesis was carried out by GenScript using their gene synthesis and 
protein expression service and is based on the published sequence for the FHR-4B variant of the 
CFHR4 gene (UniProt identifier Q92496-3). The original recombinant protein included an N-terminal 
6xHis tag (*) followed by, a linker region (**), and a TEV protease cleavage site (***). Removal of the 
N-terminal His tag results in two non-authentic N-terminal residues (****). 
extended data figure 2		Pre-absorption	test	of	anti-FHR-4	antibody.	
To test the tissue staining specificity of the anti-FHR-4 monoclonal antibody (clone 150), the normal 
10µg/ml Ab mix used throughout the study (a) is pre-incubated with pure recombinant FHR-4 
at a final concentration of 100µg/ml (i.e. 10-fold excess) (b). Staining from the pre-absorption 
experiments are strikingly similar to the blank controls (c), where no primary antibody is included.
* ** *** ****
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extended data figure 3		FHR-4	does	not	diffuse	freely	across	Bruch’s	membrane.	
a) Enriched Bruch’s membrane from donor eyes are placed inside a modified Ussing chamber where: 
a, is the enriched Bruch’s membrane; b, are the sampling access points; and c, are magnetic stirrer 
bars to maintain flow around each chamber. b) samples from either the sample chamber or diffusate 
chamber are run on a 4-12% NuPage gel Bis-Tris gel and compared to a pure protein control (FHR-4). 
The gel shows 20µl samples taken and run directly from each chamber, as well as 100µl samples 
that have been concentrated prior to running on the gel. Gel is representative of three independent 
experiments. 
extended data figure 4		FHL-1	mediated	C3b	breakdown	assay.	
The ability of FI to cleave C3b in the fluid phase in the presence of a co-factor (FHL-1) is shown. Pure 
C3b (2µg), FI (0.04µg), and FHL-1 (0.5µg) control bands are shown. FI cannot cleave the α-chain of 
C3b without a co-factor (lane ‘0’), but with increasing concentration of FHL-1 the breakdown of the 
C3b α-chain into iC3b (seen as two bands at 68kDa and 43kDa) is observed. Gel is representative of 
three independent experiments.	
A B
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extended data figure 5		Q-Q	plot	of	the	GWASes	on	log-FHR-4	levels.
Shown as black dots are the observed P-values (-log
10
(P)) compared to those expected under the null 
hypothesis.
A) GWAS without adjustment for AMD status. In the meta-analysis, adjustment for the inflation factor 
of the different cohorts was conducted (EUGENDA λ=1.004, Cambridge λ=1.003). B) GWAS adjusted 
for AMD status. In the meta-analysis, adjustment for the inflation factor of the different cohorts was 
conducted (EUGENDA λ=1.005, Cambridge λ=1.005). 
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At present, only advanced neovascular age-related macular degeneration (nvAMD) can be 
treated, by targeting vascular endothelial growth factor (VEGF). For geographic atrophy 
(GA), although several therapies are actively being developed, no established treatment is 
available to date. Also, progression of the disease cannot be halted, but it can be slowed 
down with the use of nutritional supplements. 
Due to the heterogeneity in the AMD patient population, it is plausible that the effect of 
therapeutic interventions depends on the biological drivers of disease in each individual 
patient. In essence, the patient’s genetic blueprint, in addition to demographic and 
lifestyle factors, is likely to influence how a patient responds to treatment. Consequently, 
the identification of biomarkers that can predict response to therapy in AMD could be used 
to improve AMD patient care, by tailoring medication to each patient’s individual needs. 
In this thesis, we have investigated what the influence of genetic biomarkers on treatment 
response to therapy in AMD is in chapters 2.1, 2.2 and 2.3. In chapter 3.1 we investigated 
the genetic drivers of complement activation, which is relevant in the context of novel 
treatment modalities for AMD. Finally, in chapter 3.2 we further explored the role of 
factor H related 4 (FHR-4) on AMD, as a potential new biomarker and target for therapy. 
In the Discussion, we will place these results in context and aim to provide an overview 
of the current literature investigating the association of biomarkers with response to 
supplements and anti-VEGF therapy. Moreover, we describe new therapeutic approaches 
undergoing clinical trials, and the potential use of biomarkers for patient selection for such 
new therapeutic approaches. 
1  Molecular biomarkers for current therapeutic 
interventions for AMD 
1.1 Dietary supplements for slowing disease progression
AMD-associated variants have been found to influence AMD progression and, for several 
years, there have been investigations into whether specific genotypes interact with the 
Age-Related Eye Disease Study (AREDS) supplementation affecting progression rates.1 
These studies sparked an intense debate in the field as different research groups arrived 
at different conclusions. In 2008 Klein, Seddon et al., suggested that response to AREDS 
supplements could be related to the CFH rs1061170 genotype.2 The study evaluated 876 
AREDS patients and found that for carriers of the CC genotype, dietary supplementation 
would have a smaller effect, possibly related to zinc consumption, but would still be 
beneficial. No interaction was found for the ARMS2 rs10490924 SNP. In 2013, a second 
study that included 995 AREDS participants was published by Awh et al., also proposing 
a genotypic interaction,3 and suggesting that improved outcomes could be obtained 
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after genotype selection. The authors described a deleterious interaction between CFH 
risk alleles (rs412852 and rs3766405) and supplementation with zinc, in which carriers 
of CFH risk alleles would progress to advanced AMD faster when taking zinc. Also, the 
authors claimed that individuals homozygous for the CFH and ARMS2 risk alleles would 
not benefit from the AREDS formula. After these results, the AREDS Research Group 
attempted replication in a larger AREDS cohort of 1,237 AMD patients, but did not 
identify any interaction, and concluded that reduction in the risk of AMD progression after 
supplementation was seen in all genotype groups.4 This study was followed by a series of 
contradictory results,5-7 and intense argumentation.8-10 However, the controversy seems to 
have been resolved: In a recent report, independent statistical research groups analyzed 
the data from the AREDS Research Group as well as from Awh and colleagues. Errors in 
the Awh et al., 2013 study were noted, and no interaction was reported between the CFH 
and ARMS2 SNPs and treatment response after correction for multiple testing. Therefore, 
it was concluded that AMD patients should be offered dietary supplementation regardless 
of genotype.11
1.2  Anti-VEGF antibodies for choroidal neovascularization 
treatment
Since the first publication in 2007,12 a vast number of studies have investigated 
associations of genetic variants with anti-VEGF treatment outcome in nvAMD. We reviewed 
the pharmacogenetic studies published to date, and provide a detailed overview of their 
study designs and conclusions in Table 1. Despite the large body of literature on this topic, 
with over 50 studies published, solid conclusions cannot be drawn. This is due to conflicting 
results and a high heterogeneity in study designs, which makes comparisons between 
studies challenging. Studies may involve ranibizumab treatment, bevacizumab treatment 
or both. Moreover, the definition of treatment response is highly variable: change in visual 
acuity, change in total retinal thickness, choroidal neovascularization (CNV) recurrence or 
number of injections are some of the variables used to measure treatment outcome. These 
variables are analyzed in a continuous or in a categorical manner, in which responders are 
compared to non-responders based on an arbitrary definition of response. Additionally, 
the studies evaluate response after the loading dose of 3 monthly injections or longer, and 
may therefore involve different treatment protocols. Also, correction for multiple testing 
is not applied in all studies, and the majority of studies do not provide a statistical power 
calculation.
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At the onset of the field of pharmacogenetics in AMD, a natural target to explore was the 
main genetic variant associated with AMD: SNP rs1061170 in the CFH gene. Indeed, most 
of the studies have investigated this single nucleotide polymorphism (SNP), however 
conflicting results have been reported. Several studies have reported an association of 
this genetic variant with response to anti-VEGF treatment;12-25 in all instances the AMD-
risk-conferring allele (C) led to a worse outcome after therapy. However, others have 
not identified any association.26-40 Three different meta-analyses have been carried out, 
all showing an association of rs1061170 with treatment response with a moderate level 
of significance.41-43 The most recent and comprehensive study included a total of 2,963 
individuals from 14 different studies and showed that patients homozygous for the 
AMD low risk allele (T) were more likely to have a better outcome compared to patients 
homozygous for the AMD high risk allele (C; OR=1.932, CI=1.125-3.173, P=0.017).43 In the 
genome-wide association (GWAS) study we performed in chapter 2.3, this SNP was close 
to be nominally associated with visual acuity outcome after 3 months (n=678, P=0.059) 
and showed the same direction of the effect previously reported (the T allele led to a better 
outcome). Notably, the two studies based on the Comparison of AMD Treatments Trials 
(CATT) and the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) clinical 
trials did not find any association for this variant, nor for any other variant investigated, 
despite their relatively large sample sizes (n=834 and n=509, respectively).33,34
The SNPs in ARMS2/HTRA1 (rs10490924 and rs11200638, which are in high linkage 
disequilibrium),44 have also been widely evaluated for association with treatment outcome. 
A similar scenario emerged for these SNP’s, where several studies reported an association 
in which the AMD-risk allele leads to worse response,21,26,29,31,32,37,39,45 while others did not 
report an association.12,14,21,22,24,27,30,33-35,40,46-49 Only one study, by Kang and colleagues, 
described better response for carriers of the AMD-risk allele in rs10490924, as they 
needed fewer bevacizumab injections after the loading dose.19 A meta-analysis including 
2,389 cases from 12 studies showed that patients homozygous for the AMD low risk 
allele in ARMS2 rs10490924 (GG) have a higher chance of responding better to treatment 
compared to patients heterozygous (TG) or homozygous (TT) for the AMD high risk allele 
(OR=1.34, CI=1.01-1.77, P=0.039), although no significant difference was found on the 
allele level. Also, no differences were found when the analysis was limited to patients 
of European descent.50 Another meta-analysis of 1,570 cases from 5 studies showed no 
association for the SNP rs11200638.51 In the GWAS study described in chapter 2.3, this 
SNP was not associated with visual acuity outcome after 3 months (n=678, P=0.416). 
Most study designs evaluated treatment outcome after 3 - 12 months of treatment, but a 
recent study evaluated the effect of genetic variants after 4 years of anti-VEGF treatment. 
This study by Valverde-Megías et al. examined the rs1061170 CFH and rs10490924 ARMS2 
SNPs and reported that patients homozygous for the AMD-risk allele of the ARMS2 SNP 
required more injections over this long-term follow-up period.39
Due to the nature of anti-VEGF therapy, the VEGFA gene and the KDR gene, encoding the main 
receptor for VEGF, were also considered candidates to be involved in anti-VEGF treatment 
response. Most of the SNPs investigated in these genes have recently been evaluated in a 
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meta-analysis. After evaluation of nine SNPs (rs699947, rs699946, rs833069, rs833061, 
rs2146323, rs1413711, rs2010963 and rs1570360 in VEGFA, and rs2071559 in KDR), anti-
VEGF treatment was found to be more effective in patients homozygous for the VEGFA 
rs833061 minor allele C, compared to the remaining AMD patients (OR=2.362, 95% CI 
1.41-3.95, P=0.001). This analysis was, however, limited in sample size including only 444 
AMD patients from three independent studies.52 Besides SNP rs2070296 in the neuropilin-1 
(NRP1) gene, described in chapter 2.1 of this thesis,53 other reported associations with 
treatment response include the APOE ε4 allele,54,55 IL8 rs4073,21,35,56 and PEDF rs1136287;14 
those have been analyzed in only a limited number of studies and warrant replication 
analyses. In the GWAS described in chapter 2.3, only rs429358 in the APOE gene showed a 
nominal association with visual acuity treatment response (P=0.043), in which the C allele 
leads to better outcome after treatment. The other variants previously associated with 
treatment response were not replicated in our GWAS (n=678). 
Three GWASes for anti-VEGF treatment response have been published to date.45,57,58 The first 
study, by Francis, involved only 65 AMD patients. When evaluating only candidate genes, an 
association with visual acuity outcome was reported for CFH rs1065489, and an association 
with change in macular thickness was reported for C3 rs2230205.57 In the second study, 
described in chapter 2.2 of this thesis, a total of 285 AMD patients were included in the GWAS 
discovery phase and, followed by replication in an independent cohort of 376 AMD patients. 
In this study SNP rs4910623 located in the olfactory receptor gene OR52B4 was described 
as a new variant associated with worse treatment outcome.58 In the third study, which was 
recently published, Yamashiro et al. analyzed 461 AMD patients collected in a prospective 
study design, and in a discovery and replication setting. The discovery GWAS phase with 
256 patients did not identify any genome-wide significant associations, and suggestive 
associations could not be replicated. In a candidate SNP analysis that included 9 variants, 
the G allele of ARMS2 rs10490924 was associated with additional treatment requirement 
after the loading dose.45 The GWAS study described in chapter 2.3 has a larger sample size 
compared to all the previous studies (n=678), and therefore more statistical power, however, 
it did not identify any genome-wide significant associations either for common variants. 
After replication and meta-analysis of the lead variants, rs12138564 located in the CCT3 
gene remained nominally associated with a better treatment outcome. This variants was nor 
analyzed in candidate studies nor reported in prior GWAS studies. This study analyzed for the 
first time the effect of rare genetic variants on treatment response showing a negative effect 
of rare protein-altering variants in C10ORF88 and UNC93B1 genes on treatment outcome.
In addition to the pharmacogenetic studies, other biomarkers have also been described 
to be associated with anti-VEGF treatment response in nvAMD. In aqueous humor, VEGF 
and interleukin-6 (IL-6) levels have been measured prior to treatment, and they seem to be 
indicative of the outcome.59 Lai and colleagues reported that baseline aqueous VEGF levels 
associated with persistent angiographic leakage after 3 months of bevacizumab therapy.59 
In another study by Chalam and colleagues, correlations of VEGF and IL-6 levels with 
change in central subfield macular thickness after 3 monthly injections of bevacizumab 
treatment were described, with the correlation of IL-6 levels being the strongest.60
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Studies in plasma and serum have also suggested potential systemic biomarkers. 
Kepez Yildiz et al. described higher levels of plasma IL-6 in good responders compared 
to non-responders.61 Nassar and colleagues evaluated 16 inflammatory cytokines and 
found that high IL-17 and TNF-α serum levels were associated with favorable response 
to anti-VEGF therapy.62 Lechner et al. described that plasma C3a levels were elevated in 
partial responders compared to complete responders; no differences were found for 
C4a and C5a levels.63 Additionally, Kubicka-Trzaska and colleagues analyzed serum anti-
retinal antibiodies and reported that a decrease in anti-retinal antibiodies levels after 
bevacizumab treatment correlated with functional and anatomical response.64
2  Molecular biomarkers for therapies in clinical 
trials 
2.1 Complement inhibiting therapies
Complement inhibiting therapies will presumably be most effective in AMD patients in 
which the complement system is most over-activated. Several studies have evaluated 
levels of complement components and activation fragments, which may represent useful 
biomarkers for treatment response to complement inhibiting therapies in AMD. Systemic 
levels of complement activation fragments such as Ba, Bb, C3a, C3d, C5a as well as levels 
of complement components Factor B (FB) and complement factor D (FD) seem to be 
elevated in AMD patients compared to controls.65-71 This is also the case for the C3d/C3 
ratio, which is analyzed in chapter 3.1. Systemic levels of complement component C3 and 
complement factor I (FI) levels appear, however, not different between AMD patients and 
controls.66,67,69,71-73 Factor H (FH) levels have been reported to be lower in AMD in some 
studies,74,75 but others do not report a difference.66,67,71,72,76 Specific complement component 
levels could therefore be used to identify AMD patients with high levels of complement 
activity. Nevertheless, a high variability in these systemic complement markers is found 
within the AMD and control groups, and the levels show a large overlap between cases 
and controls. Consequently, other markers may be needed as well to predict response. In a 
recent study including 31 nvAMD patients and 30 controls, differences in Ba and C3a levels 
in aqueous humor were detected, whereas in plasma these differences were not detected, 
probably due to the limited sample size. These results suggest that the difference in 
complement activation levels between patients and controls is larger locally in the eye than 
it is when measured systemically.77
Genetic variants located in or near the CFH, CFI, C9, C2/CFB, C3 and VNT genes, encoding 
components of the complement system, are known to be associated with AMD.78 Some 
of these genetic variants have shown to affect complement activation levels, and could 
therefore also be used as robust biomarkers for complement system activity in AMD. 
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We reviewed the reported associations between common AMD-associated variants and 
systemic complement system levels in Table 2. SNPs rs12144939 and rs1410996 in the 
CFH gene have been associated with the C3d/C3 ratio, and rs800292 has been associated 
with Ba and C3d levels and the C3d/C3 ratio.69,79,80 Genetic variants in the C2 and CFB 
genes have also been analyzed, and an association with complement activation fragments 
has been found for rs4151667 (with C3d/C3, Ba and FB), rs641153 (with C3d/C3), and 
rs9332739 (with Ba).69,71,79,80 SNPs rs6795735 and rs2230199 in the C3 gene seem to 
influence complement system activation as well. SNP rs6795735 associated with the 
C3d/C3 ratio, and rs2230199 with levels of C3d, C5a, and the C3d/C3 ratio.67,69,79,80 The 
association of ARMS2 rs10490924 with complement activation is inconclusive. While one 
study reported the SNP to influence C5a levels,67 in another study it did not,69 and a third 
study did not find an association with the C3d/C3 ratio.79 
In chapter 3.1 we analyzed common variants distributed across the genome in a GWAS 
on complement activation. This allowed us to detect in a unbiased manner the location 
the strongest association signal in the genome and to analyze systematically the known 
AMD-associated variants. The previous associations described for CFH and CFB/C2 were 
confirmed in our GWAS of systemic complement activation and no additional associations 
were detected. The associations of rs2230199 in C3 and rs10490924 in ARMS2 were, 
however, not confirmed. In previous studies, selected AMD-associated SNPs were analyzed. 
We analyzed for the first time the whole-genome in relation to complement activation. The 
strongest signal was surprisingly located in an SNP which did not associate with AMD and 
the AMD-associated variant that showed the strongest effect in the GWAS was rs6685931 
located in the CFHR4 gene. As a follow-up of these results, in chapter 3.2 we analyzed the 
role of FHR-4 in AMD. In this study, we found that AMD-associated variants as rs570618, 
rs10922109, rs187328863 and rs61818925 located in or near the CFH and CFHR4 genes 
associated with FHR-4 levels. 
Recently, rare coding variants in the CFH, CFI, C3 and C9 genes have been described in AMD 
patients, and have also been shown to have an effect on systemic levels of complement 
components. Carriers of CFH Arg127His,81 Arg175Pro,82 and Cys192Phe83 variants showed 
reduced FH levels. In carriers of CFI Gly119Arg,84 Gly188Ala,73 and Ala240Gly variants,85 
reduced FI levels were observed. Carriers of the C9 variant Arg95Ter showed C9 levels below 
the detection level,86 and in carriers of Pro167Ser,87 C9 levels were elevated. Other rare 
variants did not show an effect on systemic levels individually, but a functional effect on 
complement activation has been described. The effect of these rare variants has been 
recently reviewed by Geerlings and colleagues.88 Rare coding variants, in particular those 
showing an effect on complement activation, may therefore also be useful to select patients 
for complement inhibiting treatments. 
Besides genetic biomarkers, other biomarkers that associate with AMD and complement 
activity could also be used to identify AMD patients with an over-activated complement 
system. Other reported factors include low systemic triglyceride levels and high body mass 
index.79
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table 2		AMD-SNPs	associated	with	systemic	levels	of	complement	components
SNP = Single nucleotide polymorphism, NE = Not specified, NA = Not associated
Gene SNP Study Allele / 
Genotype 
tested
Complement measure-
ment(s)
Direction 
of the 
effect
P-value
CFH rs12144939 Ristau et al., 2014 T C3d/C3 - 4.6x10-6
rs1410996 Ristau et al., 2014 T C3d/C3 - 10-4
Reynolds et al., 2009 TT, CT and TT Bb, C3a, C5a, FH NA
rs800292 Hecker et al., 2010 G Ba + 7.1x10-6
Hecker et al., 2010 G C3d + 0.0013
Ristau et al., 2014 A C3d/C3 - 0.003
Paun et al., 2016 A C3d/C3 - 0.002
Hecker et al., 2010 G FB, FD, FH/FHR-1 NA
rs570618 Chapter 3.2 G FHR-4 - 2.5x10-14
rs10922109 Chapter 3.2 A FHR-4 - 6.5x10-52
KCNT2 
(upstream 
of CFH)
rs187328863 Chapter 3.2 T FHR-4 + 2.7x10-5
CFHR4 rs61818925 Chapter 3.2 T FHR-4 - 8.2x10-18
rs6685931 Lorés-Motta et al., in press C C3d/C3 6.32x10-8
CFB rs4151667 Hecker et al., 2010 T Ba + 3.9x10-6
Ristau et al., 2014 A C3d/C3 - 1.0x10-5
Paun et al., 2016 A C3d/C3 - 4.1x10-6
Hecker et al., 2010 T FB, FD, FH/FHR-1, C5a, 
C3d
NA 
Smailhodzic et al., 2012 TA FB - <0.001
rs641153 Paun et al., 2016 A C3d/C3 - 0.048
Reynolds et al., 2009 CT/TT Bb, C3a, C5a, FH NA 
C2 rs9332739 Hecker et al., 2010 G Ba + 2x10-6
Hecker et al., 2010 G FB, FD, FH/FHR-1, C5a, 
C3d
NA
Reynolds et al., 2009 CG/CC Bb, C3a, C5a, FH NA
C3 rs6795735 Ristau et al., 2014 A C3d/C3 + 0.04
rs2230199 Reynolds et al., 2009 CG/GG C5a + 0.04
Ristau et al., 2014 G C3d/C3 + 0.04
Paun et al., 2016 G C3d/C3 + 0.035
Hecker et al., 2010 C C3d + 0.039
Hecker et al., 2010 C FB, FD, FH/FHR-1, C5a, Ba NA
Reynolds et al., 2009 CG/GG Bb, C3a, FH NA 
ARMS2 rs10490924 Reynolds et al., 2009 GT/TT C5a + 0.02
Reynolds et al., 2009 GT/TT Bb, C3a, FH NA 
Hecker et al., 2010 NE FB, FD, FH/FHR-1, C5a, 
Ba, C3d
NA 
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2.2 New therapeutic approaches: Gene and cell based therapies
The high and increasing prevalence of AMD together with the limited therapeutic options 
have boosted research to develop new therapies.89 These new therapeutic strategies make 
use of recent technological advances including gene therapy, stem cells and genome 
editing.
2.2.1 Gene therapy
Gene therapy introduces specific genetic material into the patient’s cells, usually by means 
of a viral vector. The successful example of gene replacement therapy for the treatment of 
a monogenic retinal disease, Leber congenital amaurosis,90 motivated the development of 
gene therapy clinical trials for AMD. In AMD, the focus is on promoting the expression of 
a therapeutic protein in retinal pigment epithelium (RPE) cells. Viral vectors are delivered 
intravitreally or subretinally. An overview of gene therapy clinical trials for AMD is presented 
in Table 3. 
AAVCAGsCD59 is the only gene therapy trial targeting the complement system which is 
currently being tested for GA, and inhibits membrane attack complex (MAC) formation 
through CD59 expression. Other gene therapy trials target the neovascular form of AMD. 
AdGVPEDF.11D leads to expression of pigment epithelium-derived factor (PEDF), an anti-
angiogenic protein that counteracts the effects of VEGF in the choroidal neovascularization 
process.91 This therapy has not been further evaluated since the results of the phase I 
trial in 2006.92 AAV2-sFLT01 and rAAV.sFLT-1 both express soluble vascular endothelial 
growth factor receptor 1 (sFLT-1), an antagonist for VEGF.93 The results of the phase I trial 
of AAV2-sFLT01 have recently been published with positive safety data and toleration of 
the drug after 3 years.94 rAAV.sFLT-1 has already been evaluated in phase IIa, however, 
the control and the treatment groups performed worse than ranibizumab alone.95 
OXB-201, also known as RetinoStat, leads to the expression of the anti-angiogenic 
proteolytic products angiostatin and endostatin.96,97 Phase I has already been completed 
and no adverse events were observed,98 therefore, long term-safety studies are on-going. 
Finally, RGX-314 encodes a soluble anti-VEGF protein and is currently being evaluated in 
phase I clinical trials.
Anti-angiogenic factors delivered using gene therapy might also show a variability in 
response, as has been described for the currently used anti-VEGF antibodies. Therefore, 
pharmacogenetic associations found for anti-VEGF therapy might also be useful to analyze 
in clinical trials of gene therapy for nvAMD.
In addition, research on gene therapy for supplementation of FH is currently ongoing,99 and 
supplementation therapy for FI might be useful as carriers of rare variants show reduced 
FI levels. For this particular therapy, patient selection based on genotype will be required. 
Carriers of rare variants in CFH and CFI known to have strong effects on the protein function 
or levels would be the best candidates for inclusion in clinical trials. 
178 chapter 4
ta
bl
e 
3 
 G
en
e-
th
er
ap
y	
an
d	
st
em
-c
el
l	b
as
ed
	th
er
ap
ie
s	
fo
r	A
M
D
	in
	c
lin
ic
al
	tr
ia
ls
Ge
ne
 th
er
ap
y
 
 
 
 
 
Dr
ug
Ge
ne
 ex
-
pr
es
se
d
Ta
rg
et
Cl
in
ica
l p
ha
se
Re
su
lts
Re
fer
en
ce
Cl
in
ica
ltr
ial
s.g
ov
 
id
en
tifi
er
Fu
nd
in
g  
(cl
in
ica
ltr
ial
s.g
ov
)
Ad
GV
PE
DF
.11
D
PE
DF
NV
 A
M
D
Ph
as
e I
Co
m
pl
et
ed
: N
o 
se
rio
us
 ad
ve
rs
e 
ev
en
ts
 a
nd
 n
o 
do
se
-li
m
iti
ng
 
to
xic
iti
es
, t
ra
ns
ie
nt
 in
tra
oc
ul
ar
 
in
fla
m
m
at
io
n 
oc
cu
rre
d 
in
 2
5%
 o
f 
pa
tie
nt
s
Ca
m
po
ch
ia
ro
 PA
 et
 a
l.,
 
20
06
NC
T0
01
09
49
9
Ge
nV
ec
AA
V2
-s
FL
T0
1
sF
LT
10
1 
(d
om
ai
n 
2 
of
 
Flt
-1 
lin
ke
d 
to
 
hu
m
an
 Ig
G1
-Fc
)
NV
 A
M
D
Ph
as
e I
Co
m
pl
et
ed
: S
af
e a
nd
 w
el
l t
ol
er
at
ed
 
at
 a
ll d
os
es
, p
ot
en
tia
l e
ffe
ct
 o
f 
ba
se
lin
e a
nt
i-A
AV
2 
se
ru
m
 a
nt
ib
od
-
ie
s a
nd
 tr
an
sg
en
e e
xp
re
ss
io
n
He
ie
r J
S 
et
 a
l.,
 2
01
7
NC
T0
10
24
99
8
Ge
nz
ym
e,
 a
 S
an
ofi
 
Co
m
pa
ny
OX
B-
20
1 (
Re
tin
oS
ta
t)
An
gi
os
ta
tin
 a
nd
 
en
do
st
at
in
NV
 A
M
D
Ph
as
e I
Co
m
pl
et
ed
: W
el
l-t
ol
er
at
ed
 w
ith
 n
o 
do
se
-li
m
iti
ng
 to
xic
iti
es
, r
ed
uc
tio
n 
in
 le
ak
ag
e f
or
 71
%
 o
f p
ar
tic
ip
an
ts
, 
re
du
ct
io
n 
in
 fl
ui
d 
in
 1 
pa
tie
nt
Ca
m
po
ch
ia
ro
 PA
 et
 a
l.,
 
20
07
NC
T0
13
01
44
3 
Ox
fo
rd
 B
io
M
ed
ica
Ph
as
e I
 
On
go
in
g (
lo
ng
 te
rm
 sa
fe
ty
 - 
15
 ye
ar
s)
 
NC
T0
16
78
87
2
Ox
fo
rd
 B
io
M
ed
ica
RG
X-
31
4
sA
nt
i-V
EG
F 
pr
ot
ei
n
NV
 A
M
D
Ph
as
e I
On
 go
in
g
 
NC
T0
30
66
25
8
Re
ge
nx
bi
o 
In
c.
AA
VC
AG
sC
D5
9 
or
 H
M
R5
9 
CD
59
GA
 A
M
D
Ph
as
e I
On
 go
in
g
 
NC
T0
31
44
99
9
He
m
er
a 
Bi
os
cie
nc
es
rA
AV
. s
FL
T-1
sF
LT
1
NV
 A
M
D
Ph
as
e I
Co
m
pl
et
ed
: S
af
e a
nd
 w
el
l t
ol
er
at
ed
 
af
te
r 3
6 
m
on
th
s
Ra
ko
cz
y E
P 
et
 a
l.,
 2
01
5;
 
Co
ns
ta
bl
e I
J e
t a
l.,
 2
01
7
NC
T0
14
94
80
5
Lio
ns
 Ey
e I
ns
tit
ut
e,
 
Pe
rth
, W
es
te
rn
 
Au
st
ra
lia
Ph
as
e I
I 
Ph
as
e 2
a 
co
m
pl
et
ed
: S
m
al
le
r i
m
-
pr
ov
em
en
t t
ha
n 
ra
ni
bi
zu
m
ab
 a
lo
ne
Co
ns
ta
bl
e I
J e
t a
l.,
 2
01
6
NC
T0
14
94
80
5
Lio
ns
 Ey
e I
ns
tit
ut
e,
 
Pe
rth
, W
es
te
rn
 
Au
st
ra
lia
general discussion 179
St
em
 ce
ll t
he
ra
py
 
 
 
 
 
Ty
pe
 of
 th
er
ap
y
Ta
rg
et
Cl
in
ica
l p
ha
se
Re
su
lts
Re
fer
en
ce
Cl
in
ica
ltr
ial
s.g
ov
 
id
en
tifi
er
/ U
M
IN
_C
TR
 
id
en
tifi
er
Fu
nd
in
g  
(cl
in
ica
ltr
ial
s.g
ov
)
Au
to
lo
go
us
 B
M
SC
GA
 A
M
D
Ph
as
e I
/II
Un
kn
ow
n 
(e
st
im
at
ed
 co
m
pl
e -
tio
n 
da
te
 2
01
5)
 
NC
T0
20
16
50
8
Al
-A
zh
ar
 U
ni
ve
rs
ity
Au
to
lo
go
us
 B
M
SC
NV
 &
 G
A 
AM
D
Ph
as
e I
/II
Co
m
pl
et
ed
 
NC
T0
15
18
12
7
Un
ive
rs
ity
 o
f S
ao
 
Pa
ul
o
HC
NS
SC
GA
 A
M
D
Ph
as
e I
/II
Co
m
pl
et
ed
: L
on
g t
er
m
 sa
fe
ty
 
as
se
ss
m
en
t t
er
m
in
at
ed
 
NC
T0
16
32
52
7
St
em
Ce
lls
, I
nc
.
hE
SC
-R
PE
GA
 A
M
D
Ph
as
e I
/II
Co
m
pl
et
ed
: S
af
e a
nd
 p
os
sib
le
 
ac
tiv
ity
 o
f t
he
 ce
lls
Sc
hw
ar
tz 
SD
 et
 a
l.,
 2
01
2;
 S
ch
wa
rtz
 
SD
 et
 a
l.,
 2
01
5
NC
T0
13
44
99
3
As
te
lla
s I
ns
tit
ut
e 
of
 R
eg
en
er
at
ive
 
M
ed
ici
ne
Hu
m
an
 u
m
bi
lic
al
 ti
ss
ue
-d
e-
riv
ed
 ce
lls
 (P
al
uc
or
ce
l, 
CN
TO
-2
47
6)
 
GA
 A
M
D
Ph
as
e I
/II
a
Co
m
pl
et
ed
: S
ub
re
tin
al
 d
el
ive
ry
 
as
so
cia
te
d 
wi
th
 p
er
fo
ra
tio
ns
 
an
d 
de
ta
ch
m
en
t, 
we
ll t
ol
er
at
ed
, 
m
ay
 le
ad
 to
 VA
 im
pr
ov
em
en
ts
Ho
 A
C e
t a
l.,
 2
01
7
NC
T0
12
26
62
8
Ja
ns
se
n 
Re
se
ar
ch
 &
 
De
ve
lo
pm
en
t, 
LL
C
Au
to
lo
go
us
 B
M
SC
GA
 A
M
D
Ph
as
e I
Co
m
pl
et
ed
: W
el
l t
ol
er
at
ed
Pa
rk
 SS
 et
 a
l.,
 2
01
4
NC
T0
17
36
05
9
Un
ive
rs
ity
 o
f C
al
ifo
r -
ni
a,
 D
av
is
hE
SC
-R
PE
 (O
pR
eg
en
)
GA
 A
M
D
Ph
as
e I
/II
On
 go
in
g
 
NC
T0
22
86
08
9
Ce
ll C
ur
e N
eu
ro
sc
ie
nc
-
es
 Ld
t.
So
m
at
ic 
ce
ll n
uc
le
ar
 tr
an
sfe
r 
hE
SC
-R
PE
GA
 A
M
D
Ph
as
e I
On
 go
in
g
 
NC
T0
33
05
02
9
CH
A 
Un
ive
rs
ity
 
hE
SC
-R
PE
GA
 A
M
D
Ea
rly
 p
ha
se
 I
On
 go
in
g
 N
CT
03
04
64
07
Ch
in
es
e A
ca
de
m
y o
f 
Sc
ie
nc
es
hE
SC
-R
PE
GA
 A
M
D
Ea
rly
 p
ha
se
 I
On
 go
in
g
 N
CT
02
75
54
28
Ch
in
es
e A
ca
de
m
y o
f 
Sc
ie
nc
es
hE
SC
-R
PE
 in
 su
sp
en
sio
n 
an
d 
se
ed
ed
 o
n 
a s
ub
st
ra
te
NV
 &
 G
A 
AM
D
Ph
as
e I
/II
On
 go
in
g
 
NC
T0
29
03
57
6
Fe
de
ra
l U
ni
ve
rs
ity
 o
f 
Sa
o 
Pa
ul
o
Au
to
lo
go
us
 B
M
SC
AM
D
No
t s
pe
cifi
ed
On
 go
in
g
 
NC
T0
30
11
54
1
M
D 
St
em
 C
el
ls 
Au
to
lo
go
us
 iP
SC
-R
PE
GA
 A
M
D
Pr
od
uc
tio
n 
of
 th
e 
ce
lls
 
On
 go
in
g
 
NC
T0
24
64
95
6
M
oo
rfi
el
ds
 Ey
e H
os
-
pi
ta
l N
HS
 Fo
un
da
tio
n 
Tr
us
t
hE
SC
-R
PE
 (P
f-0
52
06
38
8)
NV
 A
M
D
Ph
as
e I
On
go
in
g (
lo
ng
 te
rm
 sa
fe
ty,
 
4-
ye
ar
 fo
llo
w-
up
) 
 
NC
T0
31
02
13
8
Pfi
ze
r
180 chapter 4
hE
SC
-R
PE
 o
n 
a 
pa
ry
le
ne
 
m
em
br
an
e (
CP
CB
-R
PE
)
GA
 A
M
D
Ph
as
e I
/II
On
 go
in
g
 
NC
T0
25
90
69
2
Re
ge
ne
ra
tiv
e P
at
ch
 
Te
ch
no
lo
gi
es
, L
LC
Au
to
lo
go
us
 B
M
SC
s
AM
D
No
t s
pe
cifi
ed
On
 go
in
g
 
NC
T0
19
20
86
7
Re
tin
a A
ss
oc
ia
te
s o
f 
So
ut
h 
Flo
rid
a
hE
SC
-R
PE
AM
D
Ph
as
e I
On
 go
in
g
 N
CT
02
74
97
34
So
ut
hw
es
t H
os
pi
ta
l, 
Ch
in
a
hE
SC
-R
PE
GA
 A
M
D 
Ph
as
e I
/II
On
go
in
g (
lo
ng
 te
rm
 sa
fe
ty
 a
nd
 
to
le
ra
bi
lit
y)
 N
CT
02
46
33
44
As
te
lla
s I
ns
tit
ut
e 
fo
r R
eg
en
er
at
ive
 
M
ed
ici
ne
So
m
at
ic 
ce
ll n
uc
le
ar
 tr
an
sfe
r 
hE
SC
-R
PE
GA
 A
M
D
Ph
as
e I
/II
a
On
go
in
g (
pr
el
im
in
ar
y r
es
ul
ts
: 
sa
fe
 a
nd
 to
le
ra
te
d,
 2
 p
at
ie
nt
s 
in
clu
de
d,
 o
ne
 p
at
ie
nt
 ga
in
ed
 VA
 
an
d 
th
e o
th
er
 m
ai
nt
ai
ne
d 
VA
)
So
ng
 W
K 
et
 a
l.,
 2
01
5
NC
T0
16
74
82
9
CH
A 
Bi
ot
ec
h 
CO
., 
Lt
d
hE
SC
-R
PE
 (A
SP
73
17
)
GA
 A
M
D
Ph
as
e I
b/
II
No
t o
pe
n 
ye
t
 
NC
T0
31
78
14
9
As
te
lla
s I
ns
tit
ut
e 
fo
r R
eg
en
er
at
ive
 
M
ed
ici
ne
hE
SC
-R
PE
GA
 A
M
D
Ph
as
e I
/II
No
t o
pe
n 
ye
t (
ev
al
ua
tio
n 
of
 lo
ng
 
te
rm
 sa
fe
ty
)
NC
T0
31
67
20
3 
As
te
lla
s I
ns
tit
ut
e 
fo
r R
eg
en
er
at
ive
 
M
ed
ici
ne
Au
to
lo
go
us
 fi
br
ob
la
st
 
iP
SC
-R
PE
 sh
ee
t
NV
 A
M
D
Ph
as
e I
/II
Co
m
pl
et
ed
: P
at
ie
nt
 1 
af
te
r 1
 
ye
ar
 th
e c
el
l s
he
et
 a
pp
ea
rs
 to
 
be
 sa
fe
 a
nd
 re
m
ai
ns
 in
ta
ct
, V
A 
m
ai
nt
ai
ne
d.
 P
at
ie
nt
 2
 d
id
 n
ot
 
re
ce
ive
 th
er
ap
y d
ue
 to
 co
nc
er
ns
 
ab
ou
t g
en
et
ic 
ch
an
ge
s i
n 
th
e 
iP
SC
s a
nd
 iP
SC
-d
er
ive
d 
RP
E
M
an
da
i M
 et
 a
l.,
 2
01
7
UM
IN
00
00
11
92
9
RI
KE
N
Al
lo
ge
ni
c H
LA
-m
at
ch
ed
 
iP
SC
-R
PE
NV
 A
M
D
Ph
as
e I
 O
n 
go
in
g
 
Un
kn
ow
n
RI
KE
N
N
V
 A
M
D
 =
 A
dv
an
ce
d 
ne
ov
as
cu
la
r A
M
D
, G
A
 A
M
D
 =
 A
dv
an
ce
d 
ge
og
ra
ph
ic
 a
tr
op
hy
 A
M
D
, B
M
SC
 =
 b
on
e 
m
ar
ro
w
-d
er
iv
ed
 s
te
m
 c
el
ls
, h
ES
C-
R
PE
 =
 H
um
an
  
em
br
yo
ni
c 
st
em
 c
el
l-d
er
iv
ed
 re
ti
na
l p
ig
m
en
te
d 
ep
it
he
lia
l c
el
ls
, h
CN
S
SC
 =
 H
um
an
 c
en
tr
al
 n
er
vo
us
 s
ys
te
m
 s
te
m
 c
el
ls
, i
PS
C-
R
PE
 =
 in
du
ce
d 
pl
ur
ip
ot
en
t s
te
m
  
ce
ll-
de
ri
ve
d 
re
ti
na
l p
ig
m
en
te
d 
ep
it
he
lia
l c
el
ls
, V
A
 =
 v
is
ua
l a
cu
it
y
general discussion 181
2.2.2 Stem cell therapy
Another novel therapeutic approach with great potential for AMD is the use of stem cells, 
which are reprogrammed to the cell type of interest and transplanted to the patient. 
Transplantation of RPE cells derived from stem cells for AMD treatment is currently being 
evaluated in several clinical trials (Table 3). The first clinical trial started in 2011 and 
involved human embryonic stem cell (hESC) derived RPE cells (NCT01344993). The therapy 
was found to be safe with no tumorigenicity and showed potential effectiveness.100,101 
These results have been followed up with a new improved therapy (NCT03178149, 
NCT03167203) that is currently being evaluated by developers in the Astellas Institute for 
Regenerative Medicine. Other on-going clinical trials are also based on hESC derived RPE, 
however, their use requires immunosuppressive treatment, bearing risks,102 and raising 
ethical concerns due to the use of embryonic cells. 
More recently, the use of induced pluripotent stem cells (iPSC) has begun to be explored. 
One of the key benefits of this therapy is that immunosuppression is not needed, as the 
source is the patient’s own somatic cells. However, it implies an increased cost of therapy, 
as it needs to be developed for each patient individually. The first clinical trial with iPSC 
(http://www.umin.ac.jp, UMIN000011929) has recently been performed at the Japanese 
research institute RIKEN, where a 70-year old AMD patient received a transplant of a sheet 
of autologous iPSC-RPE. After one year of follow-up, no adverse events had been detected 
and the patient’s vision remained stable.103 However, this trial has been stopped for the 
second patient enrolled due to genetic changes found in the generated iPSC.104 This group 
has recently shifted their approach towards the use of allogenic human leukocyte antigen 
(HLA)-matched iPSC-RPE, and in March 2017, it was announced that the first patient 
received allogenic iPSC-RPE.105 This approach would be less costly and would avoid the 
effect of the genetic AMD risk variants that the patients carry. Nevertheless, it would most 
likely imply the use of immunosuppressant drugs. Contrary to these promising results of 
the group in RIKEN, in a back-to-back publication, it was reported that autologous adipose 
tissue-derived stem cells were administered bilaterally to three AMD patients in a stem-cell 
clinic, leading to a severe visual loss in all cases.106 These disastrous events highlight that 
even though stem cell therapy holds promise, strict regulations should be applied before 
any treatment with stem cells is administered to patients. 
RPE stem cell therapy might be the best therapeutic option for advanced cases in which 
there is RPE degeneration, however, it involves the transplantation of new cells in a diseased 
environment and, as such, the survival of the new cells may depend on inflammation and 
oxidative stress levels in the host environment. The C3/C3 ratio as a marker of complement 
activation, malondialdehyde levels as a marker of lipid peroxidation, and homocysteine 
levels as an oxidative stress marker, are molecular biomarkers for AMD that may correlate 
with the success of such therapies.107 Moreover, autologous iPSC might not be the 
best option for AMD patients carrying highly penetrant genetic variants, and hESC or 
HLA-matched iPSC may be more effective in these patients. 
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2.2.3 Genome editing
Genome editing through the use of the CRISPR/Cas9 system is a powerful tool for therapy 
development.108 Recently, the first treatment with genome editing has been given to a man 
suffering from Hunter syndrome.109 The first studies for AMD are being carried out in animal 
models. In vivo genome editing using subretinal injections of Cas9 ribonucleoproteins that 
target the VEGFA gene has shown to reduce CNV in an AMD mouse model.110 Moreover, 
this system could be included in a viral vector and delivered to specific cells, as a form of 
gene therapy. In a mouse model of laser-induced CNV, viral delivery of the CRISPR/Cas9 
system edited the KDR gene, abolishing angiogenesis.111 In another recent study in mice, 
an adeno-associated virus vector delivering a small Cas9 targeting the VEGFA and HIF1A 
genes of RPE cells reduced the size of laser-induced CNV.110 These studies represent the 
very first steps towards the use of genome editing for therapy purposes in AMD.
This technology opens up possibilities for correcting genetic variants that give a risk for the 
disease. Several rare variants associated with AMD confer a remarkable high risk, such as 
CFH Arg1210Cys (OR=31.8), CFH Arg53Cys (OR=22.54) and CFI Gly162Asp (OR=20.29),78 
and might be potential targets for genome editing therapies. Consequently, genetic 
analysis would become indispensable in patient selection for gene-editing therapies.
3 Conclusions and future perspectives
Based on the recent findings of Assel at al.,11 dietary supplementation for slowing down 
disease progression should be prescribed to any AMD patient, irrespective of CFH and 
ARMS2 genotypes. However, these findings are based on the AREDS dataset only, and 
future independent prospective studies would be beneficial to corroborate these results, 
as well as to further investigate if other genetic variants may interact with the formulation.
In regard to the pharmacogenetics of anti-VEGF treatment, results are not conclusive yet. 
Nonetheless, recurrent results from multiple studies suggest that SNP rs1061170 in CFH 
may influence response to treatment. This finding could potentially be explained by the 
effect of this SNP on faster disease progression.112 However, this association was not 
detected in the analyses from the CATT and IVAN clinical trials,33,34 therefore warranting 
further investigation. Additionally, the magnitude of the effect of this variant might not 
reach clinical utility and would need to be combined with other genetic variants or clinical 
parameters. Other compelling candidate genetic variants for further evaluation include 
ARMS2 rs10490924, VEGFA rs833061, OR52B4 rs4910623, NRP1 rs2070296, APOE 
ε4 allele, IL8 rs4073 and PEDF rs1136287. However, based on the results of our GWAS 
on visual acuity measures (chapter 2.3) and the GWAS of Yamashiro and colleagues on 
anatomical measures,45 we propose that there is a limited contribution of common genetic 
variants to variability in nvAMD treatment response. We additionally evaluated for the first 
time the influence of rare variants on this treat and found rare variants in the C10ORF88 
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and UNC93B1 genes with large effects on treatment outcome.113 These are compelling 
candidates for replication studies as rare variants with large effects have the potential of 
being implemented in clinical practice for guidance of treatment protocols.
A key problem remains that the definition of response is not consistently defined across 
cohorts. In 2015, in order to provide a consensus, a committee of retinal specialists 
proposed definitions of good, poor and non-response based on a combination of 
anatomical and functional measurements.114 These definitions should be adopted by 
researchers in future studies, which would enable study comparisons in a standardized 
framework. Analysis of the different outcome measures used for these definitions as 
continuous variables would be also highly valuable. Additionally, prospective studies with 
sufficient statistical power would allow sub-phenotype analyses, which may reveal new or 
stronger associations. 
Biomarkers identified in aqueous humor samples are VEGF and IL-6, however, these 
samples are not taken routinely. IL-6, IL-17, TNF-α and C3a have been identified as 
potential systemic biomarkers, and therefore could be readily measured before treatment. 
Moreover, as baseline VEGF has been associated with response in aqueous humor 
samples, it could be further investigated as a systemic biomarker. Recent studies suggest 
that anti-VEGF treatment may lead to an increased risk of GA development.115 Therefore, 
screening of genetic markers together with other biomarkers and clinical parameters for 
effective anti-VEGF therapy planning may become necessary. Clinical trials would however 
be needed before the screening of these biomarkers can be implemented in the clinic.
Complement therapies are being developed for the treatment of GA, and biomarkers for 
complement activity could be useful to identify the most suitable AMD patients for these 
therapies. Based on the results of chapter 3.2, FHR-4 could potentially be a new drug target, 
and also be used as a biomarker for complement activity in AMD. Moreover, levels of the 
specific target of each drug could be a useful biomarker. Therapies undergoing trials are 
targeting FD, C3, properdin and C5. FD levels have been seen to be higher in AMD patients 
compared to controls, and therefore, they could be a useful biomarker for this specific 
therapy. C3 levels do not differ between AMD and controls and properdin and C5 levels have 
not been evaluated. A comprehensive analysis of the complement system components in 
AMD (e.g. by mass spectrometry) could identify new potential biomarkers. However, our 
findings of chapter 3.1 show that genetic variants affecting systemic levels of complement 
activation may not have an influence in the eye. Therefore, how systemic measurements 
reflect the local situation at the disease site needs to be further investigated. 
Additionally, AMD-associated SNPs that associate with systemic complement activation 
can be used as robust biomarkers. The added value of these genetic biomarkers is that, 
as they are associated with disease risk, they most probably reflect complement activity 
in the eye, whereas the overall systemic complement activation may not always be 
representative of the conditions at the disease site. rs12144939, rs1410996 and rs800292 
in CFH, rs4151667, rs641153 and rs9332739 in C2/CFB and rs6795735 and rs2230199 
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in C3 have been reported to be associated with systemic complement activation levels 
and replicated in our GWAS study on chapter 3.1, being therefore reliable markers. 
Additionally, these GWAS study revealed the strongest association for an AMD-associated 
variant in CFHR4 rs6685931, representing a new compelling biomarker for the disease. 
Moreover, rare variants in the CFH gene (Arg127His, Arg175Pro and Cys192Phe), in 
the CFI gene (Gly119Arg, Gly188Ala and Ala240Gly) and in the C9 gene (Arg95Ter and 
Pro167Ser) have been associated with altered FH, FI and C9 levels respectively. However, 
the magnitude of the effects of these genetic variants at the disease site still needs to be 
evaluated. Additionally, other AMD-associated variants for which a systemic effect has not 
been detected might have a local effect. Consequently, genetic studies on complement 
activation levels in aqueous humor samples or other local eye sample types are greatly 
needed. The identified genetic factors may be used alongside systemic complement 
activation levels and other environmental factors such as BMI and triglyceride levels to 
identify AMD patients with a burden of the complement system driving their disease. In 
this regard, we built a model of complement activation including AMD-associated factors 
in chapter 3.1, which may serve as a starting point for future studies.
Other new therapeutic approaches will most probably not be effective in for all AMD 
patients. As a consequence, a deeper molecular characterization of AMD patients including 
proteomics, metabolomics, transcriptomics and genomics is essential. Such in-depth 
characterization will help to understand the molecular drivers in each individual patient 
and to develop pharmac-omics, paving the way towards precision medicine in AMD.
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Summary
 
Age-related macular degeneration (AMD) is the most common cause of blindness in the 
elderly and affects approximately 1 in 10 individuals of 85 years of age. AMD patients 
experience a loss of central vision, blurred vision and have less ability to discriminate 
colors. As a consequence, they are impaired in their daily life activities such as reading and 
face recognition, and may lose their independency in the retirement ages. 
In AMD pathogenesis, degeneration of the central retina, termed the macula, occurs. 
This degeneration is associated with extracellular accumulation of debris called drusen, 
which can be easily identified by ophthalmologists as yellowish spots on photographs 
of the retina. Visual loss occurs in the advanced stage of AMD, which can be subdivided 
into two types:  georgraphic atropy (GA) and choroidal neovascularization (CNV). In the GA 
type, degeneration of the outer segments of the retina occurs, and in the CNV type there is 
abnormal growth of exudative blood vessels from the choroid.   
Both environmental and genetic factors play a role in AMD development, as it is a complex 
trait. The risk of AMD development increases exponentially with age, which is the strongest 
non-genetic risk factor. Genetic factors play an important role in AMD development. The 
largest genome-wide association study (GWAS) recently revealed 52 genetic variants 
that are associated with AMD. These variants locate in genes that are involved in 
neovascularization and the complement system among others, implicating these pathways 
in the molecular mechanisms of the disease.
The genetic background, demographics and lifestyle can influence how a patient responds 
to a specific treatment. Therefore, healthcare could be improved by taking into account 
the individual characteristics of each patient when prescribing medication. This emerging 
approach in medicine is termed precision medicine. For this purpose, genetic variants are 
robust and easily measurable biomarkers that can be used to predict response to a drug. 
The overarching goal of this thesis was to identify genetic biomarkers that can be used to 
adapt treatment options to the needs of each AMD patient. 
The only therapeutic intervention available for advanced AMD is the use of anti-vascular 
endothelial growth factor (VEGF) antibodies to treat the CNV form. These antibodies block 
VEGF, the master regulator of the pathological CNV formation. Although these drugs have 
led to significant vision improvement for the AMD patients, the individual patient response is 
highly variable. Around 20% of the patients continue losing vision despite receiving treatment. 
In chapter 2 of this thesis, we aimed to identify genetic biomarkers that associate with 
anti-VEGF treatment response in advanced AMD patients with CNV. To that end, we first 
conducted a candidate gene analysis described in chapter 2.1, in which we analyzed four 
single nucleotide polymorphisms (SNPs) located in the neuropilin-1 gene (NRP1). NRP1 was 
a compelling candidate because it is a co-receptor of VEGF and enhances the transduction 
of downstream signaling. Moreover, it has been described to affect the evolution of CNV 
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formation in AMD and VEGF mediated vascular leakage. The results of this study suggest 
that the SNP rs2070296 associates with worse visual acuity treatment outcome. In our next 
studies, we moved into genome-wide association analyses, in which more than a million 
variants distributed across the genome were analyzed in a hypothesis-free approach 
GWAS. In chapter 2.2, we describe the results of a GWAS performed by comparing 
pools of DNA of responders and non-responders, carried out by the group of Prof. Baird 
at the Centre for Eye Research in Australia. In our replication cohort, we confirmed that 
SNP rs4910623 in the OR52B4 gene was associated with treatment response. Finally, in 
chapter 2.3, we performed a larger GWAS on treatment response followed by a replication 
analysis, by leading a large collaboration of several groups belonging to the International 
AMD Genomics Consortium. In essence, we could not confirm any of the associations 
previously reported in literature, nor did we find an association with any of the 52 AMD-
associated variants. However, in this study we evaluated for the first time rare genetic 
variation and found that rare protein-altering variants in the C10orf88 and UNC93B1 genes 
may associate with severe vision loss despite treatment.
For GA, the second type of advanced AMD, there is no available treatment to date. However, 
several therapies that target the complement system are currently being evaluated in clinical 
trials. Due to the high variability in complement activation levels among AMD patients, we 
hypothesized that patients with higher levels of complement activation will most benefit 
from complement-inhibiting therapies. Therefore, in chapter 3 of this thesis we aimed to 
find genetic variants that associate with complement activation levels. In order to do that, 
we carried out a GWAS on systemic complement activation levels, described in chapter 3.1. 
This analysis revealed that complement activation was independently associated with the 
SNP rs3753396 located in the complement factor H gene (CFH) and the SNP rs6685931 
located in the complement factor H related 4 gene (CFHR4). The SNP rs3753396 in CFH 
did not associate with AMD, which led us to the conclusion that the relationship between 
systemic and local complement activation in the eye merits further investigation. The SNP 
rs6685931 in CFHR4 associated with AMD, and therefore may be used for selecting patients 
for complement-inhibiting therapies. This last finding led us to investigate the role of FHR-4 
in AMD pathogenesis, as described in chapter 3.2. The results of biochemical studies and 
further genetic analyses have led us to pinpoint FHR-4 as a new complement component 
involved in AMD, and a new potential target for the treatment of AMD.
In chapter 4 we reviewed the current status of literature and placed our results in context. For 
biomarkers of response to anti-VEGF drugs, definitions of response should be harmonized 
in order to facilitate study comparisons. Common genetic variants seem to have a limited 
effect on treatment response, and combining several variants may be needed to achieve 
clinical significance. Our results on the analysis of rare variants suggest stronger effects, 
although they warrant replication. For complement-inhibiting therapies, genetic variants 
in complement genes have shown association with systemic complement activation levels 
and are compelling biomarkers. The relationship between systemic and local levels of 
complement activity has therefore become highly relevant. A deep molecular characterization 
of AMD patients including proteomics, metabolomics, transcriptomics and genomics is a 
necessary next step to move forward towards precision medicine for AMD patients.
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Leeftijdsgebonden maculadegeneratie (LMD) is de meest voorkomende vorm van blindheid 
onder ouderen en treft ongeveer 1 op 10 mensen die 85 jaar of ouder zijn. LMD patiënten 
ervaren een verlies van hun centrale gezichtsveld, het onscherp worden van hun zicht, en 
ze zijn minder goed in staat om kleuren te onderscheiden.  In hun dagelijkse activiteiten 
ondervinden ze hier hinder van, bijvoorbeeld tijdens het lezen of bij het herkennen van 
gezichten. LMD beperkt ook de mate van onafhankelijkheid van mensen na hun pensioen. 
Bij patiënten met LMD vindt slijtage en afbraak plaats van het centrale deel van het netvlies, 
dat de macula wordt genoemd. Deze degeneratie is geassocieerd met een ophoping van 
afvalstoffen, drusen, die door een oogarts gemakkelijk te zien zijn als geelachtige puntjes 
op foto’s van het netvlies. Verlies van zicht treedt in de late stadia van LMD op, waarbij twee 
vormen worden onderscheiden: droog (ook wel geografische atrofie - GA) en nat (ook wel 
neovasculaire LMD). Bij GA vindt er een degeneratie plaats van het netvlies. Bij de natte 
vorm van LMD dringen lekkende bloedvaatjes uit het vaatvlies het netvlies binnen.
Zowel omgevingsfactoren als genetische factoren spelen een rol in het ontstaan van LMD. 
Het risico om LMD te krijgen stijgt exponentieel naarmate men ouder wordt, wat leeftijd 
de sterkste niet-genetische risicofactor maakt. Genetische factoren spelen een belangrijke 
rol bij LMD. De grootste genetische associatie studie vond 52 genetische varianten die 
geassocieerd zijn met de ziekte. Deze varianten zitten in genen die betrokken zijn bij het 
ontstaan van nieuwe bloedvaten (neovascularisatie) en ook in genen die betrokken zijn bij 
een onderdeel van het afweersysteem (het complement systeem), wat erop duidt dat deze 
biologische systemen betrokken zijn bij LMD.
Hoe een patiënt reageert op een behandeling kan afhangen van zijn of haar genetische 
achtergrond en levensstijl. De gezondheidszorg zou verbeterd kunnen worden door 
rekening te houden met deze gegevens bij het voorschrijven van een behandeling. Deze 
benadering is sterk in opkomst en heet ‘precision medicine’, ofwel persoonsgerichte 
zorg. Kennis van de genetica levert gemakkelijk meetbare en robuuste biomarkers op die 
gebruikt kunnen worden om behandelsucces te voorspellen. 
Het doel van dit proefschrift was om moleculaire biomarkers te vinden die behandelsucces 
kunnen voorspellen, om zo toekomstige behandelingen te kunnen optimaliseren voor de 
individuele patiënt.
Het enige geneesmiddel dat beschikbaar is voor natte LMD is de behandeling met een 
antistof die ‘vasculair endotheel groei factor’ remt (anti-VEGF).  Deze antistoffen remmen 
VEGF, een belangrijke moleculaire aanjager van het proces waarbij nieuwe bloedvaten 
worden gevormd.  Deze behandeling heeft een belangrijke bijdrage geleverd aan het 
behoud van gezichtsvermogen voor LMD patiënten, maar individuele patiënten reageren 
heel variabel op de behandeling. Ongeveer 20% van de patiënten reageert niet tot 
nauwelijks op de behandeling. In hoofdstuk 2 van dit proefschrift hebben we onderzocht 
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welke genetische biomarkers associëren met het behandelsucces van anti-VEGF in LMD. 
Eerst hebben we vier genetische varianten in het kandidaat gen neuropilin-1 (NRP1) 
geanalyseerd in hoofdstuk 2.1. NRP1 was een interessante kandidaat omdat het een co-
receptor is van VEGF en het moleculaire signaal versterkt. Daarnaast is het betrokken bij 
bloedvatnieuwvorming in LMD en lekkage van bloedvaten onder invloed van VEGF. Onze 
resultaten lieten zien dat een bepaalde genetische variant in NRP1 (rs2070296) associeerde 
met een slechtere uitkomst na behandeling. In onze vervolgstudies zijn we over gegaan 
naar genoomwijde analyses, waarbij meer dan een miljoen genetische varianten over het 
hele genoom tegelijkertijd werden getest. In hoofdstuk 2.2 beschrijven we de resultaten 
van een genoomwijde analyse, waarbij mensen die wel reageerden op de behandeling 
werden vergeleken met mensen die niet reageerden. Dit experiment werd gedaan in 
Australië, onder leiding van professor Paul Baird, van het Centre for Eye Research. In ons 
replicatiecohort konden we bevestigen dat een variant in OR52B4 (rs4910623) betrokken 
was bij behandelsucces. Tenslotte hebben we in hoofdstuk 2.3 zelf een grote genoomwijde 
associatie analyse uitgevoerd in samenwerking met verschillende groepen uit een groot 
internationaal samenwerkingsverband, het International AMD Genomics Consortium. We 
konden eerder gepubliceerde data niet bevestigen in deze studie, en we vonden ook geen 
associatie met de 52 varianten die betrokken zijn bij LMD. Wel vonden we in deze studie 
een mogelijke rol voor zeldzame genetische varianten, met name in de genen C10orf88 en 
UNC93B1, in een slechte uitkomst na behandeling. 
Voor de tweede vorm van LMD, de droge vorm, is op dit moment geen behandeling 
beschikbaar, maar verscheidene klinische studies zijn gaande waarin het complement 
systeem wordt geremd. Omdat de activiteit van het complement systeem sterk variabel 
is tussen LMD patiënten, hadden wij de hypothese dat patiënten met een verhoogde 
complement activiteit het meeste baat zouden hebben bij deze nieuwe behandeling.  In 
hoofdstuk 3 hadden wij daarom als doel om genetische factoren te vinden die geassocieerd 
zijn met complement activiteit. Wij voerden een genoomwijde associatie analyse uit 
(hoofdstuk 3.1) en vonden twee genetische varianten die sterk geassocieerd waren met 
complement activiteit (rs3753396 in het gen CFH en rs6685931 in het gen CFHR4). De 
variant rs3753396 was niet geassocieerd met LMD, wat er sterk voor pleit dat de complexe 
relatie tussen lokale complement activiteit in het oog en in het bloed nader onderzocht 
dient te worden.  De variant rs6685931 in het gen CFHR4 was wel geassocieerd met 
LMD, and kan derhalve gebruikt worden om patiënten te selecteren voor de complement 
remmende behandeling. Deze bevinding leidde er toe om de rol van FHR-4 in het ontstaan 
van LMD nader te onderzoeken, zoals beschreven in hoofdstuk 3.2. De resultaten van deze 
biochemische studies en aanvullende genetische analyses wezen erop dat FHR-4 mogelijk 
betrokken is bij LMD en dat het een nieuwe kandidaat is voor toekomstige behandelingen.
In hoofdstuk 4 vatten we de actuele literatuur over dit onderwerp samen en plaatsten we 
onze eigen resultaten in deze context. Om biomarkers voor behandelsucces na anti-VEGF te 
vinden, zou eerst een eenduidige definitie van behandelsucces opgesteld moeten worden 
zodat verschillende studies met elkaar vergeleken kunnen worden. Veelvoorkomende 
genetische varianten lijken slechts een beperkt effect te hebben op behandelsucces, en het 
summary | samenvatting | resumen 197
combineren van genetische varianten is mogelijk nodig om een klinisch significant resultaat 
te behalen. Onze resultaten suggereren dat zeldzame genetische varianten mogelijk 
sterkere effecten hebben, maar deze bevindingen dienen gerepliceerd te worden in andere 
cohorten. In de studies waarin we zochten naar biomarkers voor complement activiteit 
vonden we enkele interessante kandidaten in complement genen. Het werd duidelijk dat 
de relatie tussen complement activiteit in het oog en in het bloed zeer relevant is en nader 
onderzocht dient te worden. Een gedetailleerde profilering van LMD patiënten, waarbij 
proteomics, metabolomics, transcriptomics en genomics worden samengenomen, is een 
belangrijke vervolgstap om persoonsgerichte zorg voor LMD patiënten te ontwikkelen. 
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Resumen
 
La degeneración macular asociada a la edad (DMAE) es la causa más común de ceguera 
en la vejez y afecta aproximadamente a 1 de cada 10 personas de 85 años de edad. Los 
pacientes con DMAE experimentan una pérdida de visión central, visión borrosa y tienen 
una menor capacidad para discriminar colores. Como consecuencia, estos pacientes se 
ven perjudicados en sus actividades cotidianas, como la lectura y el reconocimiento facial, 
y pueden perder su independencia en edades de jubilación.
En la patogénesis de la DMAE se produce una degeneración de la parte central de la retina, 
denominada mácula. Esta degeneración está asociada con la acumulación extracelular de 
desechos llamados drusas, las cuales pueden ser identificadas como manchas amarillentas 
en fotografías de la retina. La pérdida de visión se produce en la etapa avanzada de la DMAE, 
que se puede subdividir en dos tipos: atrofia geográfica (forma seca) y neovascularización 
coroidea (forma húmeda). En la forma seca, se produce la degeneración de los segmentos 
externos de la retina mientras que en la forma húmeda hay un crecimiento anormal de 
vasos sanguíneos en la coroides, los cuales son exudativos.
Tanto factores ambientales como genéticos están involucrados en el desarrollo de DMAE 
ya que se trata de un fenotipo complejo. El riesgo de desarrollo de DMAE aumenta 
exponencialmente con la edad, siendo este el factor de riesgo no genético de mayor 
relevancia. Los factores genéticos juegan también un papel clave en el desarrollo de 
DMAE. El estudio de asociación del genoma completo (GWAS) más extenso llevado a cabo, 
reveló recientemente 52 variantes genéticas que están asociadas con la DMAE. Estas 
variantes se localizan, entre otros, en genes que están implicados en neovascularización y 
el sistema del complemento, implicando estas vías en los mecanismos moleculares de la 
enfermedad.
La manera en la que un paciente responde a un tratamiento específico puede variar 
dependiendo de la génetica, la demografía y el estilo de vida dicho paciente. Por ello, la 
atención médica podría mejorarse teniendo en cuenta las características individuales de 
cada paciente a la hora de prescribir medicamentos. Este enfoque emergente en medicina 
se denomina «medicina de precisión». Las variantes genéticas son biomarcadores robustos 
y fáciles de medir que pueden ser utilizados para predecir la respuesta a un fármaco y 
como consecuencia, son utilizados en el campo de la medicina de precisión. El objetivo 
general de esta tesis ha sido la identificación de biomarcadores genéticos que puedan 
utilizarse para adaptar las opciones de tratamiento a las necesidades de cada paciente 
con DMAE.
La única intervención terapéutica disponible para la DMAE avanzada consiste en 
anticuerpos contra el factor de crecimiento endotelial vascular (FCEV) para tratar la forma 
húmeda. Estos anticuerpos bloquean FCEV, que es el regulador principal de la formación 
patológica de neovascularización en la coroides. Aunque estos fármacos producen 
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una mejora significativa en la visión de los pacientes con la forma húmeda de DMAE, la 
respuesta individual de cada paciente es muy variable. De hecho, alrededor del 20% de los 
pacientes continúa perdiendo la visión a pesar de recibir tratamiento. 
El objetivo del capítulo 2 de esta tesis consiste en identificar biomarcadores genéticos 
de respuesta al tratamiento anti-FCEV en pacientes con la forma húmeda de DMAE. En 
primer lugar realizamos un análisis de genes candidatos descrito en el capítulo 2.1, en 
el cual analizamos cuatro polimorfismos de nucleótido único (SNPs) ubicados en el gen 
neuropilin-1 (NRP1). NRP1 es un correceptor de FCEV y mejora la transducción de la 
señalización aguas abajo. Además, NRP1 afecta el desarrollo de la neovascularización 
en la coroides y a la filtración vascular mediada por FCEV en DMAE. Los resultados de 
este estudio sugieren que el SNP rs2070296 está asociado con una peor respuesta al 
tratamiento en términos de agudeza visual. Es decir, tras el tratamiento, la mejora en 
agudeza visual de los pacientes con esta variante genética es menor en comparación con 
la de los pacientes que no son portadores de esta variante genética. En los siguientes 
estudios, ampliamos nuestro análisis al genoma completo y evaluamos más de un millón 
de variantes distribuidas a lo largo de todo el genoma sin tener ninguna hipótesis a priori. 
En el capítulo 2.2 describimos los resultados de un GWAS realizado comparando ADN de 
pacientes que responden a la terapia con el ADN de pacientes que no responden. Este 
trabajo se llevo a cabo en el grupo del Prof. Baird en el Centro de Investigación de Ojos 
en Australia. En nuestra cohorte de replicación, confirmamos que el SNP rs4910623 en el 
gen OR52B4 está asociado con la respuesta al tratamiento. Finalmente, en el capítulo 2.3, 
realizamos un GWAS sobre la respuesta al tratamiento seguido de un análisis de replicación 
en el que incluimos un mayor número de pacientes, liderando una gran colaboración de 
varios grupos pertenecientes al “International AMD Genomics Consortium”. En esencia, 
no pudimos confirmar ninguna de las asociaciones previamente descritas, ni encontramos 
una asociación con ninguna de las 52 variantes asociadas con la DMAE. Sin embargo, en 
este estudio se incluyeron  por primera vez variantes genéticas raras y encontramos que 
variantes genéticas raras que alteran las proteínas codificadas por los genes C10orf88 y 
UNC93B1 están asociadas con una pérdida de visión severa a pesar del tratamiento.
Para la forma seca, el segundo tipo de DMAE avanzada, no hay ningún tratamiento 
disponible hasta la fecha. Sin embargo, se están llevando a cabo ensayos clínicos que 
evalúan terapias que inhiben el sistema del complemento. Debido a que los pacientes 
con DMAE exhiben una gran variabilidad en los niveles de activación del complemento, 
planteamos la hipótesis de que los pacientes con la forma seca y los niveles más altos 
de activación del complemento serán los que más se beneficien de este tipo de terapias. 
Por ello, el propósito del capítulo 3 de esta tesis ha sido identificar variantes genéticas 
asociadas con los niveles de activación del complemento. Con este fin, llevamos a cabo un 
GWAS sobre los niveles de activación sistémica del complemento, el cual está descrito en 
el capítulo 3.1. Este análisis reveló que la activación del complemento está asociada con el 
SNP rs3753396 localizado en el gen del factor H del complemento (CFH) y el SNP rs6685931 
localizado en el gen numero 4 relacionado con el factor H del complemento (CFHR4). El 
SNP rs3753396 en el gen CFH no resultó estar asociado con la DMAE, lo que nos llevó a la 
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conclusión de que la relación entre la activación sistémica y local (en el ojo) merece mayor 
investigación. El SNP rs6685931 en el gen CFHR4 está, por el contrario, asociado con la 
DMAE y por lo tanto se puede usar para seleccionar pacientes para terapias que inhiban 
el sistema del complemento. Este último hallazgo nos llevó a investigar el papel de FHR-
4 en la patogénesis de la DMAE, como se describe en el capítulo 3.2. Los resultados de 
estudios bioquímicos y análisis genéticos sugieren que FHR-4 es un nuevo componente 
del complemento involucrado en la DMAE y que por lo tanto, podría ser suponer un nuevo 
objetivo para su tratamiento.
En el capítulo 4 analizamos la literatura actual en este campo científico y pusimos nuestros 
resultados en contexto. En relación con los biomarcadores para la respuesta a los fármacos 
anti-FCEV, es necesario armonizar las definición de la respuesta al tratamiento para 
facilitar las comparaciones entre estudios. Las variantes genéticas comunes parecen tener 
un efecto minoritario en la respuesta al tratamiento. Por ello, tendrán que combinarse 
varias variantes  para poder usarse como biomarcadores con aplicación clínica. Nuestros 
resultados en el análisis de variantes raras sugieren efectos de mayor magnitud, aunque 
es necesario  analizar resultados en otras cohortes. Para las terapias que inhiben el 
sistema del complemento, las variantes genéticas que se asocian con los niveles de 
activación sistémica del complemento son biomarcadores convincentes. Aún así, es 
necesario analizar en más profundidad la relación entre la actividad del complemento a 
nivel sistémico y local. Para concluir, una caracterización molecular profunda de pacientes 
con DMAE, que incluya proteómica, metabolómica, transcriptómica y genómica, es un 
paso necesario para avanzar hacia la medicina de precisión en pacientes con DMAE.
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